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Abstract
AIM
To determine the clinical characteristics of children with
gastrointestinal bleeding (GIB) who died during the
course of their admission.

Institutional review board statement: The study was reviewed
and approved for publication by our Institutional Reviewer.

METHODS
We interrogated the Pediatric Hospital Information
System database, including International Classification
of Diseases, Current Procedural Terminology and
Clinical Transaction Classification coding from 47
pediatric tertiary centers extracting the population of
patients (1-21 years of age) admitted (inpatient or
observation) with acute, upper or indeterminate GIB
(1/2007-9/2015). Descriptive statistics, unadjusted
univariate and adjusted multivariate analysis of the
associations between patient characteristics and
treatment course with mortality was performed with
mortality as primary and endoscopy a secondary
outcome of interest. All analyses were performed using
the R statistical package, v.3.2.3.

Conflict-of-interest statement: All the authors have no conflict
of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is
available on request from the corresponding author at tmattard@
cmh.edu.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited
and the use is non-commercial. See: http://creativecommons.
org/licenses/by-nc/4.0/

RESULTS
The population with GIB was 19528; 54.6% were
male, overall mortality was 2.07%; (0.37% in patients
with the principal diagnosis of GIB). When considering
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This deficit hinders the evidence based allocation of
resources and the implementation of standardized
protocols, potentially adversely impacting outcomes
in children.
One of the co-authors, has identified the presence
of > 3 comorbid conditions, presentation to a teaching
hospital, the presence of upper GIB; age under 5
years and health coverage with private insurance as
independent risk factors associated with an increased
[5]
rate of hospital admission with GIB . Hemorrhage
occurred in 0.5% of all discharges from inpatient care,
was more prevalent in males and older than 11 years.
Esophageal and intestinal perforation were identified
as at highest risk of associated mortality, together
accounting for 17% of all patients with GI haemor[6]
rhage and who died .
Disease classification in adult GIB cannot be
extrapolated to the pediatric population. Risk factors
identifiable in adults, foremost amongst which are
age, non-steroidal anti-inflammatory drug, selective
serotonin reuptake inhibitor, aspirin, antiplatelet and
anticoagulant therapy and chronic renal and cardiovas[7]
cular disease, are clearly not applicable to children .
Conversely, the impact of predominantly pediatric and
especially neonatal disease processes (e.g., prematurity) on the risk of GIB remain unknown. This limits
the applicability of pre- and postendoscopic predictive
scoring systems [Rockall, Blatchford (aka Glasgow),
Addenbrooke] to identify patients at high risk (need
for blood transfusion, surgical intervention, rebleeding
and mortality) and those requiring immediate endoscopic intervention as opposed to at low risk who can
[8-10]
be safely discharged
. The Sheffield Scoring system
is, to date the only successful attempt at predicting
the need for endoscopic hemostatic intervention based
on the clinical presentation, hemodynamic parameters
[11]
and need for blood products . An understanding of
the epidemiologic context of GIB in children holds the
promise of directing future research toward impro
ving predictive models of disease outcomes including
mortality.
The Pediatric Health Information System (PHIS)
database is a repository of diagnostic, therapeutic and
procedure records from 48 regional pediatric tertiary
centers in the United States that has been in existence
since 2004, the data is available in de-identified form
to health information management administrators and
academicians in the respective institutions.
Herein we report on the PHIS recorded demographic and clinical profile of children with upper or
indeterminate gastrointestinal bleeding at admission
or during their inpatient course and resulting in death.

only the mortalities in which GIB was the principal
diagnosis, 48% (12 of 25 principal diagnosis GIB
mortalities) died within the first 3 d of admission,
whereas 19.8% of secondary diagnosis GIB patients
died with 3 d of admission. Patients who died were
more likely to have received octreotide (19.8% c.f.
4.04%) but tended to have not received proton pump
inhibitor therapy in the first 48 h, and far less likely to
have undergone endoscopy during their admission (OR
= 0.489, P < 0.0001). Chronic liver disease associated
with a greater likelihood of endoscopy. Mortalities
were significantly more likely to have multiple complex
chronic conditions.
CONCLUSION
GIB associated mortality in children is highest within 7
d of admission. Multiple comorbidities are a risk factor
whereas early endoscopy during the admission is
protective.
Key words: Pediatrics; Gastrointestinal hemorrhage;
Endoscopy; Proton pump inhibitors; Mortality; Liver
disease; Hospital Information Systems; Octreotide
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: The management of gastrointestinal haem
orrhage in children is challenging insofar as the timing
and impact of different interventions remains poorly
defined. The authors analysed the characteristics and
associated interventions associated with mortality as
an outcome with gastrointestinial bleeding in children
past infancy. Death associated with gastrointestinal
haemorrhage was reported in 2% overall albeit less
(0.4%) in the cohort with haemorrhage as admitting
diagnosis. Patients who died were far less likely to have
undergone endoscopy during the admission and more
likely to have received octreotide and less likely to have
received proton pump inhibitor therapy during the first
two days of admission.
Attard TM, Miller M, Pant C, Kumar A, Thomson M.
mortality associated with gastrointestinal bleeding in children:
a retrospective cohort study. World J Gastroenterol 2017;
23(9): 1608-1617 Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i9/1608.htm DOI: http://dx.doi.
org/10.3748/wjg.v23.i9.1608

INTRODUCTION
Gastrointestinal bleeding (GIB) is a foremost indication for emergent diagnostic and therapeutic endoscopy requiring prompt, including disease-specific
[1,2]
pharmacotherapy . Although acute GIB in adults
has been exhaustively studied including epidemiology and predictors of adverse outcomes, there is a
[3,4]
paucity of the corresponding evidence in children .

WJG|www.wjgnet.com

MATERIALS AND METHODS
Data source

We conducted a retrospective cohort study using data
obtained from the PHIS, an administrative database
that contains inpatient, emergency department,
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ambulatory surgery and observation encounter-level
data from 49 not-for-profit, tertiary care pediatric hospitals in the United States. The PHIS hospitals are 49
of the largest and most advanced children’s hospitals
in America, and constitute the most demanding standards of pediatric service in America. These hospitals
are affiliated with the Children’s Hospital Association
(Overland Park, KS, United States). Data quality and
reliability are assured through a joint effort between
the Children’s Hospital Association and participating
hospitals. Portions of the data submission and data
quality processes for the PHIS database are managed
by Truven Health Analytics (Ann Arbor, MI, United
States). For the purposes of external benchmarking,
participating hospitals provide discharge/encounter
data including demographics, diagnoses, and procedures. Nearly all of these hospitals also submit
resource utilization data (e.g., pharmaceuticals, imaging, and laboratory) into PHIS. Data are de-identified at
the time of data submission, and data are subjected to
a number of reliability and validity checks before being
included in the database. For this study, data from 47
hospitals was included. This study was approved by
the Institutional Review Board (16050358).

Transaction Classification system for revenue codes.

Outcome measures

The primary outcome of interest in this study was
mortality. Secondary outcomes examined include
whether or not the patient underwent endoscopy.

Statistical analysis

Unadjusted, univariate analyses of the associations
between patient characteristics and treatment course
with mortality were carried out. Continuous variables
were summarized using the median and interquartile
ranges (IQR) and compared using the Wilcoxon ranksum test. Categorical variables were summarized using
counts and frequency as a percentage, and compared
2
using the χ test of association or Fisher’s exact test,
where appropriate. Complex chronic conditions were
treated categorically as the number of complex chronic
conditions present in a single patient. The levels
of the category were defined as 0 complex chronic
conditions, 1 or 2 complex chronic conditions, and
3 or more complex chronic conditions. These levels
were chosen after assessing the median and interquartile range of the distribution of number of CCCs.
Receipt of pharmaceuticals on the first or second day
of admission was coded as a dichotomous variable, as
was the receipt of packed red blood cell transfusions
and platelet transfusions. All procedures were coded
as 0 (procedure not billed) or 1 (procedure billed).
Unadjusted P-values were reported for the univariate
analysis.
Adjusted analysis of the association between
patient characteristics and treatment course with mortality were examined using multivariable generalized
linear mixed models to assess the odds of exposure
to treatment among mortality cases (binomial family,
logit link). A quasi-likelihood method was used to
estimate effects (Laplace approximation). All candidate
models were adjusted for potential confounding by
age in years at admission, race/ethnicity, and sex and
by the need for packed red blood cell transfusions as
a surrogate of severity of bleed. Chronic liver disease,
comorbid complex chronic conditions, and urban
vs rural zip code of residence at time of admission
were tested as covariates. Other covariates included
perforation type injury, administration of proton pump
inhibitor (PPI), H2RA, octreotide, and vasopressin pharmaceuticals on the first or second day of admission
and endoscopic procedures performed. Interactions
between vasopressin and shock, endoscopy and
chronic liver disease, and endoscopy and CCCs were
also tested to investigate potential effect modification.
To account for increased variability due to clustering
within hospitals, a random intercept was included using
a unique hospital ID. Model selection was carried out
2
using -2 log likelihood tests with the χ approximation.
Individual covariates were tested by approximation to
the Z-value. The Holm procedure was used to account

Study patients

Children between the ages of 1 and 21 years at the
time of admission were eligible for inclusion if they
were diagnosed with an upper gastrointestinal bleed
(UGIB) or GIB of indeterminate location and admitted
as an inpatient or under observation with Emergency
Department charges between January 1, 2007 and
September 30, 2015. Study participants with UGIB
were identified through International Classification of
Diseases, Ninth Revision (ICD-9) discharge diagnosis
codes (Supplementary Table 1).
Demographic characteristics included age in years
at time of admission, sex, race/ethnicity (non-Hispanic
White, non-Hispanic Black, Hispanic, Asian, Other,
Unknown), discharge disposition (routine/home,
expired and rural vs urban zip code of residence.
Complex chronic conditions (CCCs) were defined using
a previously described ICD-9 coding scheme for 9
types of CCCs (neuromuscular, cardiovascular, respiratory, renal, gastrointestinal, hematologic/immunologic,
metabolic, congenital or genetic, and malignancy),
as well as organ transplant patients and technology
[12]
dependent patients . A given patient could have
could have more than 1 CCC, and the total number
of CCCs for each patient was calculated. Chronic liver
disease was also identified by ICD-9 diagnosis codes,
and coded as a dichotomous variable. The need for
packed red blood cell transfusions was used to control
for severity of bleeding [0 = no transfusion, 1 =
transfusion(s) received].
Procedures were identified through ICD-9-CM codes
(Supplementary Table 2), and pharmaceuticals and
imaging procedures were identified through Clinical

WJG|www.wjgnet.com
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Table 1 Patient characteristics by principal and secondary diagnosis of gastrointestinal bleeding n (%)
Overall (n = 19528)

P value

9 (4, 15)

9 (4, 15)

< 0.0001
< 0.0001

2925 (43.44)
3808 (56.56)

5941 (46.43)
6854 (53.57)

8866 (45.40)
10762 (55.11)

3608 (53.59)
1180 (17.53)
1159 (17.21)
251 (3.73)
412 (6.12)
123 (1.83)

6596 (51.55)
2257 (17.64)
2580 (20.16)
332 (2.59)
779 (6.09)
251 (1.96)

10204 (52.25)
3437 (17.60)
3739 (19.15)
583 (2.99)
1191 (6.10)
374 (1.92)

5730 (85.10)
873 (12.97)
130 (1.93)

10930 (85.42)
1573 (12.29)
292 (2.28)

16660 (85.31)
2446 (12.53)
422 (2.16)

3767 (55.95)
1771 (26.30)
1195 (17.75)

5969 (46.65)
4328 (33.83)
2498 (19.52)

9736 (49.86)
6099 (31.23)
3693 (18.91)

2333 (34.65)
1983 (29.45)
52 (0.77)

4263 (33.32)
6018 (47.03)
90 (0.70)

6596 (33.78)
8001 (40.97)
142 (0.73)

0.0635
< 0.0001
0.5956

4473 (66.43)
1301 (19.32)
197 (2.93)
15 (0.22)
349 (5.18)

6038 (47.19)
2715 (21.22)
313 (2.45)
142 (1.11)
439 (3.43)

10511 (53.83)
4016 (20.57)
510 (2.61)
157 (0.80)
788 (4.04)

< 0.0001
0.0019
0.0511
< 0.0001
< 0.0001

497 (7.38)
425 (6.31)
44 (0.65)
75 (1.11)

378 (2.95)
1298 (10.14)
170 (1.33)
93 (0.73)

875 (4.48)
1723 (8.82)
214 (1.10)
168 (0.86)

< 0.0001
< 0.0001
< 0.0001
0.0070

23 (0.34)
2 (0.03)
54 (0.80)
2304 (34.22)
845 (12.55)
8 (0.12)
0 (0.0)
1 (0.01)
1265 (18.79)
194 (2.88)
880 (13.07)
171 (2.54)
4980 (73.96)
144 (2.14)
30 (0.45)
2 (1, 4)
1 (0, 2)
25 (0.37)

44 (0.34)
19 (0.15)
96 (0.75)
2317 (18.11)
845 (6.6)
8 (0.06)
5 (0.04)
5 (0.04)
2337 (18.26)
799 (6.24)
2328 (18.19)
400 (3.13)
8585 (67.10)
584 (4.56)
666 (5.21)
3 (2, 7)
2 (1, 3)
379 (2.96)

67 (0.34)
21 (0.11)
150 (0.77)
4621 (23.66)
1690 (8.65)
16 (0.08)
5 (0.03)
6 (0.03)
3602 (18.45)
993 (5.09)
3208 (16.43)
571 (2.92)
11084 (56.76%)
728 (3.73)
696 (3.56)
3 (1, 6)
1 (0, 2)
404 (2.07)

0.9999
0.0191
0.7303
< 0.0001
< 0.0001
0.1977
0.1719
0.6713
0.3808
< 0.0010
< 0.0001
0.0234
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

GI bleed
Age in years (IQR)
Gender
Female
Male
Race
Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Other
Unknown
Urban/rural
Urban
Rural
Unknown
Complex chronic conditions
0
1-2
≥3
GIH symptoms
Hematemesis
Melena
Hypovolemia
Pharmaceutical Interventions
PPI on day 0 or 1
H2RA on day 0 or 1
Erythromycin on day 0 or 1
Vasopressin on day 0 or 1
Octreotide on day 0 or 1
Diagnostic Imaging
Meckel's Scan day 0-2
Abdomen CT day 0-2
Abdomen MRI day 0-2
Arteriography day 0-2
Surgical interventions
Laparotomy, exploratory
Laparotomy, other
Laparoscopy
EGD
Other endoscopy
Transcatheter embolization
Ligation, esophag. varices
Ligation, gastric varices
Packed red blood cell transfusions
Platelet transfusions
ICU stay as part of encounter
Chronic liver disease
GIH present on admit
Shock
Sepsis
Hospital lOS (IQR)
Day of EGD
Mortality

Principal Dx (n = 6733)

Secondary Dx (n = 12795)

10 (4, 15)

< 0.0001

0.1247

< 0.0001

IQR: Interquartile ranges; GER: Gastroesophageal reflux; PPI: Proton pump inhibitor; H2RA: H2-receptor antagonists; CT: Computed tomography; MRI:
Magnetic resonance imaging; GIB: Gastrointestinal bleeding; EGD: Esophagogastroduodenoscopy.

for multiple testing of covariates for each outcome,
and the adjusted P-values are reported for the significance test of model covariates. An adjusted, two-tailed
P < 0.05 was considered statistically significant. All
analyses were performed using the R statistical package, v.3.2.3.

WJG|www.wjgnet.com

RESULTS
Descriptive statistics

There were 19528 patients with upper or indeterminate GIB discharged between January 1, 2007 and
September 30, 2015 (Table 1). Overall, 54.6% of
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Multivariable analysis

patients were male, and the median age was 9 years
(IQR 4-15). Nearly half (49.68%) of the patients had
no documented CCCs, 30.32% had 1 or 2 CCCs, and
20.01% had 3 or more CCCs. The most common CCC
was gastrointestinal conditions (28.22%), followed
[12,13]
by technology dependence
(20.24%) and neurologic and neuromuscular disorders (13.90%). Of the
patients included in the analysis, 33.78% experienced
hematemesis, 40.97% melena, 12.18% had gastroesophageal reflux (GER), 3.73% experienced shock,
3.56% experienced sepsis, and 18.45% required
packed red blood cell transfusion while 5.09% required
a platelet transfusion. Most patients resided in an
urban area (85.31%), although a small portion of the
data was missing (2.16%).
Overall mortality rate was 2.07% with 0.37% mortality among patients with principal diagnosis of GIB
and 2.96% among patients with secondary diagnosis
of GIB. The median time until death was 19 d (5, 49).
For all patients, 21.53% of deaths occurred within the
first 3 d of admission, and 31.9% occurred within 7 d
of admission. When considering only the mortalities
in which GIB was the principal diagnosis, 48% (12
of 25 principal diagnosis GIB mortalities) died within
the first 3 d of admission, and 64% expired within 7
d of admission. Among secondary diagnosis patients,
19.8% died with 3 d of admission, and 29.8% died
within 7 d of admission. Although the majority of
patients were male, females and males had similar
mortality rates (50% of mortalities were male). There
were apparent racial/ethnic distributional differences,
with non-Hispanic Whites being the only group that
comprised a smaller proportion of the mortalities than
the surviving cases.
Early intervention with pharmaceuticals was more
frequent among mortality cases (Table 2). Receipt of
PPI on the first or second day of admission occurred in
53.83% of patients, with higher usage among mortalities (68.56% vs 53.31%). H2RA were administered
on the first or second day of admission in 20.57%
of patients, with higher usage in mortality than nonmortality cases (37.62% vs 20.20%). Octreotide was
only used in 4.04% of patients; 19.80% of patients
who died received octreotide on the first or second
day of admission, and 3.70% surviving cases received
octreotide. Vasopressin was only given to 0.80% of
patients; 24.50% of the mortality cases and 0.30%
of surviving cases received vasopressin on the first or
second day of admission.
Table 3 displays the top admitting diagnosis codes
for mortalities and non-mortalities. Mortalities included
several diagnosis codes not related to GI symptoms,
including dyspnea and respiratory abnormalities,
cardiac arrest, pneumonia, diseases of white blood
cells, and respiratory failure. Non-mortalities more
frequently carried GI-specific admitting diagnoses.

WJG|www.wjgnet.com

Factors associated with mortality in all GIB
diagnoses: After adjustment for other covariates,
race was not significantly associated with mortality in
patients with a primary diagnosis of UGIB or unspecified GIB (adjusted P = 0.999). Although the majority
of patients were male, mortality tended to be higher
in females; however, gender was not significantly
associated with mortality (adjusted P = 0.339). Age
was also not significantly associated with mortality
(adjusted P = 0.999). These covariates were retained
in the model for their role as potential confounders.
Urban vs rural zip code of residence, H2RA within the
first or second day of admission, and the interaction
between endoscopy and chronic liver disease were not
statistically significant and did not improve fit, thus
2
were removed from the model [χ (4) = 4.505, P =
0.342]. Furthermore, chronic liver disease, and the
interaction between endoscopy and CCCs were not
significant and did not significantly improve model fit
2
and were also removed from the final model [χ (3) =
4.612, P = 0.203]. Although PPI on the first or second
day of the encounter was not significant after correcting for multiple testing, the inclusion of this variable
2
significantly improved model fit [χ (1) = 5.451, P =
0.020].
Those patients who died were far less likely to
have undergone an endoscopic procedure (OR =
0.489, 95%CI: 0.356-0.672, P < 0.0001), indicating a
protective association with endoscopy. Mortalities were
also less likely to have a GIB documented as present
on admission (OR = 0.464, 95%CI: 0.362-0.596, P
< 0.0001), and less likely to have had the GIB as the
principal diagnosis for the encounter (OR = 0.266
95%CI: 0.165-0.429, P < 0.0001). This may suggest
that GIB more commonly complicates inpatient stays
for patients admitted or being primarily treated for
other conditions. PPI administration on the first or
second day of admission tended to be protective;
however, the effect was not statistically significant after
correction for multiple testing (OR = 0.723, 95%CI:
0.552-0.947, P = 0.074).
The odds of having 1 or 2 CCCs compared to 0
CCCs were 9.090 times higher for mortalities over
non-mortalities (95%CI: 4.907-16.841, P < 0.0001),
and the odds of having 3 or more CCCs compared
to 0 CCCs was 27.338 (95%CI: 14.940-50.027, P <
0.0001) times higher for mortalities over non-mortalities. Mortalities have significantly increased odds
of having multiple complex chronic conditions. Table
4 differentiates the presence of concomitant CCC in
patients with GIB as principal as opposed to secondary
diagnosis whereas Table 5 summarizes the distribution
of CCCs between mortality and non-mortality patients.
Mortalities had significantly higher odds of perforation as well (OR = 5.505, 95%CI: 1.717-17.650, P =
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Table 2 Univariate analysis of factors affecting mortality n (%)

Age in years (IQR)
Gender
Female
Male
Race
Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Other
Unknown
Urban/rural
Urban
Rural
Unknown
Complex chronic conditions
0
1-2
≥3
GIH symptoms
Hematemesis
Melena
Hypovolemia
GER
Pharmaceutical interventions
PPI first 24 h
H2RA first 24 h
Erythromycin first 24 h
Vasopressin first 24 h
Octreotide first 24 h
Surgical interventions
Laparotomy, exploratory
Laparotomy, other
Laparoscopy
EGD
Other endoscopy
Transcatheter embolization
Ligation, esophag. varices
Ligation, gastric varices
Diagnostic imaging
Meckel's Scan day 0-2
Abdomen CT day 0-2
Abdomen MRI day 0-2
Arteriography day 0-2
Packed red blood cell Transfusion
Platelet transfusion
ICU stay as part of encounter
Chronic liver disease
GIB Present on admit
Principal Dx GIB
Sepsis
Shock
Hospital LOS (IQR)
Day of EGD

Survived (n = 19124)

Died (n = 404)

Overall (n = 19528)

9 (4, 15)

8 (3, 15)

9 (4, 15)

P value

8864 (46.35)
10460 (54.70)

202 (50)
202 (50)

9066 (46.43)
10662 (54.60)

10036 (52.48)
3358 (17.56)
3646 (19.07)
565 (2.95)
1156 (6.04)
363 (1.90)

168 (41.58)
79 (19.55)
93 (23.02)
18 (4.46)
35 (8.66)
11 (2.72)

10204 (52.25)
3437 (17.60)
3739 (19.15)
583 (2.99)
1191 (6.10)
374 (1.92)

16324 (85.36)
2385 (12.47)
415 (2.17)

336 (83.17)
61 (15.10)
7 (1.73)

16660 (85.31)
2446 (12.53)
422 (2.16)

9689 (50.66)
5825 (30.46)
3610 (18.88)

12 (2.97)
95 (23.51)
297 (73.51)

9701 (49.68)
5920 (30.32)
3907 (20.01)

6508 (34.03)
7899 (41.30)
131 (0.69)
2329 (12.18)

88 (21.78)
102 (25.25)
11 (2.72)
50 (12.38)

6596 (33.78)
8001 (40.97)
142 (0.73)
2379 (12.18)

< 0.0001
< 0.0001
0.0002
0.9653

10234 (53.51)
3864 (20.20)
480 (2.51)
58 (0.30)
708 (3.70)

277 (68.56)
152 (37.62)
30 (7.43)
99 (24.50)
80 (19.80)

10511 (53.83)
4016 (20.57)
510 (2.61)
157 (0.80)
788 (4.04)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

54 (0.28)
16 (0.08)
144 (0.75)
4569 (23.89)
1638 (8.57)
14 (0.07)
4 (0.02%)
6 (0.03)

13 (3.22)
5 (1.24)
6 (1.49)
52 (12.87)
52 (12.87)
2 (0.50)
1 (0.25%)
0 (0.00)

67 (0.34)
21 (0.11)
150 (0.77)
4621 (23.66)
1690 (8.65)
16 (0.08)
5 (0.03)
6 (0.03)

< 0.0001
< 0.0001
0.1347
< 0.0001
0.0031
0.0423
0.0993
0.9999

873 (4.56)
1675 (8.76)
212 (1.11)
163 (0.85)
3361 (17.57)
819 (4.28)
2863 (14.97)
536 (2.80)
13386 (70.00)
6708 (35.07)
516 (2.70)
562 (2.94)
3 (1, 6)
1 (0, 2)

2 (0.50)
48 (11.88)
2 (0.50)
5 (1.24)
241 (59.65)
174 (43.07)
345 (85.40)
35 (8.66)
179 (44.31)
25 (6.18)
180 (44.55)
166 (41.09)
19 (5, 49)
3 (1, 14)

875 (4.48)
1723 (8.82)
214 (1.10)
168 (0.86)
3602 (18.45)
993 (5.09)
3208 (16.43)
571 (2.92)
11084 (56.76)
6733 (34.48)
696 (3.56)
728 (3.73)
3 (1, 6)
1 (0, 2)

0.0001
0.0356
0.3340
0.4031
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

0.2997
0.0679

0.0005

0.2524

< 0.0001

IQR: Interquartile ranges; GER: Gastroesophageal reflux; PPI: Proton pump inhibitors; H2RA: H2-receptor antagonists; CT: Computed tomography; MRI:
Magnetic resonance imaging; GIB: Gastrointestinal bleeding; EGD: Esophagogastroduodenoscopy.

0.021). There was a significant association between
mortality and diagnosis of sepsis during the encounter
and mortality (OR = 2.583, 95%CI: 1.823-3.659, P <
0.0001). Mortalities had substantially higher odds of
shock (OR = 3.585, 95%CI: 2.489-5.163, P < 0.0001),
but this effect was modified by vasopressin. Mortalities

WJG|www.wjgnet.com

had 4.834 times the odds of experiencing shock and
receiving vasopressin compared to shock alone over
non-mortalities (95%CI: 2.729-8.562, P < 0.0001).
Vasopressin is primarily used to treat shock in critically
[3]
ill children . Higher mortality in patients receiving
vasopressin and shock does not necessarily represent
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Table 3 Top 10 admitting diagnoses for mortalities and non-mortalities
ICD-9 code description

n (%)

Fever
Other dyspnea and respiratory abnormality
Vomiting alone
Unspecified septicemia
Hematemesis
Cardiac arrest
Hemorrhage of GI tract, unspecified
Pneumonia, organism unspecified
Diseases of white blood cells
Acute respiratory failure

32 (7.92)
23 (5.69)
15 (3.71)
14 (3.47)
13 (3.22)
13 (3.22)
12 (2.97)
11 (2.72)
10 (2.48)
10 (2.48)

Hematemesis
Blood in Stool
Hemorrhage of GI tract, unspecified
Other symptoms involving abdomen and pelvis
Vomiting alone
Not available or Missing
Fever
Dehydration
Diarrhea
Anemia

3058 (15.99)
2750 (14.38)
1289 (6.74)
755 (3.95)
748 (3.91)
707 (3.70)
559 (2.92)
515 (2.69)
500 (2.61)
292 (1.53)

ICD-9 code
Mortalities
780.60
786.09
787.03
03.89
578.0
427.5
578.9
486.0
288.00
518.81
Non-mortalities
578.0
578.1
578.9
789.00
787.03
N/A
780.60
276.51
787.91
2859

GI: Gastrointestinal; ICD-9: International Classification of Diseases, Ninth Revision.

Table 4 Complex chronic conditions by principal and secondary diagnosis of gastrointestinal bleeding n (%)

GI flag
Cardiovascular flag
Hem/immunologic flag
Malignancy
Metabolic flag
Neurologic/neuromusc flag
Congenital/genetic flag
Renal/urologic flag
Respiratory flag
Technology depend flag
Transplant flag

Principal Dx is GI bleed (n = 4521)

Secondary Dx is GI bleed (n = 15007)

P value

1681 (24.39)
513 (7.44)
422 (6.12)
284 (4.12)
258 (3.74)
972 (14.1)
727 (10.55)
249 (3.61)
244 (3.54)
1353 (19.63)
318 (4.61)

3892 (15.39)
1192 (4.71)
1392 (5.5)
1015 (4.01)
1015 (4.01)
1743 (6.89)
1192 (4.71)
811 (3.21)
601 (2.38)
2599 (10.28)
578 (2.29)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.1234
0.0010
< 0.0001
0.0005
0.7331
0.5374

GI: gastrointestinal.

Table 5 Complex chronic conditions by discharge disposition n (%)

gastrointestinal flag
Cardiovascular flag
Hem/immunologic flag
Malignancy
Metabolic flag
Neurologic/neuromusc flag
Congenital/genetic flag
Renal/urologic flag
Respiratory flag
Technology depend. flag
Transplant flag

Survived (n = 19124)

Died (n = 404)

P value

5351 (27.98)
1543 (8.07)
1662 (8.69)
1164 (6.09)
1138 (5.95)
2570 (13.44)
1838 (9.61)
927 (4.85)
780 (4.08)
3710 (19.40)
802 (4.19)

159 (39.36)
162 (40.10)
152 (37.62)
135 (33.42)
135 (33.42)
145 (35.89)
81 (20.05)
133 (32.92)
65 (16.09)
242 (59.90)
94 (23.27)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

a causal chain - it may merely be highlighting the pattern that severe cases of shock were more frequently
given vasopressin. The strength of the association is
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striking and the administration of vasopressin in shock
cases did not associate with significantly improved
outcomes. The effect of vasopressin on GI bleeds
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and shock warrants further investigation in pediatric
patients.
Receiving octreotide or vasopressin was significantly
associated with having a portal hypertension diagnosis
2
[χ (1) = 3261.5, p < 0.0001], and with having varices
2
with bleeding [χ (1) = 2477.2, p < 0.0001]. Receiving
octreotide within the first 24 h was associated with
a 2.934 fold increase in odds of death (OR = 2.936,
95%CI: 1.981-4.351, P < 0.0001). This is more likely
an indicator of severity of illness and early treatment
as more severe patients who would eventually expire
received more aggressive treatment.

= 2.040, 95%CI: 1.197-3.477, P = 0.044). Mortalities
had substantially higher odds of shock (OR = 5.426,
95%CI: 3.212-9.168, P < 0.0001) but this effect was
modified by vasopressin, with a stronger association
marked in the smaller cohort. Mortalities had 12.090
times the odds of experiencing shock and receiving
vasopressin compared to shock alone over nonmortalities (95%CI: 5.327-27.442, P < 0.001).
Factors associating with endoscopy: In a separate
model, we examined the association between various patient characteristics and whether or not the
patient underwent endoscopy. A total of 5939 patients
received endoscopy. Supplementary Table 2 stratifies
therapeutic endoscopy type. The vast majority of
endoscopic procedures were esophagogastroduodenoscopy. We adjusted the model for those factors
relating to mortality and severity (shock, sepsis,
packed red blood cell transfusion, GIB diagnosis
present on admit, and GIB diagnosis as principal
diagnosis). We found that those patients with chronic
liver conditions were more likely to undergo endoscopy
(OR = 2.378, 95%CI: 1.970-2.869, P < 0.0001),
which may explain partially why this factor was not
found significant in the mortality model. If endoscopy
is protective and patients with chronic liver disease are
more likely to undergo endoscopy, it stands to reason
that they will then be less likely to die. We also found
that living in a rural area was positively associated with
endoscopy compared to living in an urban area (OR =
1.196, 95%CI: 1.076-1.329, P = 0.007). Compared
to non-Hispanic white patients, Hispanics were 18.5%
less likely to have undergone an endoscopic procedure
(OR = 0.815, 95%CI: 0.737-0.900, P = 0.001). Age
was also significantly associated with endoscopy, with
a 6.39% increase in odds for every additional year (OR
= 1.064, 95%CI: 1.058-1.070, P < 0.0001). Patients
with 1 or 2 CCCs did not have increased odds of
endoscopy (P = 0.999), but those with 3 or more had
a 24.53% reduction in the odds of endoscopy (OR =
0.755, 95%CI: 0.686-0.830, P < 0.0001). Perforation
injuries were also far less likely to undergo endoscopy
(OR = 0.169, 95%CI: 0.116-0.247). GIBs as the
principal diagnosis were associated with higher odds
of endoscopy (OR = 2.626, 95%CI: 2.448-2.817, P <
0.0001). Those who underwent endoscopy were more
likely to have experienced shock (OR = 1.752, 95%CI:
1.409-2.179, P < 0.0001), but less likely to have
become septic (OR = 0.473, 95%CI: 0.370-0.604, P <
0.0001).

Factors affecting mortality in GIB as principal,
admitting or present on admit: As a sensitivity
analysis, we isolated only those patients whose
principal diagnosis was a GIB, or the GIB was present
on admit or the admitting diagnosis to see if the trends
observed associations pertained to a more refined
group of GIB patients (n = 15539, 185 mortalities).
After applying the model-fitting procedure, the final
model yielded results similar to those observed for
the full cohort of GIB patients in PHIS, with most of
the associations being strengthened (the exception
being CCCs), suggesting the secondary GIB may
have biased estimates toward the null Age, race, and
gender were not statistically significantly associated
with mortality when controlling for other covariates (P
= 0.999, P = 0.999, P = 0.937, respectively). Again,
residing in an urban area, administration of H2RA on
day 0 or 1, chronic liver disease, and the interaction
between endoscopy and chronic liver disease were not
2
significant and did not improve model fit [χ (5) = 4.527,
P = 0.476]. Perforation-type injury and GIB present
on admission were not significant and subsequently
2
removed from the final model [χ (2) = 3.644, P =
0.162].
In this smaller cohort, patients who died were even
less likely to have undergone an endoscopic procedure
(OR = 0.327, 95%CI: 0.202-0.539, P < 0.0001).
Mortalities had marginally lower odds of receipt of
a PPI on the first or second day of admission (OR =
0.613, 95%CI: 0.417, 0.902, P = 0.051). Receiving
octreotide on the first or second day of admission was
associated with an increase in odds of death (OR =
2.219, 95%CI: 1.286-3.831, P = 0.025).
The strength of the association with CCCs was
not quite as pronounced in the smaller cohort. The
odds of having 1 or 2 CCCs compared to 0 CCCs were
8.710 times higher for mortalities over non-mortalities
(95%CI: 3.861-19.651, P < 0.0001), and the odds
of having 3 or more CCCs compared to 0 CCCs was
24.098 (95%CI: 10.778-53.884, P < 0.0001) times
higher for mortalities over non-mortalities. Mortalities
have significantly increased odds of having multiple
complex chronic conditions in the smaller cohort, but
the associations are less strong.
There was a significant association between mortality and diagnosis of sepsis during the encounter (OR
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DISCUSSION
This is the first study describing the demographic and
clinical characteristics of pediatric patients with GI
hemorrhage in tertiary referral pediatric centers. In our
cohort more than 75% of patients with GIB presented
with hematemesis or blood in the stool. Mortality at,
or before 3 d was more likely in patients with GIB as
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a primary diagnosis, and in this subgroup mortality
was highest in the first 7 d of admission. The mortality in patients with a principal diagnosis of GIB was
0.37% whereas the mortality in patients with GIB as
a secondary diagnosis was 2.96% signalling that GIB
can be a terminal event in children with other severe
disease processes.
We also found that in pediatric patients, race,
gender, and age were not significantly associated with
mortality. Death was most strongly associated with
shock, sepsis, multiple complex chronic conditions
and use of vasopressin and octreotide, although these
pharmaceutical treatments may represent aggressive
treatment of haemorrhage (octreotide) or hemodynamic support (vasopressin) for severely ill patients.
Our observations in children are analogous to published studies in adults showing mortality to be many
times higher for upper GIB complicating the inpatient
[14]
course in the presence of comorbidities . In our
cohort, we could not determine whether the increased
mortality in patients with multiple chronic comorbidities was related to the GIB event or was intrinsic to the
medical frailty of these patients. However, we observed
the association to be consistent between both patients
with any diagnosis of GIB as well as the more focused
group with primary GIB diagnosis. GIB patients with
multiple chronic illnesses are at incremental risk, and
mortality in patients with primary GIB is significantly
associated, albeit less robustly, with multiple complex
chronic conditions than children with a secondary diagnosis. More specifically, our observations support the
validity of the Sheffield Scoring System which identifies
significant pre-existing condition as an independent
[11]
determinant of the need for therapeutic endoscopy .
The observed increased mortality associated with
GIB with chronic comorbidities and infection can be
explained through several mechanisms. For example,
the strong relationship between sepsis and mortality
with GIB may relate to the development of disseminated intravascular coagulation that would exacerbate
bleeding. Conversely septicemia may be a terminal
complication in a child with multi-organ injury from
bleeding-hypovolemic shock. Similarly oncologic com
orbidities signal a greater degree of overall debility
as a function of immunosuppression, impaired fluid
and electrolyte balance, poor nutrition, suppressed
erythropoiesis and several potential iatrogenic factors
impacting homeostatic responses.
We could not, in this analysis, confirm a relationship between GIB related admission mortality and
distance travelled to care as defined by rural compared
with urban address; a significant relationship was
noted when analysis was performed looking at all GIB
associated mortality, this was not borne out when the
cohort was defined by admitting or principal diagnosis.
Endoscopy was associated with lower mortality, as
was the administration of a PPI on the first or second
day of admission. Mortality was also lower for patients
with GIB that was present on admission or the
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principal diagnosis, supporting the impression that GIB
can be viewed as an ominous complication defining a
generally more dismal outcome in children.
We did find that certain patients were more likely
to undergo endoscopy. Endoscopy during admission
with GIB diagnosis was significantly protective (OR =
0.49); the effect was most pronounced in children with
a principal diagnosis of GIB (OR = 0.28). Chronic liver
disease patients were much more likely to undergo
endoscopy, which may explain why this comorbidity, in
turn, was not found to be significantly associated with
mortality although it is a known risk factor. Racial and
urban vs rural differences were also noted. Hispanics
were significantly less likely to undergo endoscopy
during admission with GIB and mortality with GIB is
lowest in non-Hispanic white children.
The sensitivity analysis yielded similar results
when we focused on a smaller cohort of patients with
principal diagnosis of GIB, admitting diagnosis of GIB,
or GIB present on admit. The purpose of examining
the smaller cohort was to exclude as much as possible
those secondary GIB cases that arose as complication
of a non-GIB disease course. We found even stronger
association for most of the covariates, suggesting
possible masking and bias toward the null by including
more complex and severely ill patients whose hospital
stay was not chiefly attributed to a GIB.
As a retrospective observational study using
primarily administrative billing data, there are several
limitations to the study. The use of ICD-9 diagnosis
codes has been shown to be sensitive and specific for
some conditions and procedures including gastroin[15]
testinal hemorrhage
but are unknown for all ICD-9
codes. Coding practices may also vary within hospitals,
and the reliability of these codes depends on proper
documentation. Substantial risk factors or severity
factors may be missing from the data.
In summary, we have reported on the mortality
associated with admission for acute GI hemorrhage in
children. Gastrointestinal hemorrhage can be fatal but
more often defines deterioration in a child with other,
especially multiple, comorbidities. Intense pharmacologic support associates with mortality underscoring
the escalation of therapy with increased clinical compromise. Endoscopy was consistently protective from
mortality, and the timing, scope and therapeutic goals
of endoscopy in GI hemorrhage are still to be precisely
defined and universally applied in children. Emerging
scoring systems and prospective implementation of
such may go some way to identifying and stratifying
the protective effects of endoscopy in children. This
study offers new impetus to aggressive, including
endoscopic, management.
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Abstract
AIM
To quantify drug-drug-interactions (DDIs) encountered
in patients prescribed hepatitis C virus (HCV) treatment,
the interventions made, and the time spent in this
process.
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METHODS
As standard of care, a clinical pharmacist screened for
DDIs in patients prescribed direct acting antiviral (DAA)
HCV treatment between November 2013 and July 2015
at the University of Colorado Hepatology Clinic. HCV
regimens prescribed included ledipasvir/sofosbuvir
(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir
(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF),
and sofosbuvir/ribavirin (SOF/RBV). This retrospective
analysis reviewed the work completed by the clinical
pharmacist in order to measure the aims identified
for the study. The number and type of DDIs identified
were summarized with descriptive statistics.

medication adjustments and increased monitoring.
An interdisciplinary care team including a clinical phar
macist is critical to optimize patient care for new HCV
therapies.
Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ.
Optimizing hepatitis C virus treatment through pharmacist
interventions: Identification and management of drug-drug
interactions. World J Gastroenterol 2017; 23(9): 1618-1626
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i9/1618.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i9.1618

RESULTS
Six hundred and sixty four patients (83.4% Caucasian,
57% male, average 56.7 years old) were identified; 369
for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/
SOF, and 133 for SOF/RBV. Fifty-one point five per cent
of patients were cirrhotic. Overall, 5217 medications
were reviewed (7.86 medications per patient) and
781 interactions identified (1.18 interactions per
patient). The number of interactions were fewest
for SOF/RBV (0.17 interactions per patient) and
highest for OBV/PTV/r + DSV (2.48 interactions per
patient). LDV/SOF and SIM/SOF had similar number
of interactions (1.28 and 1.48 interactions per patient,
respectively). Gastric acid modifiers and vitamin/
herbal supplements commonly caused interactions
with LDV/SOF. Hypertensive agents, analgesics, and
psychiatric medications frequently caused interactions
with OBV/PTV/r + DSV and SIM/SOF. To manage these
interactions, the pharmacists most often recommended
discontinuing the medication (28.9%), increasing
monitoring for toxicities (24.1%), or separating
administration times (18.2%). The pharmacist chart
review for each patient usually took approximately 30
min, with additional time for more complex patients.

INTRODUCTION
Approximately 4.6 million Americans are estimated
to have been exposed to the hepatitis C virus (HCV),
[1]
and 3.5 million of those have active chronic infection .
The “baby boomer” generation (persons born between
1945 and 1965) have the highest incidence of chronic
[2]
HCV infection vs any other age group . Fifteen to
twenty percent of people infected with chronic HCV
progress to liver cirrhosis within twenty years, which
may lead to end-stage liver disease or hepatocellular
[3]
carcinoma . In the United States, at least 35% of
patients on the liver transplant wait list have chronic
[4]
HCV . HCV-associated mortality is close to 500000
[5]
deaths per year world-wide . The previous standard
of care, treatment with peginterferon and ribavirin,
had significant challenges to treatment including
serious adverse events, non-oral administration, and
low efficacy rates. Direct-acting antivirals (DAAs) have
improved the treatment landscape through increased
efficacy, improved safety and tolerability, and all-oral
administration. However, drug-drug interactions (DDIs)
are a significant challenge and managing the interac[6]
tions can be complex and time-consuming .
Pharmacists are recognized as important members
of the health care team. Pharmacists’ involvement in
anticoagulation services, human immunodeficiency
virus (HIV) care, cystic fibrosis, and diabetes has been
shown to increase adherence, reduce pill burden and
dosing frequency, and decrease medication-related
[7-19]
errors
. The role of pharmacists in improving
medical care and managing adverse effects in HCV
treatment is well-recognized, but the impact of pharmacy interventions on therapeutic outcomes has not
[20-24]
been adequately assessed in patients with HCV
.
Furthermore, there is a lack of evidence for managing
real-world DDIs for HCV treatments, especially with
oral DAAs.
The University of Colorado Hospital Outpatient
Hepatology Clinic has a clinical pharmacist imbedded
within the interdisciplinary care team. The hepatologist
first assesses a patient with chronic HCV infection,
determining the stage of liver fibrosis, diagnosing
advanced liver disease or cirrhosis, investigating any

CONCLUSION
DDIs are common with HCV medications and manage
ment can require medication adjustments and increased
monitoring. An interdisciplinary team including a clinical
pharmacist can optimize patient care.
Key words: Clinical pharmacist; Drug-drug interaction;
Hepatitis C virus treatment
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Identification and management of poten
tial drug-drug interactions (DDI) is a critical aspect
of current hepatitis C virus (HCV) treatment. This
retrospective analysis of patients prescribed common
HCV treatments identifies DDIs and the inter
ventions made by the clinical pharmacist, as well as
the approximate time required to complete these
activities. This novel review illustrates that DDIs are
common in this population. Identification and manage
ment of DDIs is resource intensive and requires
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disease complications, ordering all relevant baseline
labs, and prescribing HCV treatment. The clinical
pharmacist then reviews each patient prescribed
HCV treatment to ensure correct dosing and dose
adjustments as needed based on hepatic and renal
function, to minimize therapeutic duplication, and to
identify and manage DDIs. Each HCV medication has
specific interactions with cytochrome P450 enzymes
as well as transporters; and these medications can
act as both victims and perpetrators in a number
of DDIs. Potential DDIs are assessed using various resources including co-administration studies,
medication package inserts, medication databases,
and online tools such as www.hep-druginteractions.
org. In situations where co-administration has not
been studied, the pharmacology of each medication
was reviewed to determine the potential for DDIs.
Unfortunately, many herbal supplements lack data on
pharmacokinetics and drug-drug interaction potential.
If an herbal supplement did not have adequate data
to ensure safe coadministration, the recommendation
was often made to discontinue during HCV treatment.
When managing DDIs, patient-specific factors such
as vital signs, laboratory values, and concurrent use
of other medications were accounted for. The clinical
pharmacist coordinates with the internal medication
access team to gain approval of the medication
through the patient’s prescription insurance plan or
patient assistance programs. Once the patient is able
to obtain medication, he or she meets with a physician
assistant and the clinical pharmacist for a “medication
start visit”. During this visit, the specifics of treatment
are reviewed, including the medication, dosing,
administration, duration of treatment, potential side
effects, and monitoring schedule. Clinically significant
DDIs are reviewed with the patient and managed
appropriately. The patient is then assessed through
treatment by the physician assistant in conjunction
with the clinical pharmacist.
Within the context of the role of the clinical
pharmacist on the interdisciplinary team, the purpose
of this study was to quantify (1) the type of DDI
commonly encountered in patients prescribed HCV
treatment in an academic outpatient hepatology clinic;
(2) the interventions made; and (3) the time spent in
identification and management of DDIs.

and sofosbuvir/ribavirin (SOF/RBV). Ribavirin may or
may not have been used with the first three regimens.
Patients were excluded from the study if they were
coinfected with HIV or were post-liver transplant.
Demographic data including age, body mass
index (BMI), and self-identified gender, race, and
ethnicity were collected using the electronic medical
record. HCV genotype and stage of liver fibrosis
were recorded. Patients were classified as minimal to
moderate fibrosis (Stage 0-2), advanced fibrosis (Stage
3), and cirrhosis (Stage 4) including both compensated
[25]
and decompensated . Baseline medications for
each patient were collected, including prescription
medication, over-the-counter medication, and vitamin
and herbal supplements. Combination products such
as multivitamins, vitamin-mineral supplements, and
vitamin-mineral-herbal supplements were classified
as one product. The number, type, and recommended
management of DDIs were recorded for each patient.
Baseline medications that were involved with DDIs
were classified into nine categories. These categories
include analgesics, hypertension/heart failure agents,
anticonvulsants, psychiatric agents, proton pump
inhibitors (PPIs)/H2-receptor antagonists (H2RA),
antacids, steroids, vitamin and herbal supplements,
and others. The number and type of interactions were
summarized with descriptive statistics, due to the
heterogeneous nature of the retrospective study.
Management of interactions was classified as: (1)
discontinue medication; (2) increase monitoring; (3)
alter administration time; (4) separate administration;
(5) decrease dose; and (6) continue. The approximate
time required for the identification, assessment,
and management for clinical pharmacist review was
recorded.

RESULTS
664 patients fit the inclusion and exclusion criteria: 369
with LDV/SOF, 48 with OBV/PTV/r + DSV, 114 with
SIM/SOF, and 133 with SOF/RBV. Patients were 57%
male and averaged 56.7 years old. 83.4% of patients
identified as Caucasian, 6.44% as Black or African
American, 1.89% as Asian, 0.30% American Indian
or Alaska Native, and 7.97% as other or unavailable.
87% identified as Non-Hispanic and 13% Hispanic.
The majority (51.5%) of the patients in the study were
cirrhotic. See Table 1 for full demographic information.
Overall, 5217 medications were reviewed (7.86
medications per patient) and 781 interactions identified
(1.18 interactions per patient) (Table 2). The average
number of medications for each regimen was similar
and ranged from 6.50 (OBV/PTV/r + DSV) to 8.79
(SIM/SOF). The average number of DDIs was lowest
for SOF/RBV with 0.17, then 1.28 and 1.48 for LDV/
SOF and SIM/SOF, respectively. OBV/PTV/r + DSV had
the most DDIs per patient with 2.48. When accounting
for stage of liver disease, the number of medications

MATERIALS AND METHODS
This retrospective review identified all patients with
chronic HCV infection who were prescribed HCV
treatment at the University of Colorado Outpatient
Hepatology Clinic between November 2013 and July
2015. Patients were included regardless of their HCV
genotype and stage of liver fibrosis. DAAs prescribed
during the time period included ledipasvir/sofosbuvir
(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir
(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF),
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patient prescribed LDV/SOF was explicitly asked if
they were taking any prescription or non-prescription
medications for heartburn or gastric esophagitis reflux
diseas, or any other type of antacids and PPI/H2RA
agents. Another challenging aspect is that PPIs are
recommended for patients post banding ligation, a
comorbidity common in patients with advanced liver
disease. In order to manage the DDIs with PPI/H2RA
agents, 54.2% were on the appropriate dose but
were required to alter administration time; 40.2%
were required to both decrease dose and alter
administration time (40.2%). Supplements such as
milk thistle, cod liver, krill oil, garlic cap, turmeric,
and saw palmetto were recommended to be put on
hold (70.4%) or separated from LDV/SOF (28.3%)
administration time. Although there were few interactions with anticonvulsants (5/472, 0.85%), each
occurrence was associated with a contraindication
with LDV/SOF. For patients taking carbamazepine,
oxcarbazepine, phenobarbital, and phenytoin, the
recommendation was made to transition to an
alternative anticonvulsant prior to initiation of HCV
treatment.

Table 1 Baseline characteristics
Number of patients
Age (mean, yr)
Gender
Female
Male
Race
Caucasian
African American or Black
Asian American
American Indian or Alaska Native
Other and unavailable
Ethnicity
Hispanic
Non-Hispanic
Number of patients on DAAs
LDV/SOF
OBV/PTV/r + DSV
SIM/SOF
SOF/RBV
Fibrosis stage
≤ Stage 2 (minimal to moderate fibrosis)
Stage 3 (advanced fibrosis)
Stage 4 (cirrhosis)
Unknown or unavailable

664
56.7%
42.8%
57.2%
83.4%
6.44%
1.89%
0.30%
7.97%
13.6%
86.4%
369%
48%
114%
133%
35.8%
10.8%
51.5%
1.90%

LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir;
DSV: Dasabuvir; SIM: Simeprevir; RBV: Ribavirin; DAA: Direct acting
antiviral.

OBV/PTV/r + DSV

Analgesics (22/119, 18.5%), vitamins and herbal
supplements (21/119, 17.6%), and hypertensive
agents (19/119, 16.0%) frequently interact with
OBV/PTV/r + DSV. Managing interactions with
analgesics such as morphine, oxycodone, tramadol,
and hydrocodone, can be complicated due to the
variability in dosing, patient response, and opioid tolerance. In order to manage the DDIs with analgesics,
the dose was most often reduced and monitoring
increased (81.8%). Supplements were recommended
to be discontinued during HCV therapy (57.1%), separated by at least four hours (28.6%), or increased
monitoring for adverse events (14.3%). Hypertensive
agents including furosemide and amlodipine can
have a greater affect due to the DDI with OBV/PTV/r
+ DSV. Depending on the dose of the hypertensive
medications and the patient’s blood pressure, the
medications were continued at the same dose with
increased monitoring for hypotension (7/19, 36.8%)
or to decrease the dose (12/19, 63.2%) in anticipation for increased plasma concentration levels of the
hypertensive agents. Other medication classes that
interacted were erectile dysfunction agents (tadalafil),
lipid lowering agents (pravastatin, rosuvastatin),
allergy symptom medications (cetirizine), and insomnia agents (trazodone). Depending on the medication
and indication, often the recommendation was to
decrease the dose (23.5%) or discontinue the agent
(11.8%).

per patient trended upward from 6.50 for patients
with minimal fibrosis to 8.99 for patients with cirrhosis
(Table 3). Despite the greater number of concomitant
medications, there was a similar average number of
DDIs in those with minimal vs more advanced disease.
The most common interactions (identified as ≥ 10%)
were vitamin and herbal supplements (284/781,
36.4%), PPI/H2RA agents (117/781, 15.0%), and
other products (126/781, 16.1%). Table 4 summarizes
the interactions amongst the different drug classes.
Figure 1 shows the recommendations made for the
management of DDIs.

LDV/SOF

In 369 patients prescribed LDV/SOF, 472 drug-drug
interactions were identified. Common interactions
(defined as ≥ 10%) with LDV/SOF included antacids
(72/472, 15.3%), PPI/H 2 RA agents (107/472,
22.7%), and vitamin/herbal supplements (227/472,
48.1%). Ledipasvir, an NS5A inhibitor, is better
absorbed in an acidic environment. When omeprazole
20 mg was administered once daily 2 h prior to
LDV, area underneath the curve (AUC) decreases
[26]
to 0.58 . Therefore, absorption is decreased with
any medications that affect stomach acidity. Overall,
interactions with antacids and PPI/H2RA agents
occurred with (118/472, 25.0%) of our patients prescribed LDV/SOF. This interaction can be challenging
for multiple reasons. These medications are available
without prescription and often patients can forget to
report them during medication reconciliation. Each
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Analgesics (21.3%), hypertensive agents (13.0%),
psychiatrics (20.1%), and vitamins and herbal supple-
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Table 2 Drug-drug interactions identified from baseline medication list
Regimen

n = 664

Total number of
meds

Total number of
interactions, n (%)

Average number of
meds per patient

Average number of
interactions per patient

Contra-indications

369
48
114
133

2996
312
1002
964

472 (15.8)
119 (38.1)
169 (16.8)
21 (2.2)

8.12
6.50
8.79
7.25

1.28
2.48
1.48
0.16

7
4
19
1

LDV/SOF
OBV/PTV/r + DSV
SIM/SOF
SOF/RBV

LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir; DSV: Dasabuvir; SIM: Simeprevir; RBV: Ribavirin.

Table 3 Drug-drug interactions identified per fibrosis stage
Fibrosis stage
Minimal fibrosis (Stage 0-2)
Advanced fibrosis (Stage 3)
Cirrhosis (Stage 4)

n = 664

Total number of
medications

Total number of
interactions n (%)

Average number of
medications per patient

Average number of
interactions per patient

232
72
341

1508
575
3066

249 (16.5)
91 (15.8)
425 (13.8)

6.50
7.99
8.99

1.07
1.26
1.25

Table 4 Drug classes of medications identified as drug-drug
interactions from baseline medication list n (%)

side effects (56.0%) or to reduce the dose (28.0%) of
these medications (Figure 1).

Drug class

SOF/RBV

Affected portion of the cohort
n = 664

PPI/H2RA agents
Antacids
Vitamin and herbal supplements
Hypertensive agents
Analgesics
Psychiatric agents
Anticonvulsants
Steroids
Others

SOF/RBV had the fewest identified DDIs of any regimen. Ribavirin has the fewest direct interactions for
any of the HCV medications, and sofosbuvir has relatively few as well. Vitamins and herbal supplements
that have not been studied with SOF/RBV represented
the largest group of potential DDIs (81.8%). Since
DDIs have not been evaluated with supplements such
as milk thistle, turmeric, mushroom extract, and horny
goat weed, it was recommended to discontinue these
while on therapy for treating HCV infection (100%).
Due to the DDI between sofosbuvir and carbamazepine, the contraindicated medication was discontinued
prior to initiating HCV treatment in one patient.

117 (17.6)
72 (10.8)
284 (42.7)
53 (8.0)
67 (10.1)
46 (6.9)
4 (0.6)
12 (1.8)
126 (19.0)

PPI: Proton pump inhibitor; H2RA: H2-receptor antagonists.

ments (10.65%) frequently interact with SIM/SOF.
Even though most of these medications have not been
evaluated for DDIs with SIM/SOF, we anticipate the
plasma concentration of these medications to increase
due to mild inhibition of CYP3A4 and OAT1B1 from
[27]
simeprevir . As a result, increase monitoring for side
effects and decrease dose were frequently recommended for analgesics (76.3%; 21.1%), hypertensive
agents (70.0%; 25.0%), and psychiatrics (82.4%;
14.7%). Herbal supplements such as St. John’s wort
and milk thistle are contraindicated with SIM/SOF.
When administered with inducers or inhibitors of
CYP3A4 enzyme, the plasma concentration of SIM is
[28,29]
expected to change
. Therefore, both St. John’s
wort and milk thistle were recommended to be discon
tinued during the course of HCV therapy (100%).
Other medications that had potential interaction with
SIM/SOF were lipid lowering agents, anti-nausea
medications, bladder dysfunction medications, antibacterial agents, and insomnia medications. Based on
the metabolism of these medications, the most common recommendations were to increase monitoring for
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Time management

The clinical pharmacist was able to record his time
spent reviewing medications in 105 consults. These
consults included LDV/SOF, OBV/PTV/r + DSV, and
SOF/RBV, but did not include SIM/SOF. The time
requirement increased with the complexity of the
patient and the number of baseline medications and
drug-drug interactions identified. Consults for patients
prescribed OBV/PTV/r + DSV took the longest for the
pharmacist to complete, averaging 30 min per consult.
SOF/RBV and LDV/SOF were slightly shorter averaging
20 min per consult. This is consistent in relation to our
data that shows more DDIs were identified in patients
prescribed OBV/PRV/r + DSV.

DISCUSSION
Drug-drug interactions continue to be a considerable
challenge for managing patients with HCV treatment.
This study assessed the frequency and pharmacologi-
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Decrease dose and alter
administration time,
5.50%

the supplements are not prescribed, often they are
not documented in the electronic medical records.
Additionally, non-prescription medications and herbal
supplements are rarely studied for interactions. When
data were available or the potential interaction was
minimal, the clinical pharmacist usually recommended
continuing the product. However, if there were no data
to support the safe use of the supplement with HCV
treatment, the clinical pharmacist generally recommended it to be discontinued. This was especially
true with supplements that had no clear benefit to
the patient. Supplements such as multivitamins, fish
oil, and probiotics that have shown benefits in certain
populations, were most often recommended to separate from the DAAs in order to avoid any potential
absorption interaction.
As with most hepatology clinics, the University of
Colorado Hospital Hepatology Clinic largely acts as a
consult service for liver disease management. As a
result, providers through other clinics prescribe most
concomitant medications. Adjusting or switching a
medication due to DDIs can be relatively straightforward with certain medication classes such as lipid
lowering agents and antihypertensive medications.
However, management can be complex with other
DDIs. All currently available HCV therapies have DDIs
with certain anticonvulsants. These anticonvulsants
are normally prescribed and managed through a
specialty neurology clinic, sometimes outside of the
health-system. The clinical pharmacist may not have
access to the neurology clinic notes, and vice versa.
Depending on the disease state being treated and
specific patient factors, an alternative anticonvulsant
that does not interact may not be appropriate. If an
appropriate alternative is found, the switch can involve
specific titration schedules and overlap, requiring
management and specific monitoring. DDIs involving
antipsychotic medication or other mental health
medications are also complex. Patient responses
are varied and sometimes unpredictable to certain
agents, and exacerbation of mental health disease is a
significant health concern. In these situations, it may
be pertinent to choose a different HCV medication regimen with fewer interactions as opposed to switching
the concomitant medications. Prescription insurance
companies often have a specific formulary agent, and
obtaining approval for an alternative HCV regimen can
be challenging and time consuming.
Serious adverse events have been reported due
to DDIs. This includes a case of rhabdomyolysis
associated with telaprevir and simvastatin, renal
failure related to the increased levels of tacrolimus
after starting protease inhibitor therapy, new-onset
diabetes due to the interactions between LDV/SOF
and tenofovir, and severe bradyarrhythmias due to the
[32-35]
interaction between amiodarone and sofosbuvir
.
Although relatively rare, these interactions can lead to

Other,
1.16%

Separate medication
or administration,
18.20%

Discontinuation,
28.90%

Alter administration
time, 9.10%
Alternative
medication,
9.10%

Increase monitoring,
24.10%

Decrease dose,
11.10%

Figure 1 Recommendations for management of drug-drug interactions
(n = 664). Other recommendations: continue, alternative medication and alter
administration, decrease dose and increase monitoring, decrease dose and
separate administration, and increase dose.

cal category of identified DDIs in real-world patients
with HCV in addition to describing the management of
the most common DDIs encountered with the DAAs.
Published data on this topic are lacking. In 2010, a
US insurance cohort showed the top four medication
classes in patients with chronic HCV were analgesics
and/or antipyretics, antidepressants, antivirals, and
gastrointestinal agents including proton pump inhibi[29]
tors . Additionally, the study identified the average
number of baseline medications as 9.0 and 11.4 in
HCV treated and untreated patients, respectively.
[30]
Höner Zu Siederdissen et al
published an account
of potential drug-drug interactions in a cohort of
patients in Hanover, Germany. Our result for the
number of medications per patient at baseline study
(7.86 medications per patient) was comparable with
the US cohort. A significant number of DDIs predicted
in our patient cohort were with analgesics (9%), antihypertensives (7%), and psychiatrics (6%). With
the exception of psychiatrics and analgesics, this is
comparable with both the US and German cohorts.
Use of over-the-counter medications and herbal
supplements presents a challenge for assessing and
managing DDIs in patients. Herbal products are gaining popularity in the US and there is a perception that
herbal medications are safer than conventional medi[31]
cations . These supplements can be recommended
by people other than the patient’s primary healthcare
provider. Other times, patients will forget or not
realize to inform the provider about non-prescription
medications. In the HALT-C study, 44% of 1145
participants in the study with HCV infection admitted
[29]
past or current use of herbal supplements . Because
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Innovations and breakthroughs

very serious patient harm or potentially death. These
cases illustrate the importance of having knowledge
of possible drug-drug interactions to prevent severe
side effects. In our study, there were no documented
significant adverse events due to drug-drug interactions. By understanding the pharmacodynamics and
pharmacokinetic profiles of the drugs involved with
interactions, therapy can be safely and effectively
managed in patients with HCV infection.
This study is limited by the retrospective nature of
the review. Additionally, it is a single-center study at
an academic medical center and regional transplant
center, thereby limiting the relatability of the results
to smaller clinics with less complexity. Additionally,
the region lacks significant diversity and the result
may differ with patients of different racial and ethnic
backgrounds. Potential selection bias can also limit
the results, as the patients were not randomized
to each medication regimen but selected based on
patient specific characteristics, medication regimen
characteristics, provider experience and judgment,
and insurance formulary. For patients with cirrhosis,
depending on compensation and Child-Pugh Score,
he or she may not be eligible to receive certain
medication regimens. Due to all of the reasons, only
descriptive statistics were used to analyze the results.
Additionally, measuring the time requirement for the
pharmacists to complete a consult was challenging.
Anecdotally, as the pharmacist was more familiar
with the medications and common DDIs, the time
spent per patient was shortened. Additionally, due to
the nature of a consult position, interruptions were
common making it hard to capture the true amount
of time spent per consult. For these reasons, caution
should be warranted when applying these data to
other clinics.
In conclusion, DDIs are common in patients prescribed HCV medications and the involvement of
a clinical pharmacist can be beneficial to the interdisciplinary hepatology team. Identification and
management of DDIs is resource intensive and
requires medication adjustments and increased monitoring. Clinical pharmacists can encourage preventive
measures on reducing HCV transmission, increase
education adherence, assist in initiating HCV treatment, assist in monitoring clinical and adverse effects,
and facilitate medication acquisition.

Drug-drug interactions continue to be a considerable challenge for managing
patients with HCV treatment. This study assessed the frequency and pharm
acological category of identified DDIs in real-world patients with HCV in addition
to describing the management of the most common DDIs encountered with the
DAAs.

Applications

This retrospective analysis of patients prescribed common HCV treatments
identifies DDIs and the interventions made by the clinical pharmacist, as well
as the approximate time required to complete these activities. This novel
review illustrates that DDIs are common in this population. Identification
and management of DDIs is resource intensive and requires medication
adjustments and increased monitoring. An interdisciplinary care team
including a clinical pharmacist is critical to optimize patient care for new HCV
therapies.

Peer-review

Drug-drug interactions continue to be a considerable challenge for managing
patients with HCV treatment. In this study the authors assessed the frequency
and pharmacological category of identified drug-drug-interactions in realworld patients with HCV. This study suggests an interdisciplinary approach for
managing DDIs. In my opinion, publication will be valuable.
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Abstract
AIM
To evaluate the safety and efficacy of limited endo
scopic sphincterotomy (ES) before placement of selfexpandable metal stent (SEMS).
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METHODS
This was a retrospective analysis of 244 consecutive
patients with unresectable malignant biliary obstruction, who underwent placement of SEMSs following
limited ES from December 2008 to February 2015. The
diagnosis of malignant biliary obstruction and assessment of patient eligibility for the study was established
by a combination of clinical findings, laboratory investigations, imaging and pathological results. All patients
were monitored in the hospital for at least 24 h follo
wing endoscopic retrograde cholangio pancreatography
(ERCP). The incidence of immediate or early post-ERCP
complications such as post-ERCP pancreatitis (PEP) and
bleeding related to limited ES were considered as primary outcomes. Also, characteristics and complications
according to the cancer type were classified.
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RESULTS
Among the 244 patients included, the underlying
diagnosis was cholangiocarcinoma in 118 patients,
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Endoscopic retrograde cholangiopancreatography
(ERCP) along with biliary stenting is a minimally invasive procedure for palliation of biliary obstruction that
provides relief from jaundice and improves the quality
of life of patients with unresectable malignant biliary
[2]
obstruction .
Self-expandable metal stents (SEMS), compared
to plastic stents, have superior patency and are costeffective options in selected preoperative patients or in
[3-5]
patients whose life expectancy exceeds six months .
They are, however, reported to be associated with a
[6,7]
higher incidence of pancreatitis . Previous studies
indicate that performing endoscopic sphincterotomy
(ES) before stent insertion may lower the incidence
[8-10]
of post-ERCP pancreatitis (PEP)
. ES may also
facilitate cannulation of the bile duct during difficult
ERCPs, reduce resistance to the passage of stents,
improve immediate stent deployment, and increase
the luminal diameter of the distal common bile duct
[9-12]
(CBD)
. Many endoscopists routinely perform ES
before SEMS placement. However, the role of routine
ES before stenting is still controversial and no clear
guidelines exist to govern its use. Additionally, ES
is also an independent risk factor for complications
such as pancreatitis, bleeding, and perforation, with a
reported complication rate of approximately 10% and
an overall direct or indirect procedure-related mortality of 0.42%, even when performed by experienced
[2,13-17]
endoscopists
. However, an accurate assessment
of the incidence of complications based on the extent
of ES is difficult to make owing to the lack of such data
in previous studies. Herein, we studied the incidence of
early post-ERCP complications, such as PEP and bleeding following limited ES accompanying SEMS placement for biliary drainage in patients with malignant
biliary obstruction.

pancreatic cancer in 79, and non-pancreatic or nonbiliary malignancies in the remaining 47 patients. Early
post-ERCP complications occurred in 9 patients (3.7%),
with PEP in 7 patients (2.9%; mild, 6; moderate, 1)
and mild bleeding in 2 patients (0.8%). There was
no significant association between the incidence of
post-ERCP complications and the type of malignancy
(cholangiocarcinoma vs pancreatic cancer vs others,
P = 0.696) or the type of SEMS used (uncovered vs
covered, P = 1.000). Patients who had more than one
SEMS placed at the first instance were at a significantly
higher risk of post-ERCP complications (one SEMS vs
two SEMS, P = 0.031). No other factors were predictive
of post-ERCP complications.
CONCLUSION
Limited ES is feasible and safe, and effectively facilitates
the placement of SEMS, without any significant risk of
PEP or severe bleeding.
Key words: Endoscopic sphincterotomy; Endoscopic
retrograde cholangio pancreatography; Complications;
Pancreatitis; Bleeding; Cholestasis; Self-expandable
metal stent
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: The role of routine endoscopic sphincterotomy
(ES) is still controversial in biliary stenting and there
is a lack of systematic study for the extent of ES and
its correlation with the incidence of complications. We
retrospectively evaluated the safety and efficacy of
limited ES before self-expandable metal stent insertion.
We have proved in this study that limited ES doesn’t
increase the risk of post-procedure complications
such as post-endoscopic retrograde cholangio pancre
atography pancreatitis and bleeding. Also, it is
advantageous in facilitating the more complex stenting
procedures. Therefore, limited ES can be a safe,
feasible, and effective therapeutic strategy in the place
ment of self-expandable metal stent.

MATERIALS AND METHODS
Patients

This was a retrospective analysis of all patients who
underwent endoscopic biliary SEMS placement for the
first time for malignant biliary obstruction at the Pusan
National University Yangsan Hospital during the sixyear period from December 2008 to February 2015.
Patients that underwent transpapillary SEMS placement after limited ES for a diagnosis of distal or hilar
malignant biliary strictures were included in this study.
Diagnosis of the disease and assessment of patient
eligibility for the procedure was based on a combination of clinical findings, laboratory investigations and
radiological studies including computed tomography
(CT) scan, magnetic resonance imaging (MRI) and/or
endoscopic ultrasound (EUS). In case of without cholangitis, painless jaundice and/or pruritus, sometimes
anorexia, weight loss and malaise were main clinical
symptoms. The main laboratory parameters recorded
were complete blood count (CBC), total bilirubin, liver

Nam HS, Kang DH, Kim HW, Choi CW, Park SB, Kim SJ, Ryu
DG. Efficacy and safety of limited endoscopic sphincterotomy
before self-expandable metal stent insertion for malignant biliary
obstruction. World J Gastroenterol 2017; 23(9): 1627-1636
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i9/1627.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i9.1627

INTRODUCTION
Malignant biliary obstruction is mainly caused by
cholangiocarcinoma, pancreatic cancer, gallbladder
cancer, and metastatic disease. The prognosis is very
poor because the lesions are unresectable at diagnosis
in the majority of these patients, with less than 20%
[1]
of the patients being suitable for surgical resection .
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function tests including alanine aminotransferase,
alkaline phosphatase, γ-glutamyltransferase and tumor
markers such as CEA and CA 19-9. CT scan was performed for all patients as an initial test, while MRI was
performed in all patients with suspicious malignant biliary strictures. MRI was not performed in uncooperative
patients or if contraindicated owing to the presence of
intracorporeal metallic device or foreign body. EUS was
not routinely performed, and was limited to investigating indeterminate biliary strictures, nonvisible masses,
or when tissue acquisition was required for definite
diagnosis. Pathology results were reviewed in cases
where biopsy was performed during ERCP or EUS.
Exclusion criteria were previous ES or stent placement,
coagulopathy (international normalized ratio > 1.5),
low platelet count (< 50000/mL), current use of
anticoagulant or antiplatelet drugs, severe cholangitis
with or without septic shock, Billroth II anatomy or
Roux-en-Y gastrojejunostomy, and severe heart or
pulmonary disease. The study protocol was approved
by the ethics committee of the Institutional Review
Board of Pusan National University Yangsan Hospital
(IRB No. 05-2015-081).

12 cm) and the need for unilateral or bilateral stent
placement were determined based on the location and
length of the biliary stricture. Stent placement ensured
that the stent spanned the stricture with either end
of the stent extending a minimum of 1 cm beyond
the stricture. In the case of distal biliary strictures,
the distal end of SEMS was placed across the papilla
with 1 cm of the distal end of the stent exposed in the
duodenum. In the case of hilar biliary strictures, SEMS
was placed above the sphincter of Oddi. All patients
were monitored in the hospital for at least 24 h after
ERCP to identify early post-ERCP complications. CBC,
serum amylase, and lipase levels were routinely evaluated at 4 h and 24 h after the procedure. Endoscopy
was performed to evaluate ES-related-bleeding on
the day following stent placement. All adverse events
were recorded. During the follow up period, ERCP was
repeated on suspecting stent complications such as
occlusion or migration.

Definitions

According to updated Tokyo guidelines (TG13) for
diagnosis and severity grading of acute cholangitis,
cholangitis was defined as fever and/or shaking chills,
increased inﬂammatory response (abnormal white
blood cell counts, increased serum C-reactive protein
levels) and jaundice (total bilirubin ≥ 2 mg/dL) or
abnormal liver function tests (> 1.5 × upper limit of
[18]
normal value) . Severe cholangitis is defined as the
presence of accompanying organ dysfunction caused
by biliary sepsis, and requiring intensive care such
[18]
as respiratory and circulatory support . Limited ES
was defined as sphincterotomy less than one-third the
[19]
extent of major ES . Definitions of individual postprocedure complications were according to the descrip[20]
tions given by Cotton et al . PEP was defined as newonset or worsening abdominal pain lasting more than
24 h after the procedure, in conjunction with pancreatic enzyme (amylase and/or lipase) elevation that was
at least three times the upper limit of the normal, with
or without radiographic evidence of acute pancreatitis.
The severity of PEP was graded by using the number
of hospitalization days: mild, when hospitalization was
prolonged by 2 to 3 d, moderate, by 4 to 10 d, and
[20]
severe, by more than 10 d . Bleeding was defined as
the presence of melena or hematemesis, irrespective
of the need for blood transfusion or repeat endoscopy.
Mild bleeding was defined as hemoglobin drop within
2 g/dL, with no necessity for blood transfusion. The
presence of bleeding was identified based on patient’s
history (melena or hematemesis) and a drop in
hemoglobin level following the procedure. Perforation
was considered as perforation of retroperitoneum or
bowel walls documented by any of the radiographic
[21]
techniques . Complications were graded according
[20]
to the grading system described by Cotton et al .
Early complications or adverse events were defined as
any ERCP-related complications occurring within 30 d

Study protocol

Patient characteristics including age, sex, history
of previous procedures and baseline biochemical
and hematological values were collected prior to
performing ERCP. SEMS placement was performed in
all patients by one of two experienced endoscopists
(endoscopist A had performed > 10000 ERCPs over
20 years; endoscopist B had performed > 2000 ERCPs
over 10 years). All patients received intravenous (IV)
broad-spectrum antibiotics. Nafamostat mesilate (20
mg) was administered for all patients for preventing
post-ERCP pancreatitis. Nonsteroidal anti-inflammatory
drugs were not used routinely. All procedures were
performed under conscious sedation by using IV midazolam and pethidine, with the patient in the supine
or left lateral decubitus position. Cimetropium bromide
10 mg IV was administered to reduce duodenal peristalsis. All ERCPs were performed by using a standard
side-viewing duodenoscope (JF-260 V or TJF-240;
Olympus Optical Co., Ltd., Tokyo, Japan). Selective
cannulation of the bile duct was achieved by using a
pull-type double-lumen sphincterotome (Ultratome XL,
Boston Scientific, Natick, Mass) or by a conventional
ERCP catheter (Fluoro Tip, Boston Scientific), with or
without a hydrophilic guidewire (0.025- or 0.035-inch
Jagwire, Boston Scientific). A wire-guided cannulation
technique was attempted first, followed by the conventional contrast-assisted cannulation technique if biliary
cannulation was not achieved within 10 min. After successful guidewire placement, limited sphincterotomy
was performed with blended current. Limited ES was
defined as ES limited to one-third the extent of major
ES. A metal stent was then inserted over the guidewire
under fluoroscopic control. Stent length (4 cm to
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of the procedure. Patency interval was defined as the
period between the first SEMS deployment and the
occurrence of stent complications such as occlusion or
migration.

Table 1 Patient characteristics and endoscopic retrograde
cholangio pancreatography related data n (%) (n = 244)
Characteristics
Age (yr), mean ± SD (range)
Sex
Male
Female
Aspirin
Total bilirubin (mg/dL), pre-procedure, mean ±
SD (range)
Normal
Elevated
Hyperamylasemia, pre-procedure
Cholangitis, pre-procedure
Diagnosis
Cholangiocarcinoma
Hilar
Distal
Pancreatic cancer
Head
Body/Tail
Gallbladder cancer
Ampullary cancer
Hepatocellular carcinoma
Others
Pancreatic duct invasion
Yes
No
Lymph node metastasis
Yes
No
Pancreatic duct injection
0
1-2
≥3
ERPD
Stent success rate
Number of initially inserted SEMS
1
2
Stent type
Uncovered
Covered
Post-ERCP complication
Present
Absent'
Post-ERCP complication type
Pancreatitis
Mild / moderate
Bleeding, mild
Perforation
Post-ERCP hyperamylasemia
Stent complication
None
Stent occlusion
Stent migration
Patency
No further procedure
ERBD restent
SEMS restent
PTBD

Value
70.8 ± 10.2 (44-95)

Statistical analysis

The primary outcomes measured were immediate or
early complications within 30 d of the procedure. For
inter-group differences, Student’s t-test was performed
2
for continuous variables, and χ test or Fisher’s exact
test were performed for categorical variables. Results
were considered statistically significant at a P value
< 0.05. Data were analyzed by using SPSS software
version 18.0 (SPSS, Chicago, IL, United States).

130 (53.3)
114 (46.7)
3 (1.2)
7.09 ± 6.45 (0.2-28.9)
53 (21.7)
191 (78.3)
14 (5.7)
68 (27.9)
118 (48.4)
75 (63.6)
43 (36.4)
79 (32.4)
68 (86.1)
11 (13.9)
21 (8.6)
18 (7.4)
3 (1.2)
5 (2.0)

RESULTS
A total of 244 patients that underwent limited ES
and biliary stenting for malignant biliary obstruction
between December 2008 and February 2015 were
included in the study. The etiology of malignant biliary
obstruction included cholangiocarcinoma (n = 118,
48.4%), pancreatic cancer (n = 79, 32.4%), and
others including gallbladder cancer (n = 21, 8.6%),
ampullary cancer (n = 18, 7.4%), and hepatocellular
carcinoma and metastatic cancer (n = 8, 3.2%). Mean
age was 70.8 ± 10.2 (range, 44-95) years and 130
(53.3%) were males and 114 (46.7%) were females.
Stents were successfully deployed in all patients.
Early post-ERCP complications occurred in 9
patients (3.7%), including PEP in 7 patients (2.9%;
mild, 6; moderate, 1), and mild bleeding in 2 patients
(0.8%). All patient with post-ERCP complications
responded to conservative management. Stent occlusion and migration developed in 44 patients (18.0%)
and 1 patient (0.4%), respectively. Patients with late
complications underwent repeat ERCP or percutaneous
transhepatic biliary drainage. Patient characteristics
and ERCP related data are summarized in Table 1.
On categorizing patients into three groups on the
basis of cancer location, PEP developed in 4 patients
(3.4%, 4/118) with cholangiocarcinoma, 1 patient
(1.3%, 1/79) with pancreatic cancer, and 2 patients
(4.3%, 2/47) with non-pancreatic, non-biliary cancers
(P = 0.681). There were no significant differences
among these three groups as to the incidence of
immediate or early complications (P = 0.696) (Table
2). In the cholangiocarcinoma group, the incidence of
PEP was 4.0% and 2.3% with hilar and distal cholangiocarcinoma, respectively (P = 0.537). One patient
with hilar cholangiocarcinoma had mild bleeding (Table
3). In the pancreatic cancer group, one patient had
PEP and another had mild bleeding. Both complications
developed in patients with pancreatic head cancer and
none were reported in cases of pancreatic body and/or
tail cancer (Table 4).

85 (34.8)
159 (65.2)
170 (69.7)
73 (29.9)
187 (76.6)
24 (9.8)
33 (13.5)
4 (1.6)
244 (100)
230 (94.3)
14 (5.7)
190 (77.9)
54 (22.1)
9 (3.7)
234 (95.9)
7 (2.9)
6 (2.5)/1 (0.4)
2 (0.8)
0 (0)
30 (12.3)
199 (81.6)
44 (18.0)
1 (0.4)
199 (81.6)
1 (0.4)
32 (13.1)
12 (4.9)

SEMS: Self-expandable metal stent; ERPD: Endoscopic retrograde pancreatic
drainage; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous
transhepatic biliary drainage.

WJG|www.wjgnet.com

1630

March 7, 2017|Volume 23|Issue 9|

Nam HS et al. Limited endoscopic sphincterotomy for biliary stenting
Table 2 Characteristics and complications according to the cancer type n (%)

Age (yr), mean ± SD
Hyperamylasemia, pre-procedure
Cholangitis, pre-procedure
Pancreatic duct invasion
Yes
No
Lymph node metastasis
Yes
No
Pancreatic duct injection
0
1-2
≥3
Number of initially inserted SEMS
1
2
Post-ERCP complication
Present
Absent
Post-ERCP complication type
Pancreatitis
Mild/moderate
Bleeding, mild
Perforation
Post-ERCP hyperamylasemia
Stent complication
None
Stent occlusion
Stent migration
Patency
No further procedure
ERBD restent
SEMS restent
PTBD

Cholangiocarcinoma
n = 118

Pancreatic cancer
n = 79

non-pancreaticobiliary cancer
n = 47

P value

73.5 ± 9.4
6 (5.1)
28 (23.7)

67.8 ± 10.4
3 (3.8)
19 (24.1)

69.3 ± 10.3
5 (10.6)
21 (44.7)

0.002
0.273
0.021
< 0.001

12 (10.2)
106 (89.8)

64 (81.0)
15 (19.0)

9 (19.1)
38 (80.9)

77 (65.3)
41 (34.7)

58 (73.4)
21 (26.6)

35 (74.5)
12 (25.5)

92 (78.0)
8 (6.8)
18 (15.3)

59 (74.7)
9 (11.4)
11 (13.9)

36 (76.6)
7 (14.9)
4 (8.5)

106 (89.8)
12 (10.2)

79 (100.0)
0 (0.0)

45 (95.7)
2 (4.3)

5 (4.2)
113 (95.8)

2 (2.5)
77 (97.5)

2 (4.3)
45 (95.7)

4 (3.4)
3 (2.5)/1 (0.8)
1 (0.8)
0 (0)
13 (11.0)

1 (1.3)
1 (1.3)/0 (0)
1 (1.3)
0 (0)
9 (11.4)

2 (4.3)
2 (4.3)/0 (0)
0 (0)
0 (0)
8 (17.0)

90 (76.3)
27 (22.9)
1 (0.8)

70 (88.6)
9 (11.4)
0 (0)

39 (83.0)
8 (17.0)
0 (0)

90 (76.3)
1 (0.8)
20 (16.9)
7 (5.9)

70 (88.6)
0 (0)
9 (11.4)
0 (0)

39 (83)
0 (0)
3 (6.4)
5 (10.6)

0.345

0.606

0.004

0.696

0.914
0.681

0.539

0.161

SEMS: Self-expandable metal stent; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

Table 3 Rates of complications on biliary stenting with limited endoscopic sphincterotomy according to location of
cholangiocarcinoma n (%)
Hilar

Post-ERCP complication type
Pancreatitis
Mild/moderate
Bleeding, mild
Perforation
Post-ERCP hyperamylasemia
Stent complication
None
Stent occlusion
Stent migration

Distal

n = 75

n = 43

3 (4.0)
2 (2.7)/1 (1.3)
1 (1.3)
0 (0.0)
7 (9.3)

1 (2.3)
1 (2.3)/0 (0)
0 (0.0)
0 (0.0)
5 (11.6)

57 (76.0)
17 (22.7)
1 (1.3)

33 (76.7)
10 (23.3)
0 (0.0)

P value
0.717

0.756
1.000

ERCP: Endoscopic retrograde cholangio pancreatography.

occurred in 2 patients (1.1%) in the uncovered SEMS
group alone. No significant differences were found
between these two groups as to the incidence of postERCP complications (P = 1.000) (Table 5).
On comparing patients with no complications (n =
235) and those with complications (n = 9), the only

On categorizing patients based on the type of
SEMS deployed, 190 patients (78%) had uncovered
SEMS while 54 patients (22%) had covered SEMS.
Rates of PEP with uncovered and covered SEMS were
2.6% (5/190; mild, 4; moderate, 1) and 3.7% (2/54,
both mild), respectively (P = 0.652). Mild bleeding
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Table 4 Rates of complications on biliary stenting with limited endoscopic sphincterotomy according to location of pancreatic
cancer n (%)

n = 68

Head

Body / Tail
n = 11

1 (1.5)
1 (1.5)
1 (1.5)
1 (1.5)
8 (11.8)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (18.2)

60 (88.2)
8 (11.8)
0 (0.0)

10 (90.9)
1 (9.1)
0 (0.0)

P value

Post-ERCP complication type
Pancreatitis
Mild/moderate
Bleeding, mild
Perforation
Post-ERCP hyperamylasemia
Stent complication
None
Stent occlusion
Stent migration

1.000

0.624
1.000

ERCP: Endoscopic retrograde cholangio pancreatography.

Table 5 Rates of complications on biliary stenting with limited endoscopic sphincterotomy according to stent type n (%)

Normal
Abnormal
Post-ERCP complication
Present
Absent'
Post-ERCP complication type
Pancreatitis
Mild / moderate
Bleeding, mild
Perforation
Post-ERCP hyperamylasemia
Stent complication
None
Stent occlusion
Stent migration
Patency
No further procedure
ERBD restent
SEMS restent
PTBD

Uncovered
n = 190

n = 54

Covered

181 (95.3)
9 (4.7)

49 (90.7)
5 (9.3)

7 (3.7)
183 (96.3)

2 (3.7)
52 (96.3)

5 (2.6)
4 (2.1) / 1 (0.5)
2 (1.1)
0 (0)
25 (13.2)

2 (3.7)
2 (3.7) / 0 (0)
0 (0)
0 (0)
5 (9.3)

156 (82.1)
33 (17.4)
1 (0.5)

43 (79.6)
11 (20.4)
0 (0)

156 (82.1)
1 (0.5)
28 (14.7)
5 (2.6)

43 (79.6)
0 (0)
4 (7.4)
7 (13)

P value

1.000

0.838

0.638
0.758

0.012

SEMS: Self-expandable metal stent; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous transhepatic biliary drainage; ERCP: Endoscopic
retrograde cholangio pancreatography.

[9]

factor that was significantly different between the two
groups was the number of SEMS initially deployed [one
SEMS vs two SEMS (bilateral), P = 0.031] (Table 6). Of
the 231 patients with one SEMS, 5 patients developed
PEP and 2 patients developed mild bleeding, while of
the 13 patients with two SEMS, 2 patients developed
PEP.

tion and pancreatitis . Some studies have reported
that the risks of ES might exceed any benefits owing to
[15]
a high incidence of ES-related complications . Cotton
[20]
et al
reported bleeding and pancreatitis as major
[15]
early complications with ES. Freeman et al
evaluated early complications following ES and reported
their incidence as 9.8% (pancreatitis, 5.4%; bleeding,
2.0%).
Previous studies, however, lack details regarding
the extent of ES and its correlation with the incidence
of complications. In this study, we performed limited
ES before SEMS placement and described the safety of
limited ES by evaluating early post-ERCP complications
in patients with malignant biliary obstruction. The overall rate of early post-ERCP complications after SEMS
placement with limited ES was 3.7%, including a 2.9%
incidence of PEP, and 0.8% of mild bleeding. These

DISCUSSION
ES is an established technique and is commonly used
to facilitate biliary stone removal. In contrast, the role
of routine ES prior to stent insertion is still controversial. Many endoscopists prefer to perform ES before
stenting to reduce the risk of PEP, achieve better biliary
drainage, and facilitate stent placement. However,
sphincterotomy carries risks such as bleeding, perfora-
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Table 6 Characteristics according to complications on biliary stenting with limited endoscopic sphincterotomy n (%)

Age (yr), mean ± SD (range)
Gender
Male
Female
Total bilirubin (mg/dL), pre-procedure, mean ± SD
Normal
Elevated
Hyperamylasemia, pre-procedure
Cholangitis, pre-procedure
Diagnosis
Cholangiocarcinoma
Hilar
Distal
Pancreatic cancer
Head
Body/tail
Gallbladder cancer
Ampullary cancer
Hepatocellular carcinoma
Others
Pancreatic duct invasion
Yes
No
Lymph node metastasis
Yes
No
Pancreatic duct injection
0
1-2
≥3
Number of inserted SEMS
1
2
Stent type
Uncovered
Covered
Stent complication
Stent occlusion
Stent migration
Patency
No further procedure
ERBD restent
SEMS restent
PTBD

No complication
n = 235

Complication
n =9

P value

70.61 ± 10.33

75.27 ± 5.55

0.993
1.000

126 (53.6)
109 (46.6)
7.00 ± 6.46
52 (22.2)
183 (77.8)
13 (5.5)
64 (27.2)

5 (55.5)
4 (44.5)
8.38 ± 6.54
1 (11.1)
8 (88.9)
1 (11.1)
4 (44.4)

112 (47.6)
71 (30.2)
41 (17.4)
77 (32.8)
66 (28.1)
11 (4.7)
20 (8.5)
18 (7.7)
3 (1.3)
5 (2.1)

6 (66.7)
4 (44.4)
2 (22.2)
2 (22.2)
2 (22.2)
0 (0.0)
1 (11.1)
0 (0.0)
0 (0.0)
0 (0.0)

80 (34.0)
155 (66.0)

5 (55.6)
4 (44.4)

166 (70.6)
69 (29.4)

5 (55.6)
4 (44.4)

181 (77.0)
23 (9.8)
31 (13.2)

6 (66.7)
1 (11.1)
2 (22.2)

224 (95.3)
11 (4.7)

7 (77.8)
2 (22.2)

183 (77.9)
52 (22.1)

7 (77.8)
2 (22.2)

42 (17.9)
1 (0.4)

2 (22.2)
0 (0.0)

192 (81.7)
1 (0.4)
31 (13.2)
11 (4.7)

7 (77.8)
0 (0.0)
1 (11.1)
1 (11.1)

0.362
0.453
0.485
0.472
0.748

0.324

0.176

0.662

0.031

1.000

1.000

0.512

SEMS: Self-expandable metal stent; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous transhepatic biliary drainage; ERCP: Endoscopic
retrograde cholangio pancreatography.

rates of complications are relatively low compared to
the complication rates of approximately 10% and an
[2,13-17]
overall mortality of 0.42% in published data
.
Bleeding is a serious complication of ES and its
[12,22-25]
incidence is reported to be between 1 and 10%
.
In our study, only 2 patients (0.8%) developed mild
bleeding, which could be managed by conservative
treatment. No instances of moderate or severe bleed[26]
ing were reported. Wang et al , in their analysis of
delayed hemorrhage following ES in 1741 patients
did not find delayed bleeding in any patient who
underwent small ES (n = 194). These results might be
related to the limited extent of the ES and the com[27]
pressive effect of the SEMS . On the basis of these

WJG|www.wjgnet.com

studies, limited ES does not seem to be associated
with clinically significant bleeding.
[28]
A recent meta-analysis by Cui et al , analyzing
biliary stenting for malignant biliary obstruction
reported that the incidence of PEP was significantly
lower with ES than without ES (3.5% vs 8.9%, P = 0.04,
OR = 0.34, 95%CI: 0.12-0.93) and recommended ES
before stent placement as a useful option to reduce
the incidence of PEP. Similar low rates (2.2%) were
[29]
reported by Giorgio et al in their randomized control
trial involving 10 Fr plastic stent after ES for inoperable
malignant common bile duct (CBD) obstruction. In our
study, despite the absence of a control group, the low
rate of PEP (2.9%) is comparable to the results of the
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two above-mentioned studies. Our PEP rates are also
low compared to the rates of 9.4% and 6.3%, with
metal stent placement following ES for distal biliary
[17]
strictures, reported by Hayashi et al and by Kahaleh
[30]
et al , respectively. In our study, the incidence of PEP
was 4.0% in hilar cholangiocarcinoma and 2.3% in distal cholangiocarcinoma. Although the outcomes with ES
for malignant biliary strictures, especially cholangiocarcinoma, are controversial, several previous studies have
demonstrated a lower incidence of PEP in the ES group
[8,9,31]
[8]
compared to the non-ES group
. Jeong et al
investigated the risk of pancreatitis in patients with
malignant obstructive jaundice following percutaneous
or transpapillary stent placement. They also studied
the effect of preliminary ES in the transpapillary stent
group. Their results demonstrated a higher rate of
pancreatitis in the transpapillary stent group (P = 0.502)
and the authors concluded that SEMS placement
through the intact sphincter of Oddi may increase the
risk pancreatitis.
The management of hilar obstruction is more difficult than distal bile duct strictures because of the
underlying anatomical and technical complexity.
Bilateral stent placements for Bismuth type Ⅱ to Ⅳ
hilar cholangiocarcinoma are also very complicated
[32]
and result in increased endoscopic manipulations .
The higher incidence of post-ERCP complications in
patients who had two SEMS (bilateral stents) placed
could be related to these reasons. In these situations, limited ES before stenting could be an effective
strategy for facilitating more complex stenting pro[33]
cedures . Limited ES may allow for easier stent
placement and reduce resistance to biliary instrumentation. Additionally, proximal bile duct strictures
may contribute to a fulcrum effect resulting in medial
displacement of the distal stent and, consequently,
[9]
stent related compression of the pancreatic duct .
Limited ES might prevent the risk of pancreatitis by
reducing stent-related pancreatic duct obstruction. In
case of distal CBD strictures, ES may allow the stent
to achieve a better final diameter, and thus, better
drainage.
Our data demonstrated a lower rate of PEP in
patients with cholangiocarcinoma compared to previous studies. Limited ES, therefore, could be an
effective and useful technique to prevent PEP following stenting for cholangiocarcinoma, especially hilar
tumors. The incidence of PEP was lesser in pancreatic
cancers than in cholangiocarcinoma in this study (1.3%
vs 3.4%, P = 0.681). Some studies demonstrated that
pancreatic cancers with obstruction of the main pancreatic duct had a lower degree of PEP, possibly due to
diminished pancreatic exocrine function and suggested
[12,17,28,32]
that ES may be unnecessary in such cases
.
Although further confirmation is required, we noted
that performing limited ES prior to SEMS placement
in patients with unresectable pancreatic cancers did
not result in a higher incidence of adverse events
[17]
compared to published data . Additionally, it is pos-
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sible that ES may be advantageous in selected cases,
depending on pancreatic duct status, stent diameter, stent type (especially fully covered SEMS) or
ampulla size, in rendering the procedure easier as biliary strictures secondary to pancreatic cancer tend
to be narrow and rigid. ES may also facilitate stent
[32]
exchange during the follow-up period
as demonstrated in our study, where the success rate of SEM
restenting, when indicated, was 97%.
Stent migration is a late complications of biliary
stenting with ES. Stent migration seems to be associated with stent type as well as ES. Covered SEMS are
not fully embedded in bile duct, and therefore, are
associated with the potential risk of stent migration. A
previous study reported increased frequency of stent
migration when ES was performed before placement
[16]
of covered SEMS . In contrast, other studies did not
[29,34]
support this finding
. In our study, stent migration
occurred in only 1 patient (0.4%) and limited ES did
not seem to be a significant factor associated with
migration, regardless of the stent type.
This retrospective study has a few limitations. First,
the possibility of inaccurate data collection cannot be
overlooked. For example, procedure-related abdominal
pain is difficult to distinguish from the breakthrough
pain of malignancy and may have contributed to a bias
in measuring the rate of PEP. Second, this study had a
single-center design without a control group (non-ES
group), which might influence the interpretation of the
effect of limited ES. Further prospective multicenter
studies with the inclusion of control groups are needed
to overcome these limitations.
In conclusion, limited ES is a feasible, safe and
effective procedure to facilitate placement of SEMS in
patients with malignant biliary obstruction. Limited ES
is not significantly associated with complications like
severe bleeding or PEP and its use may represent a
better strategy to achieve successful stent placement,
especially in cases like hilar strictures that require
complex procedural techniques.
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Endoscopic biliary stent placement has become the primary management
therapy for palliation in patients with malignant biliary obstruction. Endoscopic
sphincterotomy (ES) is performed to reduce the risk of post-ERCP pancreatitis
(PEP) and facilitate stent placement. Although many endoscopists routinely
perform ES before self-expandable metal stent (SEMS) placement, the role
of ES is still controversial in biliary stenting. Effects and complications on the
degree of ES also need to be investigated. There have been few studies on the
complications or effects of limited ES.

Research frontiers

At present, there have been some reports to evaluate the safety and efficacy of
ES before placement of SEMS and the existing data is contradictory. Currently,
there are no guidelines regarding ES for biliary stenting. There is a lack of
detail, regarding the extent of ES, and its correlation with complications.
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Limited ES is not significantly associated with complications like severe
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bleeding or PEP. It may be useful to achieve successful stent placement.
Limited ES is a feasible, safe and effective procedure to facilitate placement of
SEMS in patients with malignant biliary obstruction.

10

Applications

This retrospective study showed that limited ES could be useful to facilitate
placement of SEMS, especially in cases, like hilar strictures, requiring complex
procedural techniques without major complications. Further large randomized
controlled trials are required.

11

Terminology

ES is a method to provide access to the biliary system for therapy, which means
cutting of the sphincter or muscle that lies at the juncture of the intestine with
both the bile and pancreatic ducts. Limited ES is defined as sphincterotomy
less than one-third the extent of major ES.
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This is an interesting manuscript that has not been published extensively. The
authors showed in this study that the clinical outcomes in patients who did
undergo limited ES before placement of SEMS for malignant biliary obstruction.
The results provide new evidence that limited ES could be a feasible strategy
for SEMS placement without significant complications.
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Abstract
AIM
To assess the efficacy and safety of fibrin sealant for
closure of mucosal penetration at the cardia during
peroral endoscopic myotomy (POEM).
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METHODS
Twenty-four patients who underwent POEM and
experienced mucosal injury of the cardia during the
procedure were retrospectively identified. Of the
24 patients, 21 had mucosal penetration and 3 had
only slight mucosal damage without penetration.
The 21 patients with mucosal penetration received
fibrin sealant for closure at the site of penetration.
Penetration-related characteristics, treatment, and
recovery were reviewed for all 21 patients to assess
the efficacy and safety of fibrin sealant for closure
of mucosal penetration at the cardia. Clinical data,
including general characteristics, procedure-related
parameters, Eckardt scores, lower esophageal sphincter
pressures (LESP), and esophagogastroduodenoscopy
(EGD) results, were analyzed to determine their influ
ence on treatment success after mucosal penetration
during POEM.
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RESULTS
All 21 patients had a solitary mucosal penetration in
the cardia (12 in esophageal region of the cardia, 9
in the stomach region of the cardia, and 1 in both
the esophageal and stomach regions). Twelve had a
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hole-like penetration and 9 had a linear penetration.
For those with a hole-like penetration, the mean size
2
2
was 0.14 cm (0.02-0.32 cm ). For those with a linear
penetration, the median size was 0.37 cm (0.10-1.00
cm). Closure of the mucosal penetration using fibrin
sealant was performed successfully in all 21 patients
(two patients required 5 mL fibrin sealant, and the
remaining 19 patients required 2.5 mL). Two patients
had a nasogastric tube placed for five days after POEM;
the remaining 19 patients were kept fasting for 3 d.
All 21 patients were discharged after a median of 5 d
(range: 5-7 d) postoperatively. During a median 42
mo (range: 9-62 mo) follow-up, all 21 patients with
a mucosal penetration successfully healed without
the occurrence of infection, ulcer, or esophagitis.
Furthermore, the median LESP decreased from 31.9
mmHg (range: 21.9-67.1 mmHg) preoperatively to
20.3 mmHg (range: 6.0-41.0 mmHg) postoperatively
(P < 0.05). The median preoperative and postoperative
Eckardt scores were 5.0 (range; 4-10) and 1.0 (range:
0-4), respectively (P < 0.05). Of the 21 patients with
mucosal penetration, symptom remission, which is
defined as a postoperative Eckardt score ≤ 3, was
achieved in 20 patients (95.2%) indicating that mucosal
penetration did not influence the success of POEM
treatment if closed successfully using fibrin sealant.

Zhang WG, Linghu EQ, Li HK. Fibrin sealant for closure of
mucosal penetration at the cardia during peroral endoscopic
myotomy: A retrospective study at a single center. World J
Gastroenterol 2017; 23(9): 1637-1644 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v23/i9/1637.htm DOI:
http://dx.doi.org/10.3748/wjg.v23.i9.1637

INTRODUCTION
Peroral endoscopic myotomy (POEM) is an effective
and safe procedure for achalasia, and is becoming
[1-4]
one of the first-line therapies to treat achalasia .
However, some major perioperative adverse events
after POEM have been reported; mucosal penetration
[1,2,5,6]
is one of the most dangerous adverse events
.
Mucosal penetration has been reported to occur in
[1,2,5,7]
4.2%-17.3% of POEM procedures
. Different
studies have reported on different treatment strategies, including observation without special treatment,
sealing of the penetration injury by hemostatic clips,
and closing the penetration defect using fibrin seal[8,9]
ant
. Mucosal penetration usually occurs at the
cardia, where a myotomy is performed during POEM.
We previously reported the usage of fibrin sealant
for mucosal penetration at the cardia in two cases in
[7]
2012 . However, long-term outcomes with a larger
population are needed to further assess this treatment
strategy. To the best of our knowledge, there is still no
evidence regarding the treatment response to fibrin
sealant for mucosal penetration during POEM in a
larger cohort. The purpose of the present study was
to evaluate the efficacy and safety of fibrin sealant for
closure of mucosal penetration at the cardia during
POEM.

CONCLUSION
Fibrin sealant is safe and effective for closure of
mucosal penetration during POEM. Mucosal penetra
tions do not appear to influence the treatment success
of POEM if closed successfully using fibrin sealant.
Additional studies regarding the feasibility, efficacy, and
safety of fibrin sealant for closure of larger mucosal
penetrations is warranted.
Key words: Fibrin sealant; Mucosal penetration; Peroral
endoscopic myotomy; Efficacy; Safety
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

MATERIALS AND METHODS

Core tip: Mucosal penetration is one of the most dan
gerous adverse events during peroral endoscopic
myotomy (POEM). We first reported the feasibility of
fibrin sealant for closure of mucosal penetration at the
cardia in two cases in 2012. However, there remains
a lack of evidence about the treatment response to
fibrin sealant for mucosal penetration in a cohort of
patients who experienced this complication. Thus, we
retrospective identified and analyzed the cases for
21 patients who experienced a mucosal penetration
and received fibrin sealant for penetration closure
during POEM, providing further support for the efficacy
and safety of fibrin sealant for penetration closure.
Moreover, instructions regarding the usage of fibrin
sealant for penetration closure were provided for
endoscopists who might be worried about mucosal
penetrations during POEM.

Twenty-four patients who underwent POEM and
experienced mucosal injury of the cardia during the
procedure between November 2010 and February
2016 were identified and collected. Of these, 21 had
mucosal penetration and 3 had only minor mucosal
damage without penetration. All 21 patients with a
penetrating injury received fibrin sealant for closure
of the mucosal penetration; these 21 patients were
included in the analysis.
Prior to undergoing POEM, all patients had undergone esophagogastroduodenoscopy (EGD), highresolution manometry (HRM), and had their symptoms
evaluated using Eckardt scores to confirm a diagnosis
of achalasia.

WJG|www.wjgnet.com

Patients

POEM procedure

Patients were admitted and fasted for 48 h before
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over the GEJ to approximately 2-3 cm into the proximal stomach. The myotomy started 2 cm distal to the
incision and extended 2-3 cm into the stomach. After
complete hemostasis and ensuring that an endoscope
could easily pass the cardia, the mucosal incision was
sutured with hemostatic clips.
In the present study, four different types of myo
tomy were performed, including inner circular muscle
myotomy, full-thickness myotomy, glasses-style antireflux myotomy, and progressive full-thickness myotomy.
Glasses-style anti-reflux myotomy retains about 1
cm of longitudinal muscle at the level of the dentate
line after incision of the inner circular muscle, and
makes selective incision of the longitudinal muscle
right above and below the dentate line. The retained
1 cm of longitudinal muscle is expected to achieve the
best result to prevent reflux after POEM.

A

B

Closure of mucosal penetration

Once mucosal penetration occurred during the POEM
procedure, fibrin sealant was sprayed into the penetrating injury in the submucosal tunnel under direct
endoscopic visualization to ensure that the fibrin sealant fully covered the defect (Figure 1). The amount
of fibrin sealant consumed was based on the size of
the defect. For large penetrations, which were difficult
to close only using fibrin sealant, a hemostatic clip
was used to make a preliminary clipping that approxi
mated the edges of the defect; then, fibrin sealant
was sprayed to fully cover the penetration defect
(Figure 2).

C

Postoperative treatment

X-ray or chest and abdomen computed tomography
(CT) was routinely performed postoperatively to
evaluate for gas-related complications immediately
after POEM. Delayed hemorrhage, pulmonary infection, and other complications were also monitored
under EGD after the procedure. Evaluation of tunnel
infection or penetration-raised esophagitis also occurs
during the postoperative EGD examination, especially
if the mucosa was penetrated during the procedure.
After fasting for 3 d postoperatively, a liquid diet was
followed for 1 d, then a soft diet. A regular diet was
resumed 1 mo after POEM. Postoperative medications,
including double-dose proton pump inhibitor (PPI) and
antibiotics, were prescribed; PPI was required for at
least 4 wk.

Figure 1 Closure of the mucosal penetration using fibrin sealant. A:
Spraying fibrin sealant in the submucosal tunnel; B: Fibrin sealant fully covers
the penetration (imaging from esophageal lumen); C: Fibrin sealant fully covers
the penetration (imaging from stomach lumen).

POEM. Patients underwent EGD prior to POEM to
ensure that there was no residual food in the esophageal lumen. During the procedure, patients were kept
in a supine position with the right shoulder elevated,
and general anesthesia was administered with
continuous monitoring of electrocardiography (ECG),
respirations, blood pressure, and oxygen saturation.
An additional cap attached at the top of the gastroscopy was required. With the outside cap diameter
(12.0 mm) as reference, the penetration size was estimated. Then, POEM was performed. First, a submucosal injection was performed with methylene blue saline
solution (1:10000), and a mucosal incision was made
at the right posterior esophageal wall approximately
6-10 cm from the gastroesophageal junction (GEJ).
Then, a submucosal tunnel was established, passing
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Follow-up

Patients were scheduled for a follow-up visit at 3 mo,
6 mo, 1 year, and 2 years after POEM. EGD, highresolution manometry, and 24-h esophageal pH
monitoring were required at the follow-up to assess
the healing of the mucosal penetration or the entry
incision, lower esophageal sphincter pressures, and
postoperative esophagitis, respectively. For patients
who experienced mucosal penetration during POEM,
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A

Table 1 Clinical characteristics and procedure-related
parameters for 21 consecutive patients who experienced
mucosal penetration during peroral endoscopic myotomy
procedure
Patient characteristics
Sex, female/male (n)
Age (yr), mean (range)
Symptom duration (mo), median (range)
Previous treatment (n)
Botox injection
Bouginage
Chicago classification (n)
Type Ⅰ
Type Ⅱ
Type Ⅲ
Procedure-related parameters
Procedure time (min.), median (range)
Tunnel length (cm), mean (range)
Myotomy length (cm), mean (range)
Myotomy type (n)
Inner circular muscle myotomy
Full-thickness myotomy
Glasses-style anti-reflux myotomy
Progressive full-thickness myotomy

B

12/9
38.0 (15-64)
26.0 (10-360)
3
1
2
18
1
58.9 (20.0-141.0)
11.7 (7-18)
5.6 (3-10)
10
1
1
9

Table 2 Characteristics of the 21 mucosal penetrations and
the treatment outcomes using fibrin sealant

C

Penetration shape, n (%)
Hole-like penetration
Linear penetration
Penetration location
Esophageal part of cardia
Stomach part of cardia
Both esophageal and stomach parts of cardia
Penetration size
Hole like penetration (cm2), mean (range)
Linear penetration (cm), median (range)
Consumed fibrin sealant amount (n)
5.0 mL
2.5 mL
Postoperative treatment
Placement of nasogastric tube (n)
Postoperative stay (d), median (range)

Figure 2 Closure of a 0.8 cm × 0.4 cm mucosal penetration using a
hemostatic clip and fibrin sealant. A: The appearance of the 0.8 cm × 0.4
cm mucosal penetration (imaging from the submucosal tunnel); B: A hemostatic
clip was used to make a preliminary clipping (imaging from esophageal lumen);
C: Fibrin sealant fully covers the preliminary clipped penetration (imaging from
stomach lumen).

12 (61.9)
8 (38.1)
1 (4.8)
0.14 (0.02-0.32)
0.37 (0.10-1.00)
3
18
2
5 (5-7)

RESULTS
Patient characteristics and procedure-related
parameters

two additional follow-ups at one week and six weeks
postoperatively were added. Postoperative complications and Eckardt scores for each patient were
recorded via the telephone. Treatment success was
defined as Eckardt scores no greater than 3.

As shown in Table 1, the study cohort consisted of 9
men and 12 women, aged 15 to 64 years (mean, 38.0
years). Among the 21 patients with mucosal penetration, the median duration of symptoms was 26.0 mo
(range, 10-360 mo). Three patients had a previous
Botox injection, and one had a previous bouginage.
According to the Chicago classification, 2 patients were
classified as type Ⅰ , 18 as type Ⅱ, and 1 as type Ⅲ.
All 21 patients successfully underwent POEM with a
median operative time of 58.9 min (range, 20.0-141.0
min). The mean length of the submucosal tunnel and
myotomy was 11.7 cm (range, 7-18 cm) and 5.6 cm

Statistical analysis

All statistical analyses were performed using SPSS
software version 17.0. Variables are expressed as
mean or median. Paired-samples Student’s t-test or
Wilcoxon matched-pairs signed-ranks test was used
to estimate the treatment outcomes of POEM. All
reported P-values are two-tailed; P-values of < 0.05
were considered statistically significant.

WJG|www.wjgnet.com
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9 (42.9)
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A

A

B

B

C

Figure 4 Healing process of the mucosal penetration after being closed
using fibrin sealant. A: The appearance of penetration at one week after
peroral endoscopic myotomy (POEM) (imaging from esophageal lumen); B: The
appearance of penetration at six weeks after POEM (imaging from esophageal
lumen).

the median size was 0.37 cm (range, 0.10-1.00 cm).
Closure of mucosal penetration using fibrin sealant
was performed successfully in all 21 patients. Two
cases, one of which was a relatively longer linear
penetration (1.0 cm), consumed 5 mL of fibrin sealant.
Only 2.5 mL of sealant was required for the remaining
19 cases. One case had a 0.8 cm × 0.4 cm hole-like
penetration that was difficult to close using only fibrin
sealant; thus, one hemostatic clip was used to make
a preliminary closure of the penetration, and fibrin
sealant was then sprayed to fully cover the mucosal
defect. The first two patients to experience mucosal
penetration had a nasogastric tube placed for 5 d after
POEM; the remaining 19 patients were kept fasting for
3 d. The mucosal penetrations had an appearance on
EGD at one week postoperatively as shown in Figure
4A and an appearance at 6 wk as shown in Figure 4B.
All 21 patients were discharged after a median of 5 d
(range, 5-7 d) postoperatively. During a median 42 mo
(range, 9-62 mo) follow-up, all 21 mucosal penetrations successfully healed without the occurrence of
penetration-raised tunnel-infection, ulcer, esophagitis,
mediastinal leak, or peritoneal leak. Detailed data of
the 21 patients with mucosal penetrations are shown
in Table 3.

Figure 3 Two kinds of mucosal penetration under esophagogastroduod
enoscopy. A: Hole-like penetration (imaging from submucosal tunnel); B:
Hole-like penetration (imaging from esophageal lumen); C: Linear penetration
(imaging from esophageal lumen).

(range, 3-10 cm), respectively.
With regards to myotomy type, 10 patients
received an inner circular muscle myotomy, 9 had
a progressive full-thickness myotomy, 1 had a fullthickness myotomy, and 1 had a glasses-style antireflux myotomy.

Mucosal penetration characteristics and treatment
outcomes after fibrin sealant

As shown in Table 2, all 21 patients had a solitary
mucosal penetration in the cardia (12 in the esophageal region of cardia, 9 in the stomach region of cardia,
and 1 in both the esophageal and stomach regions).
Twelve patients had a hole-like penetration, while 9
had a linear penetration (Figure 3). Among those with
2
a hole-like penetration, the mean size was 0.14 cm
2
(range, 0.02-0.32 cm ). For the linear penetrations,
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Treatment outcomes of POEM and complications

Symptom remission, which was defined as postopera-
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Table 3 Detailed data of the mucosal penetrations from all 21 patients
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Shape

Location

Estimated size
2
(cm/cm )

Postoperative
treatment

Postoperative stay (d)

Amount of consumed
fibrin sealant (mL)

Postoperative complaint

Hole like
Hole like
Hole like
Linear
Hole like
Linear
Linear
Linear
Linear
Hole like
Linear
Hole like
Linear
Hole like
Linear
Hole like
Hole like
Hole like
Hole like
Linear
Hole like

GOC
GOC
GOC
EOC
EOC
EOC
EOC
GOC
GOC
EOC
EOC
EOC
BOC
EOC
EOC
GOC
EOC
GOC
EOC
GOC
EOC

0.4 × 0.4
0.4 × 0.5
0.3 × 0.2
0.3
0.4 × 0.3
0.3
0.1
0.4
0.4
0.3 × 0.2
0.2
0.2 × 0.2
1.0
0.8 × 0.4
0.3
0.5 × 0.5
0.4 × 0.4
0.3 × 0.3
0.4 × 0.4
0.3
0.1 × 0.2

NG tube
NG tube
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting

7
7
7
7
7
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5

5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
5
2.5 (one hemostatic clip)
2.5
2.5
2.5
2.5
2.5
2.5
2.5

Slight abdominal pain
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal

NG tube: Nasogastric tube; GOC: Gastric part of the cardia; EOC: Esophageal part of the cardia; BOC: Both gastric and esophageal parts of the cardia.

treatment; 6 patients did not undergo post-operative
HRM due to procedure-related discomfort or for other
personal reasons. The median lower esophageal
sphincter (LES) pressure decreased from 31.9 mmHg
(range, 21.9-67.1 mmHg) preoperatively to 20.3
mmHg (range, 6.0-41.0 mmHg) postoperatively (P
< 0.05), indicating a statistically significant decrease
after POEM. All the treatment outcomes, mentioned
above, indicated that mucosal penetration did not
influence the treatment success of POEM if the defect
was closed successfully using fibrin sealant.
In terms of complications, 3 patients had postPOEM esophagitis on EGD; 2 were classified as Los
Angeles classification B and one as Los Angeles
classification A. Moreover, another 3 patients had gasrelated complications: 1 experienced pneumothorax,
1 experienced pneumoperitoneum, and 1 experienced
pneumomediastinum.

Table 4 Symptom relief, manometry outcomes, and reflux
complications of the 21 patients who experienced mucosal
penetration during peroral endoscopic myotomy
Follow-up period (mo), median (range)
Symptom relief
Eckardt score, median (range)
Pre-treatment
Post-treatment
Pre/post-treatment difference value
Treatment success (Eckardt score ≤ 3), n (%)
Manometry outcomes
Manometry follow-up rate, n (%)
LESP (mmHg), median (range)
Pre-treatment
Post-treatment
Pre/post-treatment difference value
Post-POEM esophagitis on EGD
LA-A
LA-B
Overall, n (%)
Gas-related complications, n
Pneumothorax
Pneumoperitoneum
Pneumomediastinum
Overall

42.0 (9-62)

5.0 (4-10)
1.0 (0-4)
4.8 (1-9)
20 (95.2)
15 (71.4)
31.9 (21.9-67.1)
20.3 (6.0-41.0)
14.1 (9.6-35.2)
1
2
3 (14.3)
1
1
1
3

DISCUSSION
Esophageal achalasia is an esophageal motility
disorder of unknown cause and is characterized by
failure of the LES to relax and impaired peristalsis of
[10]
the esophageal body . Conventional therapies for
achalasia include pharmacological therapy, endoscopic
balloon dilation, and Heller-Dor surgery. With recent
advances in endoscopic treatment techniques and
[9]
devices, Inoue et al have developed peroral endoscopic myotomy, in which the myotomy is performed
through a submucosal tunnel. Excellent long-term out[1,2]
comes after POEM have been reported , and POEM
is expected to become a first-line therapy for achalasia

POEM: Peroral endoscopic myotomy; EGD: Esophagogastroduod
enoscopy; LA-A: Los Angeles classification A; LA-B: Los Angeles
classification B; LESP: Lower esophageal sphincter pressure.

tive Eckardt score ≤ 3，was achieved in 20 patients
(95.2%) during a median of 42 mo (range, 9-62
mo) follow-up (Table 4). The median preoperative
and postoperative Eckardt score were 5.0 (range,
4-10) and 1.0 (range, 0-4), respectively (P < 0.05).
A total of 15 patients had HRM both before and after
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requiring surgical intervention. However, some major
perioperative adverse events from POEM have also
been reported, with mucosal penetration being one
[1,2,5,6]
of the most dangerous adverse events
. Mucosal
penetration during POEM occurs at a rate ranging from
[1,2,5,7]
4.2%-17.3% depending on the study
. Treatment
for this complication has varied, with some patients
undergoing observation without special treatment,
being sealed by multiple clips or an endoscopic suture
device (OverStitch™ Endoscopic Suturing System;
Apollo Endosurgery Austin, Texas), or being treated
[11-15]
with the defect being closed using fibrin sealant
.
Closure using hemostatic clips is not an ideal method.
Once target mucosa is clipped, adjacent mucosa has
the tendency to spontaneously split, making it hard
to completely seal the penetration. Using endoscopic
suture with the OverStitch system is usually considered
when the mucosal penetration is large and difficult to
close using conventional clips.
We first reported the usage of fibrin sealant for
closure of mucosal penetration at the cardia in two
[7]
cases in 2012 . The present study further supports
the efficacy and safety of fibrin sealant for closure of
mucosal penetration, including long-term follow-up in
a larger population (21 patients). The biggest risk of
mucosal penetration is that the fluids from the stomach or the esophagus could flow into the submucosal
tunnel or the mediastinum and cause tunnel-infection,
ulceration, esophagitis, mediastinal leak, or peritoneal
[15,16]
leak
. In our study, all 21 mucosal penetrations
healed successfully without tunnel-infection, ulceration, esophagitis, mediastinal leak, or peritoneal leak
occurring. Of note, all 21 mucosal penetrations in the
present study occurred at the cardia; one explanation
for this might be that the small operating space and
abundant submucosal vessels that demand repeated
electrocoagulation during the POEM procedure make
the mucosa in this area vulnerable. We presented
the healing process of the mucosa after being closed
using fibrin sealant (Figure 4). During a median 42 mo
(range, 9-62 mo) follow-up, all patients had completely
healed.
The required amount of fibrin sealant to adequately
cover the mucosal injury was based on the size of the
penetration; the endoscopist must ensure that the
penetration is fully covered. In this cohort, we utilized
5 mL of fibrin sealant in the first patient with penetration because of lack of experience using this technique.
Another patient who had a longer linear penetration
(1.0 cm) consumed 5 mL fibrin sealant. The remaining
19 cases only required 2.5 mL. Of note, for penetration
injuries that create larger defects, which are difficult to
close using only fibrin sealant, it is suggested that one
or two hemostatic clips be used to make a preliminary
clipping that approximates the edges of the mucosal
defect before then using fibrin sealant to fully cover the
hole. Nasogastric tubes were placed postoperatively
in the first two cases with penetration, again due to
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lack of experience with patient recovery from this
technique. However, the remaining 19 cases did not
require a nasogastric tube and had excellent healing
results, suggesting that the postoperative placement
of a nasogastric tube is not necessary in cases with a
relatively small penetration.
The treatment outcomes of POEM for the 21
patients with mucosal penetration were excellent, with
a 95.2% treatment success (Eckardt score ≤ 3), a
14.3% rate of gas-related complications, and a 14.3%
rate of post-POEM esophagitis, indicating that mucosal
penetration did not influence the treatment success of
POEM if closed successfully using fibrin sealant.
Given that the sizes of the mucosal penetrations
in this study were all relatively small, it is not clear
whether the defects could have been observed and
would have closed spontaneously. Therefore, a prospective randomized controlled trial comparing obser
vation without special treatment to treatment with
fibrin sealant is warranted. In previous studies evaluating intraoperative mucosal penetration during POEM,
the injured mucosa could be closed only by prolonged
fasting in those who received inner circular muscle
myotomy. In the present study, 10 patients had an
inner circular muscle myotomy, 1 had a full-thickness
myotomy, 1 had a glasses-style anti-reflux myotomy,
and 9 had a progressive full-thickness myotomy.
Further research is needed to determine if the injured
mucosa was more likely to close spontaneously in
those who received inner circular muscle myotomy
than in those who received a full-thickness myotomy.
Our study is not without limitations. One limitation was
that the submucosal defects in our study were all relatively small, so we cannot draw conclusions regarding
the feasibility, efficacy, and safety of fibrin sealant in
closing large mucosal penetrations. Additionally, with
a small sample size of only 21 patients, we were not
able to stratify our results to draw conclusions regarding the required amount of fibrin sealant based on the
penetration size. Another limitation is that this was a
single center study, suggesting that our results may
not be representative of findings in other hospitals.
However, to the best of our knowledge, this is the largest published study regarding the treatment response
to fibrin sealant for mucosal penetration during POEM,
incorporating data from 21 patients. The present study
also provides instruction regarding the usage of fibrin
sealant for penetration closure for endoscopists, which
may be especially helpful for those who are unfamiliar
with the technique or who might be worried about
mucosal penetrations during POEM.
In conclusion, the use of fibrin sealant to close
mucosal penetration during POEM is safe and effective.
Mucosal penetrations do not appear to influence the
treatment success of POEM if closed successfully using
fibrin sealant. However, further research regarding
the feasibility, efficacy, and safety of fibrin sealant for
closing larger mucosal penetrations is warranted.
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Abstract

situations according to the following characteristics:
defect size, duration since onset, and indication. The
individualized choice of the suction method is the most
important factor determining OTSC success.

AIM
To demonstrate the clinical outcomes of a multicenter
experience and to suggest guidelines for choosing a
suction method.

Kobara H, Mori H, Fujihara S, Nishiyama N, Chiyo T, Yamada
T, Fujiwara M, Okano K, Suzuki Y, Murota M, Ikeda Y, Oryu
M, AboEllail M, Masaki T. Outcomes of gastrointestinal defect
closure with an over-the-scope clip system in a multicenter
experience: An analysis of a successful suction method. World
J Gastroenterol 2017; 23(9): 1645-1656 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v23/i9/1645.htm DOI:
http://dx.doi.org/10.3748/wjg.v23.i9.1645

METHODS
This retrospective study at 5 medical centers involved
58 consecutive patients undergoing over-the-scope
clips (OTSCs) placement. The overall rates of technical
success (TSR), clinical success (CSR), complications,
and procedure time were analyzed as major outcomes.
Subsequently, 56 patients, excluding two cases
that used the Anchor device, were divided into two
groups: 14 cases of simple suction (SS-group) and 42
cases using the Twin Grasper (TG-group). Secondary
evaluation was performed to clarify the predictors of
OTSC success.

INTRODUCTION
Conventional endoscopic therapy-resistant gastrointestina diseases have traditionally required invasive
surgery. These diseases mainly consist of GI refractory
bleeding and leaks, including perforations, anastomotic
leakage, and fistulae, which are encountered during
endoscopic evaluation and are related to significant
[1]
morbidity and mortality . Recently, with the develop[2]
ment of endoscopic submucosal dissection (ESD)
and natural orifice transluminal endoscopic surgery
[3]
(NOTES) , technological advances in endoscopic
devices have allowed for the endoscopic closure of
GI defects. Among several full-thickness suturing
[4,5]
devices , the over-the-scope clip (OTSC) (Ovesco
Endoscopy GmbH, Tübingen, Germany) has the advan
tage of rapid and convenient use in rescue therapy.
[6-10]
Currently, many case reports
and preliminary case
[11-14]
series
have reported on the efficacy of OTSCs
for the closure of GI defects, eliminating the need for
invasive surgery.
However, there are few studies that have used
[15]
large samples , and few randomized controlled tri[16,17]
als
have been performed with OTSCs. Specifically,
a strategy for choosing a suction method into the
application cap of the OTSC system has not been
clearly described. Successful OTSC closure depends
on the secure suction of the target lesion into the
application cap. The options available for OTSC closure
include three suction methods, including simple suction
(SS), which is similar to endoscopic variceal band ligation, and two accessory devices (Ovesco Endoscopy
GmbH), which are referred to as the Twin Grasper (TG)
and the tissue-anchoring device called the Anchor.
Functioning as grasping forceps, the TG is applied
to easily approximate the grasping edges of a large
lesion, whereas the Anchor can better approximate
indurated tissue. As both devices are expensive,
selection of the appropriate suction method needs to
be made according to the characteristics of the target
lesion, which include the size of the defect, indications, and the duration since onset. The primary goal

RESULTS
The TSR, CSR, complication rate, and median proce
dure time were 89.7%, 84.5%, 1.8%, and 8 (range
1-36) min, respectively, demonstrating good outcomes.
However, significant differences were observed
between the two groups in terms of the mean proce
dure time (5.9 min vs 14.1 min). The CSR of the SSand TG-groups among cases with a maximum defect
size ≤ 10 mm and immediate or acute refractory
bleeding was 100%, which suggests that SS is a better
method than TG in terms of time efficacy. The CSR in
the SS-group (78.6%), despite the technical success
of the SS method (TSR, 100%), tended to decrease
due to delayed leakage compared to that in the
TG-group (TSR, CSR; 88.1%), indicating that TG may
be desirable for leaks and fistulae with defects of the
entire layer.
CONCLUSION
OTSC system is a safe and effective therapeutic option
for gastrointestinal defects. Individualized selection
of the suction method based on particular clinical
conditions may contribute to the improvement of OTSC
success.
Key words: Over-the-scope clip; Leak; Gastrointestinal
refractory bleeding; Fistula; Endoscopic closure
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: The efficacy of over-the-scope clips (OTSCs)
for gastrointestinal defects has been widely known.
However, few large studies with more than 50 cases
have been performed. Additionally, an optimal strategy
for selecting a suction method, which is a critical factor
of OTSC success, is needed. This study, with a large
number of cases and a multicenter design, demon
strated excellent outcomes of OTSC and revealed which
type of suction method was appropriate for particular
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MATERIALS AND METHODS

Table 1 Demographics and characteristics of patients,
defects, and over-the-scope clips
Characteristics

Details

Age, median (range), yr
Indications, n
Refractory bleeding

Study design

This retrospective study was conducted at 5 medical centers in the Shikoku area of Japan. Between
November 2011 and November 2015, fifty-eight
patients who underwent attempted OTSC placement
for GI refractory bleeding, leaks, or fistulae were
enrolled. The detailed clinical data are summarized in
Table 1. Patient characteristics, including age, indications with details, location of the defect, maximum
defect size (D, mm), duration from onset to OTSC
placement (immediate, ≤ 1 d, acute, 1-7 d, or chronic,
> 7 d), and the numbers of OTSC deployments, were
collected. The indication for OTSC application for
GI nonvariceal and refractory bleeding was defined
as cases in which 2 time trials by conventional
interventions failed to achieve complete hemostasis.
Perforations, deep defects of the gut with the risk of
delayed perforations, and anastomotic leakages were
included as leaks. Subsequently, 56 patients, excluding
two cases that used the Anchor, were divided into
two groups: 14 cases of simple suction (SS-group)
vs 42 cases using the Twin Grasper (TG-group). All of
the data were extracted and compiled into a central
database at Kagawa University. Written informed consents related to the use of OTSCs were obtained from
all patients. The Clinical Ethics Committee of Kagawa
University Hospital and each institution approved
this study. This study was registered under UMIN
000017767.

Total patients
(n = 58)
77 (37-98)

Ulcer (peptic, Behçet’s,
anastomosis)
Mallory-Weiss tear
Diverticula
Post-endoscopic resection
Leaks
Peptic ulcer
Boerhaave
Iatrogenic (ESD)
Iatrogenic (ERCP)
Iatrogenic (surgery)
Iatrogenic (other)
Fistula
PEG
Rectum-bladder
Rectum-pelvis
Gastric tube-trachea
Gastric-pseudopancreatic cyst
Colon-gallbladder
Location, n
Esophagus
Stomach
Duodenum
Small intestine
Colon
Maximum defect size (D)
mm, n

18
12
1
2
3
28
3
1
16
2
4
2
12
6
1
2
1
1
1
3
28
13
2
12

D ≤ 10
10 < D ≤ 20
20 < D
Median (range), mm
Duration since onset to
OTSC placement, n

25
9
24
15 （3-50）

Immediate ≤ 1 d
1 < Acute ≤ 7 d
Chronic > 7 d
Suction method into the
applicator cap

25
11
22

Simple suction
Twin Grasper (TG)
assist

14
42

Anchor assist
The number of OTSC
deployments, n

2

OTSC procedures

The OTSC system is primarily composed of an OTSC
mounted onto an application cap and a hand wheel.
Users can easily apply the simple mechanism. As
[18]
previously reported , the OTSC procedure involved
several steps. First, the endoscope on which the cap
with the loaded OTSC was mounted was inserted into
the GI tract either orally or anally. Either a gastroscope (GIF-Q260J, ø 9.9 mm or H260Z, ø 10.8 mm
Olympus, Tokyo, Japan) or a colonoscope (PCF-Q260AI,
ø 11.3 mm, Olympus) with a maximum diameter of
9.9 mm and a working channel with greater than a
2.8 mm diameter was applied. Second, the defect in
the GI tract was sucked to an application cap using
SS or application aids such as the TG or the Anchor.
The choice of the suction method ultimately depended
on the discretion of the operator in this study. Finally,
the clip was fired by stretching the wire with the hand
wheel, and the entire defect of the lesion was completely closed. The OTSC procedures for the SS and TG
methods and the Anchor assist are shown as schemas
in Figure 1. Additional OTSCs were deployed until the
defect was entirely closed. Regarding the types of
OTSCs that were used, the gastrostomy closure type
for gastric walls and the traumatic (t) type for other
organs with thin walls were introduced, depending

21
39
12
5

0
1
2
3

1
Procedural inability. OTSC: Over-the-scope clip; PEG: Percutaneous
endoscopic gastrostomy; ERCP: Endoscopic retrograde cholangiopancrea
tography; SS: Simple suction; TG: Twin Grasper.

of this study was to demonstrate clinical outcomes of
a multicenter experience with OTSCs for the management of GI refractory bleeding, leaks, and fistulae.
The secondary goals were to propose a directional
strategy for choosing a suction method into the
application cap of the OTSC system by comparing the
clinical data of SS to that of TG.
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B
B

A

Table 2 Results of major outcomes
Total patients (n = 58)

Outcomes
Technical success rate, % (95%CI)
Clinical success rate, % (95%CI)
Complications, n (%)
The procedure time, median (range), min

89.7 (81.0-98.4)
84.5 (74.3-94.7)
1 (1.8)
in 56 cases used
8 (1-36)
in 52 successful cases

C
since onset (immediate, acute, or chronic) were compared between the SS- and TG-groups. We supposed
that a maximum defect size of 10 mm might be suitable for complete closure in the SS-group, considering
the caliber of the application cap (11 or 12 mm in
diameter). Previous studies have shown that factors
that promote OTSC failure include a large defect size
[14]
(greater than 20 mm) , fibrosis of the target tissue,
such as a fistula, and the duration from onset to OTSC
[15]
placement . Thus, the maximum defect size was
defined using the cut-off values of 10 and 20 mm, and
the duration from onset was evaluated as one parameter. Simultaneously, the CSRs in both groups in terms
of the combined parameters, the defect size, and
the duration since the onset of each indication were
estimated to better clarify the quality of each method.

Figure 1 Key factor for the success of over-the-scope clips: schema of
three suction methods into the application cap of the target lesion. A:
Simple suction, similar to endoscopic variceal band ligation (simple suction
method); B: Assist of grasping forceps: Twin Grasper device (Twin Grasper
method); C: Assist of tissue anchoring device (Anchor assist).

on the lesion and the assessment of the operator;
the atraumatic (a) type was not used in this study.
Six expert endoscopists (H.K., H.M., T.Y., N.N., M.M.,
and M.O.) who had gained experience with the OTSC
system procedure in a porcine model during a handson seminar session performed the OTSC deployments.

Statistical analysis

Normally distributed data are presented as medians
and ranges. The TSRs, CSRs and complication rates
in the SS- and TG-groups were compared using twosided Fisher’s exact tests. The mean procedure times
of both methods were compared using two-sided
Wilcoxon/Kruskal-Wallis tests. The TSRs and CSRs of
2
each parameter were compared using a χ test. P <
0.05 was considered statistically significant. All stati
stical analyses were conducted using JMP version 9.0
(SAS Institute Inc., Cary, NC, United States).

Outcome measures

Major outcomes: The overall rates of technical
success (TSR), clinical success (CSR), complications,
and procedure time of the 58 patients were examined.
Technical success was defined as the complete closure
of the entire defect by the successful deployment of
OTSCs. Clinical success was defined as the resolution
of the troubled situation by the assessment of blood
analysis, endoscopic, and/or radiographic imaging
(surgery or further endoscopic intervention was not
required during at least 1 mo of follow-up after OTSC
placement). The procedure time of the suction method
was defined as the duration between the attempts at
aspiration or the application of the TG or Anchor on the
target lesion and complete closure of the defect with
OTSC placement, as reviewed by endoscopic images
and/or movies. The number of OTSC placements per
single defect was calculated when the entire defect of
the lesion was completely closed.

RESULTS
The results for the major outcomes are summarized
in Table 2. The TSR and CSR were 89.7% and 84.5%,
respectively. The complication rate was 1.8% in the 56
cases analyzed. The median procedure time (range)
was 8 (1-36) min in 52 successful cases. Additionally,
the TSR and CSR of each parameter are shown in
Table 3. While the TSR decreased as defect size and
duration since onset increased, the CSR decreased as
duration since onset increased.
The results of the comparison between the SSand TG-groups with respect to the major outcomes
are summarized in Table 4. No significant differences
were identified between the SS- and TG-groups in
terms of TSR [100% (14/14) vs 88.1% (37/42),
respectively] and CSR [78.6% (11/14) vs 88.1%
(37/42), respectively], P > 0.05). However, the CSR in
the SS-group [78.6% (11/14)], despite the technical

Secondary outcomes: A secondary evaluation was
performed to clarify the predictors of OTSC success
in the SS- and TG-groups. The TSR, CSR, procedure
time, and complication rates of both groups were
compared.
Subsequently, the TSR and CSR of each parameter
and the indications, location of the defect, maximum
defect size (≤ 10, 10-20, or > 20 mm), and duration
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Table 3 Results of the technical and clinical success rates for
each parameter

Table 4 Outcomes of the simple suction and Twin Grasper
methods n (%)

Total patients (n = 58)

Parameters

Indications
Refractory bleeding
Leak
Fistula
Location
Upper GI tract
Lower GI tract
Maximum defect size (D), mm
D ≤ 10
10 < D ≤ 20
20 < D
Duration since onset, % (n)
Immediate ≤ 1 d
1 < Acute ≤ 7 d
Chronic > 7 d
Suction method into the
applicator cap
Simple suction (SS)
Twin Grasper (TG)
Anchor assist
The number of OTSC
deployments, n
1
2
3

Technical success
rate

Clinical success
rate

88.9 (16/18)
89.3 (25/28)
91.7 (11/12)

83.3 (15/18)
85.7 (24/28)
83.3 (10/12)

86.4(38/44)
100 (14/14)

81.8 (36/44)
92.9 (13/14)

96 (24/25)
88.9 (8/9)
83.3 (20/24)

84 (21/25)
88.9 (8/9)
83.3 (20/24)

96 (24/25)
90.9 (10/11)
81.8 (18/22)

96 (24/25)
81.8 (9/11)
72.7 (16/22)

100 (14/14)
88.1 (37/42)
50 (1/2)

78.6 (11/14)
88.1 (37/42)
50 (1/2)

92.3 (36/39)
100 (12/12)
80 (4/5)

84.6 (33/39)
100 (12/12)
80 (4/5)

TG-method
(n = 42)

P value

Technical success rate

14 (100)

37 (88.1)

0.1761

Clinical success rate
Procedure time, median
(range), min
Complications

11 (78.6)
5 (1-16)
0 (0)

0.3781
37 (88.1)
12 (3-36)
0.00042
in 37 successful cases
0.5871
1 (2.4)

1

Fisher’s exact test (2-sided), 2Wilcoxon/Kruskal-Wallis test. SS: Simple
suction; TG: Twin Grasper.

≤ 10). These aspects of the SS method suggest that

the TG is desirable for leaks and fistulae with defects of
the entire layer.

Case presentation

A representative success of SS in refractory bleeding
is shown in Figure 3. In a failure case in the SS-group
with D ≤ 10 and a chronic duration, conventional
therapy-resistant ulcer bleeding that in the terminal
ileum occurred during steroid treatment for myelodysplastic syndrome. Despite the successful closure of
the defect with the SS method, additional surgery was
needed because of re-bleeding that might have been
caused by angiogenesis from the steroid treatment in
specific circumstances (Table 7, case No. 1). The CSR
of the TG-group among cases with D > 20 showed the
lowest success rate, 33.3% (1/3). In these 2 failure
cases of chronic, fibrotic ulcers with D > 20, technical
success could not be achieved due to an inability to
suck rigid tissues into the cap, even when using the
TG (Table 7, case No. 2 and No. 3). Although the use
[18]
of the Anchor might have been helpful , we did not
introduce the device because of the risk of perforation by the bear claw of the device. Finally, these
bleeds were managed with conventional therapies
using hemostatic forceps. At the indication of a leak,
the TG method provided good clinical outcomes for
defects with D ≤ 10 and immediate duration during
endoscopic retrograde cholangiopancreatography
(ERCP); an image of a representative case is shown in
Figure 4. On the other hand, there were three clinical
failure cases with leaks: one with SS with D ≤ 10 and
an acute duration, one with the TG with 10 < D ≤ 20
and an immediate duration, and one with the TG with
D > 20 and an acute duration. In the first case, an
acute anastomotic leakage with D ≤ 10 after surgery
for gastric cancer that was located in the esophagealgastric junction was successfully closed using SS, but
additional surgery was needed because of a delayed
leakage (Table 7, case No. 4). In the second case, a
large perforation of approximately 20 mm occurred
during ERCP, and the TG was used to approximate
the defect. The collapse of the intestine because of air
leakage made technical success impossible, and this

success of the procedure (TSR, 100%), tended to
decrease compared to that in the TG-group (TSR,
CSR; 88.1%). Additionally, no significant differences
were identified between the two groups in terms of
the rate of complications [0% (0/14) vs 2.4% (1/42),
P > 0.05]. However, significant differences were
observed between the two groups regarding the mean
procedure time (SS, 5.9 vs TG, 14.1 min, P < 0.05).
A flow diagram of patient enrollment and outcomes is
illustrated in Figure 2.
There were no significant differences in the TSRs
and CSRs between the two groups for any parameter (P
> 0.05) (Table 5). The CSR in the TG-group decreased
as defect size and duration since onset increased. The
CSRs of the combined parameters, defect sizes and
duration since onset in each indication are summarized
in Table 6. For refractory bleeding, the CSRs for cases
of D ≤ 10 were 85.7% (6/7) in the SS-group and
100% (2/2) in the TG-group. The CSR of the SS- and
TG-groups among cases with D ≤ 10 and immediate
or acute refractory bleeding was 100%, which suggested that SS is a better method than TG in terms of
time efficacy. However, the CSRs of cases with leaks
and fistulae and D ≤ 10 were 71.4% (5/7) in the
SS-group and 100% (7/7) in the TG-group. Delayed
leakages occurred in two cases in the SS-group (D ≤
10 and acute leakage and D ≤ 10 and chronic fistula).
These data suggest that the SS method sometimes
fails to provide an acceptable clinical outcome despite
the technical success, even if the defect size is small (D
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OTSC
(n = 58)

Excluded:
Anchor assist
1
(n = 2)

OTSC
(n = 56)

SS group
(n = 14)

TG group
(n = 42)

Technical success
(n = 14)

Clinical success
(n = 11)

Technical success
(n = 37)

Clinical failure
(n = 3)

Technical failure
(n = 5)

Clinical success
(n = 37)

Endoscopic
intervention

Surgery
(n = 3)

Surgery
(n = 3)

(n = 2)

Figure 2 Flow diagram of patient enrollment and outcomes. 1Clinical outcomes of two cases that used the Anchor: one case with an incomplete closure of an
esophageal-gastric anastomotic leakage, and another case with clinical success of gastric fistula after percutaneous endoscopic gastrostomy. SS: Simple suction; TG:
Twin Grasper.

Table 5 Results of the technical and clinical success rates of the simple suction- and Twin Grasper-groups for each parameter
Parameters

Technical success rate

Indication
Refractory bleeding
Leak
Fistula
Location
Upper GI tract
Lower GI tract
Maximum defect size (D), mm
D ≤ 10
10 < D ≤ 20
20 < D
Duration since onset, % (n)
Immediate ≤ 1 d
1 < Acute ≤ 7 d
Chronic > 7 d

Clinical success rate

SS (n = 14)

TG (n = 42)

P value1

SS (n = 14)

TG (n = 42)

P value1

100 (7/7)
100 (2/2)
100 (5/5)

81.8 (9/11)
92 (23/25)
83.3 (5/6)

0.2315
0.6776
0.3384

85.7 (6/7)
50 (1/2)
80 (4/5)

81.8 (9/11)
92 (23/25)
83.3 (5/6)

0.8288
0.0690
0.8865

100 (8/8)
100 (6/6)

85.3 (29/34)
100 (8/8)

0.8725

75 (6/8)
83.3 (5/6)

85.3 (29/34)
100 (8/8)

0.8725
0.2308

100 (14/14)
-

100 (9/9)
88.9 (8/9)
83.3 (20/24)

-

78.6 (11/14)
-

100 (9/9)
88.9 (8/9)
83.3 (20/24)

0.1364
-

100 (3/3)
100 (3/3)
100 (8/8)

95.5 (21/22)
87.5 (7/8)
75 (9/12)

0.6994
0.1247
0.1250

100 (3/3)
66.7 (2/3)
75 (6/8)

95.5 (21/22)
87.5 (7/8)
75 (9/12)

0.6994
0.1247
1.0000

1 2

χ test (2-sided). SS: Simple suction; TG: Twin Grasper.

case required surgical repair (Table 7, case No. 5). In
the third case, a delayed perforation with a 50-mm
defect size occurred after gastric endoscopic submucosal dissection. The defect could not be closed with the
TG because of a narrow lumen in the prepylorus and
the large defect size. The misplacement of the OTSC
on the exposed muscularis propria induced additional
tears, which represents the only case of an OTSC
complication in this study. Although the use of several
hemoclips at the perforation site seemed to be effective, surgery was performed due to the re-appearance
of free air in computed tomography (CT) images 3 d
after endoscopic therapy (Table 7, case No. 6, shown
as the only complication in Figure 5). Among the
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fistula cases, there were two clinical failures: one with
SS with D ≤ 10 and a chronic duration and one with
TG with 10 < D ≤ 20 and a chronic duration. The first
case was an 8-mm gastric fistula that occurred after
an interventional endoscopic ultrasound for a pseudopancreatic cyst (Table 7, case No. 7), which is shown
in Figure 6. Although the fistula was successfully
closed using SS, leakage occurred 2 wk after OTSC
placement, which necessitated additional surgery. The
other case was a large (22 mm in diameter) gastric
tube-tracheal fistula that occurred after radiation for
esophageal carcinoma. The fistula could not be treated
with the TG and required surgery (Table 7, case No. 8).
Details of these 8 clinical failure cases are summarized
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Table 6 Comparison of the clinical success rates for the combined parameters in each indication
Clinical success rate
Refractory bleeding (n = 18)

Indications
Combined parameters
D ≤ 10, Immediate
D ≤ 10, Acute
D ≤ 10, Chronic
10 < D ≤ 20, Immediate
10 < D ≤ 20, Acute
10 < D ≤ 20, Chronic
D > 20, Immediate
D > 20, Acute
D > 20, Chronic

Leak (n = 27)

Fistula (n = 11)

SS (n = 7)

TG (n = 11)

SS (n = 2)

TG (n = 25)

SS (n = 5)

TG (n = 6)

100%
100%
66.7%
-

100%
100%
100%
100%
100%
100%
33.3%

50%
-

100%
100%
66.7%
100%
100%
75%
-

80%
-

100%
100%
50%

SS: Simple suction; TG: Twin Grasper.

Table 7 Details of over-the-scope clips clinical failure cases (n = 8)
Indication

Max. defect
size, mm

Cause, comorbidity

Location

Refractory
bleeding

8

Ileal ulcer bleeding due
to steroid treatment
for myelodysplastic
syndrome

Terminal ileum

Refractory
bleeding
Refractory
bleeding
Leak

20

Leak

21

Leak

50

50
7

Fistula

8

Fistula

22

Prior therapy

Duration Technical Technical or clinical Additional
since onset success
failure factor
therapy

EI
Chronic
(hemoclips and
coagulation)

Peptic ulcer, Refractory
Stomach (body)
EI
Chronic
neurogenic disease
(coagulation)
Peptic ulcer, Advanced
Stomach (body)
EI
Chronic
gallbladder carcinoma
(coagulation)
Anastomotic leakage Esophageal gastric
None
Acute
after surgery for
junction
gastric cancer
Perforation during Duodenal 2nd portion
None
Immediate
ERCP
Delayed perforation Stomach (prepyrolus)
None
Acute
after ESD
Interventional EUS Gastric (prepyrolus)None
Chronic
pseudopancreatic cyst
Radiation for
Gastric tube-trachea
Bronchial
Chronic
esophageal carcinoma
embolization

Clinical
outcome

Yes

Suspicion of
angiogenesis due to
steroid in particular
circumstances

Elective
surgery

Survival

No

Fibrotic tissue

Retry of EI

Survival

No

Fibrotic tissue

Retry of EI

Survival

Yes

Leakage by mucosal
suture (suspected)

Elective
surgery

Survival

No

Inability of
Emergency
platform
surgery
Location with
Elective
narrow lumen
surgery
Leakage by mucosal Elective
suture (suspected)
surgery
Fibrotic tissue
Elective
surgery

No
Yes
No

Survival
Survival
Survival
Survival

SS: Simple suction; TG: Twin Grasper; EI: Endoscopic intervention; ERCP: Endoscopic retrograde cholangiopancreatography; EUS: Endoscopic ultrasound.

[14,15]

in Table 7.

ously described
. Therefore, an optimal strategy
for choosing a suction method for the OTSC system is
needed. This study is the first to clarify these issues by
comparing the clinical data of SS to TG.

DISCUSSION
A newly developed endoscopic full-thickness suturing
device, the OTSC system, has allowed for the endoscopic closure of conventional therapy-resistant GI
defects. The efficacy of OTSC has been widely known
since its introduction in 2009 in Western countries.
However, there have been few studies that used large
samples of more than fifty cases and a multicenter
design.
Additionally, the type of suction method that should
be applied to each target lesion based on the particular
lesion characteristics remains unclear. Successful OTSC
closure depends on the secure suction of the target
lesion into the application cap. This success is closely
related to the extent of tissue fibrosis in proportion to
the duration from onset to OTSC placement, as previ-
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SS vs TG

Compared to TG, SS has the advantage of rapid and
convenient use with a system that is similar to endoscopic variceal band ligation (mean procedure time; SS
5.9 min vs TG 14.1 min, P < 0.05). Moreover, another
merit of SS is its lower cost if accessory devices are
not applied. A maximum defect size of 10 mm per clip
can be completely closed with the SS method, considering the caliber of the application cap. If OTSC is
not fired due to insufficient suction into the cap during
SS method, TG assist can be an alternative choice to
close the defect. Although no significant differences in
TSR or CSR were observed between the two groups in
this study, the CSR of the SS-group (78.6%, 11/14),
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A

B

Figure 3 Representative clinical success case in the simple suction-group that exhibited refractory bleeding with a defect size of ≤ 10 mm and an
immediate duration since onset. A: A spurting, bleeding ulcer that was located in a rectal anastomotic site; B: Complete hemostasis via over-the-scope clip closure
using the simple suction method after the failure of conventional endoscopic intervention.

A

B

C

Figure 4 Representative clinical success case in the Twin Grasper-group of a leak with a defect size of ≤ 10 mm and an immediate duration since onset.
A: An iatrogenic perforation site approximately 10 mm in size, located in the 2nd portion of the duodenum during endoscopic retrograde cholangiopancreatography; B:
Application of the Twin Grasper device; C: Complete defect closure three months after over-the-scope clip deployment.

A

B

C

Tear

Figure 5 Representative case with an over-the-scope clips complication. A: A delayed perforation with a 50-mm defect size after gastric endoscopic submucosal
dissection; B: The misplacement of the over-the-scope clips to the exposed muscularis propria induced additional tears (black arrows); C: The defect could not be
closed by the Twin Grasper due to a narrow lumen located in the prepylorus.

despite its technical success (TSR, 100%, 14/14),
tended to decrease compared to the TG-group (TSR,
CSR; 88.1%, 37/42) due to delayed leakage. This
finding indicates that the SS method might result in
some clinical failures despite its technical success.
Therefore, a secondary evaluation regarding each
parameter or combined parameters for each indication

WJG|www.wjgnet.com

was performed to better clarify the quality of each
method. The CSR of the SS-group with D ≤ 10 and
immediate or acute refractory bleeding was 100%,
which suggested that SS was a better method than TG
in terms of time efficacy. However, the CSRs of leaks
and fistulae with D ≤ 10 were 71.4% (5/7) in the
SS-group and 100% (7/7) in the TG-group. Delayed
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A

B

C

D

Figure 6 Clinically unsuccessful case in the simple suction-group of a fistula with a defect size of ≤ 10 mm and a chronic duration. A: An 8-mm gastric
fistula after interventional endoscopic ultrasound for a pseudo-pancreatic cyst; B: Complete closure with one over-the-scope clip (OTSC) using the simple suction
method; C: A delayed leakage (black arrows) that occurred 2 wk after OTSC placement; D: X-ray contrast photo via a percutaneous drainage tube that revealed the
delayed leakage.

leakages occurred in two cases in the SS-group (D ≤
10 and acute leakage and D ≤ 10 and chronic fistula).
These interesting data suggest that the SS method
might sometimes fail in full-thickness suturing and
could result in mucosal suturing for the target tissue,
even if the defect size is small. Moreover, OTSC system
using TG assist after clinical failure of SS method is not
applicable for the same defect, because it is difficult
to remove endoscopically the deployed OTSC on the
target lesion. In this situation, surgery will be the only
suitable therapy as shown in Figure 2. Thus, the use of
TG may be desirable for leaks and fistulae with defects
of the entire layer.
The TG is commonly used for large defects, but
details regarding defect sizes and indications are
unknown. The CSR in the TG-group decreased as
defect size and duration since onset increased (Table
5). In particular, the success rate in the TG-group was
the lowest for defects with D > 20 and those that were
chronic, which indicates the limitations of the TG for
large defects with fibrosis. If the TG method fails in this
condition, a retrial with the Anchor might be valuable.
Further comparative studies that include the Anchor
are needed to clarify its efficacy and limitations.

clinical studies including more than 50 cases, as in
the present study, are rare. Here, we summarized the
overall CSR in human studies between 2011 and 2015
that involved a minimum of 2 wk of follow-up, and we
included several important parameters (e.g., defect
[19-26]
size, use of accessory devices) (Table 8)
. The
mean rate of overall clinical success was 68.4% (range
53-90) (329/481 cases), which includes our results.
Our data revealed a high rate of overall clinical success (84.5%). This finding may be why no significant
differences in TSR or CSR were observed between the
two groups in this study. Additionally, the proportion
of fistulae and/or the defect size included in other
studies may be associated with the OTSC success rate.
According to a large sample of data, a defect type with
fibrotic tissue, such as a fistula, is the most important
[15]
predictor of OTSC failure . Therefore, we evaluated the success rates of three types of indications
separately (refractory bleeding, leaks, and fistulae).
The mean rates of overall clinical success in refractory
bleeding, leaks, and fistulae were 87.8%, (79/90
cases), 83.2% (109/131), and 53.0% (133/251),
respectively.
Similar to the overall mean rate of complications
(1.66%, 8/481), there was only one case in which
the misplacement of the OTSC to exposed muscularis
propria induced additional tears in this study (1.8%
complication rate). Although OTSCs have been dem-

Overall clinical success

Currently, there are limited data from large sample
[15]
[16,17]
sizes
and few comparative studies
. Specifically,
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Table 8 Current clinical outcomes of over-the-scope clips for each indication
Ref.

Year

Country

Patients
Overall clinical success rate, (success/ total)
(n )
Refractory
Leaks and/or
Fistula Others Total
bleeding
perforations

Albert et al[20]
Surace et al[21]

2011
2011

Kirschniak et al[22]

2011

Germany
France,
Monaco
Germany

Baron et al[19]

2012 United States

45

Manta et al[23]
2013
Italy
Haito-Chavez et al[15] 2014 International2

30
188

19
19
50

57.1 (4/7)
-

87.5 (7/8)
-

25 (1/4)
74
(14/19)
92.6 （25/27） 100 (11/11) 37.5 (3/8) 100
(4/4)
100 (7/7)
62.5 (5/8)
67.9
50
(19/28) (1/2)
90 (27/30)
Leaks 73.3
42.9
(22/30), 21
(39/91),
Perforations 90
171
(36/40), 81
53
(25/47)
100 (1/1)
66.7 (4/6)
63.6
100
(7/11) (3/3)

Law et al[24]

2014 United States

47

Sulz et al[25]

2014

Switzerland

21

Mercky et al[26]

2015

France,
Monaco

30

-

-

53
(16/30)

Our study

2016

Japan

58

83.3 (15/18)

85.7
(24/28)

83.3
(10/12)

507

87.8 (79/90)

83.2 (109/131)

Total

63.2
73.7

Mean defect Described data Complications,
size (mm)
of suction
n (%)
method
Unknown
Unknown

Unknown
Unknown

0
1 (5)

86

6

Unknown

0

71

Unknown

90
60.2

53

TG: 8 cases
AC: 17 cases
Unknown
Unknown
Leaks: 8
Use of TG
Perforations: 7 and/or AC,
Fistula: 5
50% (70/140
cases)3
Unknown
Unknown

71.4

8

-

53

7.2

-

84.5

19.6

53.0
88.9
68.4
(133/251) (8/9) (329/481)

SS:4 100%
(10/10)
TG:100% (1/1)
AC: 87.5%
(7/8) TG +
AC: 0% (0/1)
SS: 17
procedures
TG: 9
procedures
AC: 5
procedures
CSR
SS4: 78.6%
(11/14)
TG: 88.1%
(37/42)
AC: 50%
(1/2)

2 (4.4)
0
0

0
0

4 (13.3)

1 (1.8)

8/481 (1.66)

1

Excluded number of patients lost to follow-up; 2United States, Netherlands, Germany, Italy, and Chile; 3Use of accessory devices was not a predictor of
clinical success; 4Clinical success rate. SS: Simple suction; TG: Twin Grasper; AC: Anchor.

onstrated to be safe, a careful approach is needed to
avoid OTSC placement on exposed muscularis propria,
which can occur in a defect after endoscopic resection.

success and our CSR were 83.2% (range 62.5-100)
(109/131) and 85.7% (24/28), respectively, the OTSC
is valuable in avoiding emergency surgery for leaks.

GI refractory bleeding

Fistulae

The OTSC system offers the strongest impact in
regards to GI bleeding compared to other indications,
as evidenced by the mean rate of overall clinical
success of 87.8%, (79/90 cases), which is similar to
the findings in our study (83.3%, 15/18). Therefore,
an OTSC is a good device with which to achieve
hemostasis in conventional therapy-resistant GI bleeding. However, as our 2 failure cases with D > 20 and
chronic fibrotic ulcers revealed, OTSC usage may be
limited in particular situations.

Among all of the indications, the mean rate of overall
clinical success for fistula was the lowest (53.0%,
range 25-81.8, 133/251 cases). Similarly, recent
studies have demonstrated a limited success rate
of approximately 50%. Despite the introduction of
the OTSC system, fistula closure appears to be a
challenge. However, compared to other studies, our
study delivered good outcomes with both technical
(91.7%, 11/12 cases) and clinical success (83.3%,
[24]
10/12 cases). Law et al
reported that nearly 50%
of patients with endoscopic and radiologic evidence of
fistula closure at completion of the index procedure
went on to require additional interventions in the
subsequent days and months due to fistula recurrence.
Accordingly, we recommend the use of sufficient suc-

Leaks

Perforations, deep defects with the risk of delayed perforations, and anastomotic leakages were included as
leaks in this study. As the mean rate of overall clinical
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option for GI defects. Moreover, individualized selection of the suction method
based on particular clinical conditions may contribute to the improvement of
OTSC success.

tion into the cap with the aggressive use of accessory
devices for the successful long-term closure of fistulae.
In the future, the issue of managing refractory fistulae
may be overcome by utilizing one or more of the
[27]
following modalities: the injection of tissue sealants ,
[28,29]
stent placement
, and newly developed endoscopic
[4,5,30]
suturing devices
.

Terminology

OTSC: A newly developed endoscopic full-thickness suturing device applicable
for refractory bleeding, perforations, anastomotic leakage, and fistulae. Suction
method: a method to suck the target lesion into the application cap, which is a
critical factor of OTSC success among OTSC procedures.

Limitations

Peer-review

The main limitation of this study is its retrospective
design. Additionally, the selection of the suction
method depended on the operator’s discretion, so
patient inclusion criteria were subjective. Therefore,
the Anchor device was applicable only for a small
number of cases in our experience.

The authors reported a multicenter retrospective study analyzing the role of the
OTSCs for GI defects based on the suction method. The authors suggested that
TG is desirable for leaks and fistulae with defects of the entire layer. However,
further prospective studies by comparing suction methods are needed to clarify
the type of suction method that should be applied to each target lesion based
on the particular lesion characteristics.

Strengths of this study

REFERENCES

This study has several strengths. Compared to related
studies, it is a relatively large, multicenter study.
Additionally, this study is the first to investigate which
type of suction method is appropriate for particular
situations according to the following characteristics:
defect size, duration since onset, and indication.
In conclusion, the OTSC system is a safe and effective therapeutic option for the treatment of GI defects.
The individualized choice of the suction method in
the OTSC system is the most important factor for
OTSC success. Thus, OTSCs can serve as reliable and
productive devices for GI refractory diseases when the
size of the defect, the duration since onset and the
indication are considered.
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a successful key of OTSC closure depends on the secure suction into the
application cap of the target lesion. There are three suction methods: simple
suction (SS) and two accessory devices, referred to as the Twin Grasper (TG)
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This study demonstrates clinical outcomes of OTSCs using large samples
and proposes a directional strategy for choosing a suction method into the
application cap of the OTSC system.

Compared to related studies, this is a multicenter study with a large number
of cases. Additionally, this study is the first to investigate which type of suction
method is appropriate for particular situations according to the following
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Abstract
AIM
To investigated the usefulness of a novel slim type balltipped FlushKnife (FlushKnife-BTS) over ball-tipped
FlushKnife (FlushKnife-BT) in functional experiments
and clinical practice.

Informed consent statement: All study participants provided
informed written consent prior to study enrollment.
Conflict-of-interest statement: Dr. Toyonaga invented
FlushKnife-BT and FlushKnife-BTS in conjunction with Fujifilm
and receives royalties from their sales.

METHODS
In order to evaluate the functionality of FlushKnifeBTS, water aspiration speed, resistance to knife inser
tion through the scope, and waterjet flushing speed
were compared between FlushKnife-BTS and BT. In
clinical practice, esophageal endoscopic submucosal
dissection (ESD) performed using FlushKnife-BTS or
BT by an experienced endoscopist between October
2015 and January 2016 were retrospectively reviewed.
The treatment speed and frequency of removing and
reinserting the knife to aspirate fluid and air during ESD
sessions were analyzed.

Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited
and the use is non-commercial. See: http://creativecommons.
org/licenses/by-nc/4.0/
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RESULTS
Functional experiments revealed that water aspiration
speed by the endoscope equipped with a 2.8-mm
working channel with FlushKnife-BTS was 7.7-fold
faster than that with conventional FlushKnife-BT.
Resistance to knife insertion inside the scope with a
2.8-mm working channel was reduced by 40% with
FlushKnife-BTS. The waterjet flushing speed was faster
with the use of FlushKnife-BT. In clinical practice, a
comparison of 6 and 7 ESD using FlushKnife-BT and
BTS, respectively, revealed that the median treatment
2
speed was 25.5 mm /min (range 19.6-30.3) in the BT
2
group and 44.2 mm /min (range 15.5-55.4) in the BTS
group (P = 0.0633). However, the median treatment
speed was significantly faster with FlushKnife-BTS
2
when the resection size was larger than 1000 m (n =
2
4, median 24.2 mm /min, range 19.6-27.7 vs n = 4,
2
median 47.4 mm /min, range 44.2-55.4, P = 0.0209).
The frequency of knife replacement was less in the BTS
group (median 1.76 times in one hour, range 0-5.45)
than in the BT group (7.02 times in one hour, range
4.23-15) (P = 0.0065).

INTRODUCTION
Endoscopic submucosal dissection (ESD) is a standard
treatment for early-stage tumors in the digestive
[1-6]
tract . Many devices have been developed to safely
[7-14]
and efficiently facilitate this procedure
. One of
these devices is FlushKnife and the subsequently
developed ball-tipped FlushKnife (FlushKnife-BT)
(DK2618JN, DK2618JB; Fujifilm Medical Co., Ltd.,
[13,14]
Tokyo, Japan)
. Some of the features and functions
of these knives are advantageous such as injection,
irrigation by waterjets, dissection, hemostasis, and
[15]
vessel sealing . However, when they are used with
endoscopes equipped with a working channel of 2.8
mm, difficulties are associated with aspirating fluid and
air in the working space and finely controlling the knife
length due to limited space with friction resistance in
the channel with a knife with a diameter of 2.7 mm.
Therefore, a novel slim type FlushKnife BT
(FlushKnife-BTS, DK2620JBS; Fujifilm) was developed
to provide more space in the working channel (Figure
1). FlushKnife-BTS is characterized by its slim sheath
(2.2 mm), but same sized sheath tip (2.7 mm,
approximately 30 mm long) as the conventional knife,
which maintains stable maneuverability.
In an attempt to clarify whether the performance
of ESD is better with FlushKnife-BTS than with
FlushKnife-BT, we retrospectively investigated the
usefulness of FlushKnife-BTS over FlushKnife-BT in
functional experiments and clinical practice. In the
clinical practice, we included esophageal ESD because
esophagus is a narrow tract compared to stomach and
colorectum, which procedure is affected easily by air
inflation, and was thought to be a good candidate for
first investigation into the efficiency of FlushKnife-BTS.

CONCLUSION
Our results indicate that FlushKnife-BTS enhances the
performance of ESD, particularly for large lesions, by
improving air and fluid aspiration and knife insertion
during ESD and reducing the frequency of knife removal
and reinsertion.
Key words: Endoscopic submucosal dissection; Novel
slim type ball-tipped FlushKnife; ball-tipped FlushKnife;
Resistance to knife insertion; Water aspiration speed
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Devices utilized in endoscopic submucosal
dissection (ESD) play an important role in facilitating
the safe and effective procedure. A novel slim type balltipped FlushKnife (FlushKnife-BTS) has been developed
to enhance the performance of aspiration and insertion
of the knife through the scope. We herein investigated
the usefulness of FlushKnife-BTS over FlushKnife-BT in
functional experiments and clinical practice. FlushKnifeBTS showed a faster water aspiration speed, reduced
resistance to knife insertion, a faster treatment speed
when the resection size was large, and low frequency of
knife replacement. Our results indicate that FlushKnifeBTS supports the efficient performance of ESD, parti
cularly for large lesions.

MATERIALS AND METHODS
Functional experiment

Water aspiration speed with the knife inserted in the
scope, resistance to knife insertion inside the scope,
and waterjet flushing speed were compared between
FlushKnife-BTS and FlushKnife-BT. Regarding the
speed of water absorption, a total of 200 mL water in
a graduated cylinder was aspirated using the 2.8-mm
scope and 3.2-mm channel with FlushKnife-BT or
FlushKnife-BTS inserted, and the amount of water
aspirated in 10 s was measured. The experiment
was repeated 9 times. Resistance to the insertion of
Flushknife-BT or Flushknife-BTS inside the scope was
measured with various endoscopic angles. A measu
ring instrument named force gage FGP-5 produced
by NIDEC-SHIMPO CORPORATION was equipped with
the FlushKnife-BTS and FlushKnife-BT, inserted into
the endoscope equipped with a working channel of 2.8
mm and the resistance during the insertion was determined. The experiment was repeated 3 times. The
waterjet flushing speeds of the knives were measured

Ohara Y, Toyonaga T, Hoshi N, Tanaka S, Baba S, Takihara H,
Kawara F, Ishida T, Morita Y, Umegaki E, Azuma T. Usefulness
of a novel slim type FlushKnife-BT over conventional
FlushKnife-BT in esophageal endoscopic submucosal dissection.
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fluid and air when required, to clean the endoscope
lens for better visualization, and/or when the thread[17]
traction method was needed .

2.6 mm
FlushKnife-BT

2.2 mm

Evaluated points

2.7 mm

The patient and lesion characteristics including sex,
age, lesion site, circumference of the resected area,
major axis diameter of the resected specimen, size
of resected area, major axis diameter of the tumor,
histology of the tumor and depth of the tumor were
investigated.
Furthermore, the procedure time, treatment speed,
frequency of knife removal and reinsertion for aspiration, en bloc resection rate, and adverse events were
assessed and compared between the FlushKnife-BTS
(BTS) group and FlushKnife-BT (BT) group.
The procedure time was defined as the time
between the first submucosal injection and completion
of dissection. The treatment speed was calculated
by dividing the area of the resected specimen by the
2
procedure time (cm /min). The approximate oval area
2
(cm ) of the resected specimen was calculated as
follows; 3.14 × 0.25 × long axis diameter × short axis
diameter.

FlushKnife-BTS

Figure 1 Ball-tipped FlushKnife and a novel slim type ball-tipped
FlushKnife. FlushKnife-BT: Ball-tipped FlushKnife; FlushKnife-BTS: A novel
slim type FlushKnife-BT.

at three different water pressure settings 9 times using
waterjet equipment (JW-2; Fujifilm, waterjet volume;
min/mid/max 80/135/190 mL/min).

Patients

All cases that underwent esophageal ESD performed
using FlushKnife-BTS or FlushKnife-BT at Kobe
University Hospital and Kishiwada Tokushukai Hospital
between October 2015 and January 2016 were retrospectively reviewed. Of these, cases that underwent
ESD performed by an experienced endoscopist (T.T.)
were analyzed in the study.
Indications for esophageal ESD were defined
according to the esophageal ESD guidelines issued by
[16]
the Japan Esophageal Society : (1) absolute criteria;
lesions that do not exceed the mucosal layer (T1a),
those remaining within the mucosal epithelium (EP)
or the lamina propria mucosae (LPM), and (2) relative
criteria; lesions reaching the muscularis mucosae (MM)
or slightly infiltrating the submucosa (up to 200 μm,
T1b-SM1). ESD was not recommended for a 10%-15%
risk of lymph node metastasis with lesions filling the
relative criteria; however, it was performed on patients
who were too frail to tolerate more invasive surgical
approaches due to comorbidities, those who requested
a diagnostic endoscopic treatment before surgery, or
those who requested ESD with chemoradiation.
All patients underwent an initial screening examination including esophagogastroduodenoscopy with magnified narrow band imaging and computed tomography
in order to evaluate submucosal invasion and lymph
node metastasis. When submucosal invasion was suspected, endoscopic ultrasonography was performed.

Adverse events

Perforation and postoperative bleeding were counted
as adverse events related to the procedure.
Postoperative bleeding was recorded if one of the
following conditions was identified: (1) bleeding that
required endoscopic hemostatic treatment; and (2)
bleeding with a reduction in total hemoglobin of more
than 2 g/dL from the preoperative level. Perforation
was diagnosed by endoscopic findings during ESD or
by the presence of free air on computed tomography.

Ethics

All patients were informed of the risks and benefits
of ESD, and provided written informed consent to
undergo the procedure. This study was approved by
the Ethics Committees of Kobe University Hospital
(No. 160051) and Kishiwada Tokushukai Hospital (No.
28-10).

Statistical analysis

The Mann-Whitney U test was used to compare
2
continuous variables, and the χ test or Fisher’s exact
probability test was used to compare categorical
variables. P < 0.05 was considered significant. All
statistical analyses were performed using JMP version
10 (SAS Institute Inc., Cary, NC, United States).

ESD procedure

Patients were mainly sedated using dexmedetomidine
hydrochloride, flunitrazepam, and pentazocine. ESD
was performed with a single-channel endoscope
equipped with a working channel of 2.8 mm (GIF-Q240,
H290Z; Olympus Corporation, Tokyo, Japan). ERBE VIO
300 D high performance cautery (Erbe Elektromedizin
GmbH, Tubingen, Germany) was utilized in all cases.
Carbon dioxide insufflation was routinely used.
The knife was removed and reinserted to aspirate
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Results of functional experiments

The results of the functional experiments revealed that
water aspiration speed by the endoscope equipped
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Figure 2 Water aspiration speed. A total of 200 mL water in a graduated cylinder was aspirated by scopes with 2.8-mm and 3.2-mm channels with FlushKnife-BT
or FlushKnife-BTS inserted, and the amount of aspirated water in 10 s was measured. The column denotes mean data and the bar shows the range of experiments
performed 9 times. Water aspiration speed was markedly faster with FlushKnife-BTS than with FlushKnife-BT. aP < 0.05, BT vs BTS. FlushKnife-BT: Ball-tipped
FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.
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Figure 3 Resistance to knife insertion inside the scope. Resistance to the insertion of Flushknife-BT or Flushknife-BTS inside the scope at various endoscopic
angles was measured using a measuring instrument by NIDEC-SHIMPO CORPORATION. The column denotes mean data and the bar shows the range of
experiments performed in triplicate. Resistance was lower at all endoscopic angles with Flushknife-BTS than with Flushknife-BT. aP < 0.05, BT vs BTS. FlushKnife-BT:
Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.

was 2.7-fold faster with FlushKnife-BTS than with
FlushKnife-BT. Resistance to knife insertion through
the 2.8-mm working channel in a straight endoscopic
position was 40% less using the new slim knife than

with a 2.8-mm working channel with FlushKnife-BTS
inserted was 7.7-fold faster than that with FlushKnifeBT (Figure 2). Even when using an endoscope with
a 3.2-mm working channel, water aspiration speed
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Figure 4 Waterjet flushing speed. Waterjet flushing speed was faster with FlushKnife-BT than with FlushKnife-BTS at all pump settings tested. aP < 0.05, BT vs
BTS. FlushKnife-BT: Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.

61 esophageal lesions in 49 patients were treated with 56 ESD procedures
between October 2015 and January 2016
Excluded; ESD performed by endoscopist other than an experienced
endoscopist
13 ESD procedures performed in 9 patients by an experienced endoscopist consisting of 6
and 7 ESD using Flush knife-BT or Flush knife-BTS, respectively, were included in the study

Figure 5 Flow diagram of cases that underwent endoscopic submucosal dissection included in the analysis. FlushKnife-BT: Ball-tipped FlushKnife;
FlushKnife-BTS: A novel slim type FlushKnife-BT; ESD: Endoscopic submucosal dissection.

Table 1 Patient and lesion characteristics
FlushKnife-BT (n = 6)
Male/Female
Age, median (range), years
Lesion site Ut/Mt/Lt
Circumference of the resected area, median (range)
Major axis diameter of the resected specimen, median (range), mm
Resected area, median (range), mm²
Major axis diameter of the tumor3, median (range), mm
Histology of the tumor HGIN/SCC
Depth of the tumor EP/LPM/MM

2

2

3 /1
73.5 (68-78)
0/4/2
68% (25-100)
39.5 (30-55)
1117 (636-2547)
33 (19-42)
0/6
0/5/1

FlushKnife-BTS (n = 7)
2

4 /1
57 (57-74)
0/6/1
75% (50-92)
40 (31-60)
1193 (511-2418)
32 (25-50)
0/7
1/5/1

P vaule1
0.559
0.0235
0.559
0.599
0.277
0.943
0.616
0.000
0.629

1

The Mann-Whitney U test was used to compare continuous variables, and the chi-squared test or Fisher’s exact probability test was used to compare
categorical variables; 2One patient had multiple esophageal lesions treated by endoscopic submucosal dissection; 3In the case of multiple lesions resected
simultaneously, the maximum distance between the edges of each tumor was defined as the major axis diameter of the tumor. FlushKnife-BT: Ball-tipped
FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.

Clinical results

the conventional knife (Figure 3). Reductions in resis
tance were detected using both scopes with 2.8-mm
and 3.2-mm working channels and at any endoscopic angle. Waterjet flushing speed was lower with
FlushKnife-BTS than with FlushKnife-BT at all water
pressure settings tested (Figure 4). This difference
became larger with increases in water pressure.
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During the study period, 61 esophageal lesions in 49
patients were treated with 56 ESD procedures. Of
these, 13 ESD procedures performed in 9 patients,
consisting of 6 and 7 ESD using FlushKnife-BT and
FlushKnife-BTS, respectively, were completed by
an experienced endoscopist and these cases were
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The circumference of the resected area ranged
between 25% and 100% with a median of 68% in the
BT group, and between 50% and 92% with a median
of 75% in the BTS group (P = 0.599).
The median major axis diameters of resected
specimens were 39.5 mm (range 30-55) and 40 mm
(range 31-60) respectively (P = 0.277) in BT and BTS
groups, respectively.
2
The median resected area was 1117 mm (range
2
636-2547) in the BT group and 1193 mm (range
511-2418) in the BTS group (P = 0.943).
The median major axis diameter of tumors was 33
mm (range 19-42) in the BT group and 32 mm (range
25-50) in the BTS group (P = 0.616). In the case of
multiple lesions resected together, the maximum distance between the edges of each tumor was defined
as the tumor size.
The histology of tumors revealed SCC in all cases.
The depths of tumors (EP/LPM/MM) were 0/5/1 in the
BT group and 1/5/1 in the BTS group (P = 0.629). The
outcomes of ESD are shown in Table 2. The threadtraction method was performed on 3 out of 6 cases in
the BT group and 2 out of 7 cases in the BTS group (P
= 0.592). Median procedure times were 48 min (range
24-106) and 33 (range 27-51) min in the BT and BTS
groups, respectively (P = 0.389).
2
The median treatment speed was 25.5 mm /min
2
(range 19.6-30.3) in the BT group and 44.2 mm /min
(range 15.5-55.4) in the BTS group (P = 0.0633).
However, it was significantly faster with FlushKnife-BTS
when the resection size of ESD was larger than 1000
2
m (n = 4, median 24.2, range 19.6-27.7 vs n = 4,
2
median 47.4 mm /min, range 44.2-55.4, P = 0.0209)
(Table 3). The relationship between the resected area
and treatment speed is shown in Figure 6; the treatment speed was faster with FlushKnife-BTS when the
resected size was large, but was similar to that with
FlushKnife-BT when it was small.
The number of times the knife was replaced was
5.5 (range 4-10) and 1 (range 0-3) in the BT and BTS
groups, respectively (P = 0.0025).
The frequency of knife replacement was lower
(median 1.76, range 0-5.45 vs median 7.02,
range 4.23-15 times in one hour, P = 0.0065) with
FlushKnife-BTS than with FlushKnife-BT. Figure 7
shows the relationship between the resected area and
frequency of knife replacement, and demonstrates
a reduced frequency of knife replacement with
FlushKnife-BTS regardless of the resected size and
slightly reduced frequency as the resected size became
larger. En bloc resection rates were 100% and muscle
injury was detected in one case in the BT group.

Resected area and treatment speed
BT or BTS
BT
BTS

50

2

Treatment speed (mm /min)

60

40

30

20

10

500

1000

1500

2000

2500

2

Resected area (mm )

Figure 6 Treatment speed was faster with a novel slim type ball-tipped
FlushKnife when the resected size was large, but was similar to that with
the conventional knife when the resected size was small. FlushKnife-BT:
Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.

Frequency of knife replacement (t/h)

Resected area and frequency of knife replacement
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Figure 7 Frequency of knife replacement was reduced with a novel
slim type ball-tipped FlushKnife regardless of the resected size, while a
slightly reduced frequency was observed as the resected size became
larger. FlushKnife-BT: Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim
type FlushKnife-BT.

included in the study (Figure 5).
The characteristics of the patients and lesions are
shown in Table 1. There were 3 males and 1 female
in the BT group, and 4 males and 1 female in the BTS
group. Two patients in the BT group and one patient in
the BTS group had multiple lesions that were treated
separately. Ages ranged between 68 and 78 years
with a median age of 73.5 years in the BT group,
and between 57 and 74 years with a median age of
57 years in the BTS group (P = 0.0235). Lesion sites
(Ut/Mt/Lt) were 0/4/2 and 0/6/1, respectively (P =
0.559).
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DISCUSSION
ESD is the first-line therapeutic option for superficial
[1,6,18-20]
gastrointestinal tract tumors
. The devices used
in ESD are important for performing the procedure
safely. A large number of devices have been developed
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Table 2 Outcomes of endoscopic submucosal dissection by novel slim type ball-tipped FlushKnife and ball-tipped FlushKnife

Use of the thread-traction method, yes/no
Procedure time, median (range), min
Treatment speed, median (range), mm2/min
Number of times the knife was replaced, median (range), times
Frequency of knife replacement, median (range), times/hour
En bloc resection rate
Adverse events, Perforation/muscle injury/postoperative
bleeding

FlushKnife-BT (n = 6)

FlushKnife-BTS (n = 7)

3/3
48 (24-106)
25.5 (19.6-30.3)
5.5 (4-10)
7.02 (4.23-15)
6/6 (100%)
0/1/0

2/5
33 (27-51)
44.2 (15.5-55.4)
1 (0-3)
1.76 (0-5.45)
7/7 (100%)
0/0/0

P vaule1
0.592
0.389
0.0633
0.0025
0.0065
0.000
0.462

1

The Mann-Whitney U test was used to compare continuous variables, and the χ 2 test or Fisher’s exact probability test was used to compare categorical
variables. FlushKnife-BT: Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim type FlushKnife-BT.

the resected size.
The faster aspiration of bubbles, air, mucus, and
fluid by FlushKnife-BTS contributed to a clear field of
view, which may have, in turn, reduced the frequency
of knife removal from the working channel.
The reason why treatment speed only improved
with FlushKnife-BTS when the resection size was large
may be that, in ESD of a small resection size, the
effects by a reduced frequency of knife replacement,
smooth knife insertion, and fine knife control with
FlushKnife-BTS were not clearly reflected due to the
short procedure time and fewer knife replacements,
but became more evident as the resection size became
larger and the procedure time increased. Therefore,
FlushKnife-BTS is considered to exhibit its effectiveness
when large resection is needed.
Waterjet flushing speed was slower with FlushKnifeBTS in functional experiments. This result was expected
due to the difference in the diameters of the two
knives. However, this did not markedly affect the clinical practice of ESD in our analysis. Since FlushKnife-BT
offers a high-flow flushing function, the speed reductions observed with FlushKnife-BTS do not appear to
be of clinical importance. Moreover, the mid pump
setting is typically used in clinical practice and may
be resolved by turning up the setting to its maximum
where necessary.
Although the safety and efficacy of ESD in the
[2,6,22]
esophagus have already been reported
, intraoperative perforation, muscle layer damage, and bleeding may occur because of the anatomically thin wall
and narrow working space. Moreover, postoperative
esophageal stricture is one of the main complications
[23,24]
associated with large esophageal ESD
. Muscle
layer damage with entire circumferential esophageal
ESD has been linked to refractory post-ESD steno[25]
sis . Hence, ESD in the esophagus requires a highly
skilled endoscopic technique and careful operation,
and the provision of a more comfortable environment
for ESD will contribute to reductions in complications.
Based on the results presented above, FlushKnife-BTS
is considered to contribute to safer esophageal ESD.
Though the present clinical study focused on only
esophageal ESD because esophagus is the narrow

Table 3 Treatment speed of endoscopic submucosal
2
dissection for a resected size more than 1000 mm
FlushKnife-BT
(n = 4)

FlushKnife-BTS
(n = 4)

P vaule

Treatment speed, median 24.4 (19.6-27.7)
(range), mm2/min

47.4 (44.2-55.4)

0.0209

FlushKnife-BT: Ball-tipped FlushKnife; FlushKnife-BTS: A novel slim type
FlushKnife-BT.
[8-10,12,13]

to date
. FlushKnife-BT is one of the most frequently used knives and has advantageous functions
including injection, irrigation by waterjets, dissection,
[14]
and vessel sealing . However, when this knife is used
with endoscopes equipped with a 2.8-mm channel,
difficulties are associated with the aspiration of fluid
and mucus in the working space during the procedure
and finely controlling the knife length because of its
diameter of 2.7 mm. Uncontrolled fluid and mucus
pooling and air inflation/deflation may complicate
ESD. In order to precisely dissect the appropriate
plane between the vessel network in the submucosa
[21]
and muscle layer , subtle endoscope movements in
addition to adjustments in knife length are needed.
Therefore, smooth aspiration and delicate knife control
are essential for performing this procedure safely and
efficiently.
In an attempt to overcome these limitations, we
developed a novel slim type FlushKnife-BT.
Functional experiments revealed that fluid aspiration speed by the endoscope with a 2.8-mm working
channel with FlushKnife-BTS inserted was 7.7-fold
faster than that with the conventional knife. Resistance
to the insertion of the knife inside the scope with a
2.8-mm working channel was 40% less with the new
knife than with the conventional knife.
In clinical practice, though the number of the
patients was small, increase was achieved in the treatment speed with FlushKnife-BTS when large resection
was required, but remained the same as that with the
conventional knife when the resected size was small.
The frequency of knife replacement was less with
FlushKnife-BTS than with FlushKnife-BT regardless of
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tract in which inflated air inside affects the procedure
easily, further investigation including ESD in other
organs such as stomach and colorectum would be
desired in the near future.
The limitations of this study include its retrospective design and small patient population. Furthermore,
the procedure was only performed by one endoscopist. Therefore, the generalizability of the results
obtained remains unclear and, thus, further studies
with more cases undergoing ESD performed by other
endoscopists including less experienced operators
are warranted. However, our results still support
FlushKnife-BTS creating better conditions for and
contributing to the efficient performance of ESD.
In conclusion, our results demonstrate that
FlushKnife-BTS supports the efficient performance
of ESD, particularly for large lesions, by improving
air and fluid aspiration and allowing for smooth knife
insertion without frequent knife removal and reinsertion during ESD.

2
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Abstract

Institutional review board statement: The study was reviewed
and approved by the institutional review boards of the First
Affiliated Hospital of Zhengzhou University.

AIM
To investigate the correlation of iodine concentration
(IC) generated by spectral computed tomography (CT)
with micro-vessel density (MVD) and vascular endo
thelial growth factor (VEGF) expression in patients with
advanced gastric carcinoma (GC).

Informed consent statement: All study participants provided
informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts
of interest.

METHODS
Thirty-four advanced GC patients underwent abdominal
enhanced CT in the gemstone spectral imaging mode.
The IC of the primary lesion in the arterial phase (AP)
and venous phase (VP) were measured, and were then
normalized against that in the aorta to provide the
normalized IC (nIC). MVD and VEGF were detected by
immunohistochemical assays, using CD34 and VEGF-A
antibodies, respectively. Correlations of nIC with MVD,
VEGF, and clinical-pathological features were analyzed.

Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited
and the use is non-commercial. See: http://creativecommons.
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RESULTS
Both nICs correlated linearly with MVD and were higher
in the primary lesion site than in the normal control
site, but were not correlated with VEGF expression.
After stratification by clinical-pathological subtypes,
nIC-AP showed a statistically significant correlation with
MVD, particularly in the group with tumors at stage T4,
without nodular involvement, of a mixed Lauren type,
where the tumor was located at the antrum site, and
occurred in female individuals. nIC-VP showed a positive correlation with MVD in the group with the tumor
at stage T4 and above, had nodular involvement, was
poorly differentiated, was located at the pylorus site, of
a mixed and diffused Lauren subtype, and occurred in
male individuals. nIC-AP and nIC-VP showed significant
differences in terms of histological differentiation and
Lauren subtype.

which requires more attention.
Angiogenesis is fundamental to the growth, invasion, and metastasis of GC, and greatly influences the
[3]
response to anti-tumor therapies . To date, the standard method for studying angiogenesis has been histopathological counting of micro-vessel density (MVD),
which is specimen- and immunostaining-dependent.
This is impractical in advanced patients undergoing
anti-angiogenesis or chemotherapy. Compared with
MVD counting, using preoperative imaging modalities
for the noninvasive assessment of tumor angiogenesis
is more acceptable and feasible. A previous study
has revealed that MVD, vascular endothelial growth
factor (VEGF), and the absolute enhanced value show
some positive correlations with conventional contrast[4]
enhanced computed tomography (CT) . Additionally,
CT perfusion has shown the potential for evaluating
[5,6]
tumor angiogenesis , but the complicated measurement and high radiation dosage have limited the
extensive application of CT in this regard.
The recently developed spectral CT yields materialdecomposition (MD) images that can quantitatively
map the iodine concentration (IC) of the tissue in
enhanced images. This IC value has been proven
to show a strong correlation with the actual iodine
[7]
concentration in the phantom . Recently, preliminary studies have reported the use of the IC value
to differentiate benign and malignant lesions, to find
embolisms, and to evaluate the efficacy of anticancer
[8-11]
therapy
. Particularly in the evaluation of neoadjuvant chemotherapy of GC, the IC value was proven to
be a more robust imaging biomarker than the mor[11]
phology index . However, it was not clear how this
correlated with radiological-pathological features. On
the other hand, the IC value has shown a correlation
with vascularization in solid tumors, such as pancreatic carcinoma, hepatocarcinoma, and non-small-cell
[12-14]
lung cancer
, while there has been no such report
for GC, to provide a basis for using image indicators,
other than morphology, for assessing chemo-efficacy.
Therefore, our purpose was to investigate the correlation between IC value and angiogenesis in GC cases
with clinical-pathological data.

CONCLUSION
The IC detected by spectral CT correlated with the
MVD. nIC-AP and nIC-VP can reflect angiogenesis in
different pathological subgroups of advanced GC.
Key words: Micro-vessel density; Iodine concentration;
Spectral computed tomography; Vascular endothelial
growth factor; Gastric cancer
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: We investigated the correlation between iodine
concentration (IC) value generated from spectral computed tomography (CT) and angiogenesis in gastric
cancer (GC) with clinical-pathological data. Our results
showed that normalized IC (nIC) in both the arterial
(AP) and venous phases (VP) had a positive linear correlation with micro-vessel density. nIC-AP reflected the
angiogenesis in relatively earlier and well-differentiated
GC, while nIC-VP reflected this in further advanced and
poorly differentiated GC. Spectral CT with quantitative
IC value offers a new choice for evaluating the angiogenesis of gastric cancer noninvasively.
Chen XH, Ren K, Liang P, Chai YR, Chen KS, Gao JB. Spectral
computed tomography in advanced gastric cancer: Can iodine
concentration non-invasively assess angiogenesis? World J
Gastroenterol 2017; 23(9): 1666-1675 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v23/i9/1666.htm DOI:
http://dx.doi.org/10.3748/wjg.v23.i9.1666

MATERIALS AND METHODS
Study population

Adult patients with advanced GC confirmed by endos
copic biopsy, who were scheduled for surgery, were
enrolled. This study was approved by the institutional
review board, and informed consent was obtained from
each participant. All procedures were performed in
accordance with the ethical standards of the institution.
Exclusion criteria were: (1) allergies to intravenous
contrast media; (2) cardiac or renal insufficiency; (3)
history of chemotherapy or radiotherapy; (4) inability
to visualize the tumor on CT; (5) early tumor staging
(T1) or presence of distant metastasis (M1); and (6)

INTRODUCTION
Despite a recent decrease, gastric cancer (GC) remains
the most common cancer and is the third leading
[1]
cause of cancer-related death globally . In China, the
incidence and mortality rates of GC remain high, and
[2]
the vast majority of cases are in the advanced stage ,
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specimen with poor fixation for immunostaining.
From June 2014 to May 2015, a total of 41 patients
prospectively underwent spectral CT examination. Of
these, two patients with serious interface artifacts on
CT images, one patient with tumor tissue necrosis that
influenced MVD counting, one patient with no tumor
cells on hematoxylin and eosin (HE) slices, and three
patients with failed immunostaining were excluded.
Ultimately, the data of 34 patients were collected
and statistically analyzed. Patient records and pathological data, including gender, age, tumor size, tumor location, invasion depth, lymph nodes involvement, Lauren
subtypes, and differentiation, were documented.

necrosis, and vessels were carefully avoided (mean
2
2
square: 871 mm ; range: 122-1308 mm ). For the
normal site, we chose a distance longer than 5 cm
from the lesion edge that was thick enough to place
the ROI. Three small circular ROIs with a diameter
exceeding 2 mm were measured as ROI-normal.
Images were compared to ensure the measurements
were as consistent as possible in both phases. The ICs
in the AP (IC-AP) and in the VP (IC-VP) were generated simultaneously (unit: 100 µg/mL). At the same
time, a round ROI was placed on the abdominal aorta
in the same layer as the target, to calculate the nor[15]
malized IC (nIC = ICtarget/ICaorta) , aiming to reduce
the individual circulatory variability. All the ICs and
nICs obtained from the same patient were averaged
and disagreement on measurement was resolved by
consensus.

CT scan methods

After fasting overnight, all patients were administered
10 mg anisodamine (Minsheng Pharmaceutical
Group Co., Ltd., Hangzhou, China) intramuscularly
to reduce gastrointestinal motility 20 min prior to CT
examination, and ingested 800-1000 mL of water to
distend the stomach. During scanning, patients were
instructed to suspend respiration.
All examinations were performed on a Discovery
CT750 HD system (GE Healthcare, Milwaukee, WI,
United States), and included bi-phasic enhanced
spectral scanning in the arterial and venous phases
(AP and VP, respectively). Spectral CT imaging was
performed with a 0.5 ms switch of tube voltage
between 140 kVp and 80 kVp; a rotation speed of 0.6
s, and a helical pitch of 1.375:1. The scan range was
from the diaphragmatic dome to the symphysis pubis.
Non-ionic contrast material, iohexol (350 mg I/mL,
GE Pharmaceutical, Shanghai of China), at 1.3 mL
per kilogram of body weight was used (total volume:
60-110 mL) at a flow rate of 2.5-4.5 mL/s was injected
via a peripheral vein, using a dual high-pressure
syringe. The AP acquisition time was triggered at 9
s after the attenuation of diaphragmatic abdominal
aorta reached 100 HU (SmartPrep; GE Healthcare).
The VP followed with a 30 s interval. Raw data were
reconstructed to 1.25-mm slice images, using decompose projection-based software. An additional 40%
adaptive statistical iterative reconstruction algorithm
was applied to suppress image noise and decrease the
radiation dose required for spectral CT.

Histopathologic evaluation

A surgeon (K.R) and a radiologist (X.C) performed
sampling together to guarantee that the specimen
and the ROI were from virtually the same level, by
re-examining the axial and multi-planar reconstruction
images. The distance to the cardia or pylorus of the
sample site and the thickness were compared on both
CT images and surgical specimens. Then, the selected
samples (tumor and normal wall) were fixed overnight
in 10% formalin, and subsequently dehydrated in
alcohol and paraffin-embedded. Wax blocks comprising
the central part of the adenocarcinoma were sectioned
into 4-µm-thick slices. A ready-to-use two-step streptavidin-peroxidase method was applied. The mouse
anti-CD34 monoclonal antibody (diluted 1:150) and
rabbit anti-VEGF-A polyclonal antibody (diluted 1:200)
(Beijing Zhongshan Goldenbridge Company, Beijing,
China) were used to stain all pathological tissues.
Positive and negative immunohistochemistry controls
were prepared as routine. A pathologist (K.C, with 25
years’ experience in MVD and VEGF immunostaining),
who was blinded to the spectral CT imaging results,
performed the counting and evaluation of all slides.
MVD counting was performed using the Weidner
[16]
method . The area where vascular endothelial cells
stained most intensively was first identified at low (×
100) magnification. Then, five fields were randomly
selected at × 400 magnification to count the CD34positive cell clusters and the mean was recorded as the
final value (Figures 1 and 2). VEGF (stained brown),
located in the cytoplasm, was scored using an estab[17]
lished method : scores of the percentage of positive
tumor cells and signal intensity were summed. If the
score was less than 4, the section was considered
negative, whereas a score of 4 or more was considered
positive (Figures 1 and 2).

Image analysis

All CT images were transferred to a commercially
available workstation (Advantage Windows 4.6; GE
Medical Systems, Chicago, IL, United States) to generate iodine-based MD images (Figures 1 and 2). Two
experienced radiologists (J.G. and P.L., with 25 and 5
years of experience with abdominal CT, respectively),
who were blinded to the pathological results, analyzed
the images. Three manually drawn regions of interests
(ROIs) that encompassed the maximum lesion in the
consecutive 1.25-mm layers of bi-phasic axial images
were measured. Areas containing prominent artifacts,
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Statistical analysis

All statistical procedures were performed with a software package (SPSS 21.0, Chicago, IL, United States).
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Figure 1 Detection of the iodine concentration value in a 51-year-old man with poorly differentiated adenocarcinoma, with staging Ⅲc (T4aN3M0). A:
The monochromatic image shows focal wall thickening in the gastric antrum; B: The iodine-water image with iodine concentration (IC) value 12.83 (100 µg/cm3),
normalized IC (nIC) value 0.11 in the arterial phase. Monochromatic image (C) and iodine-water image (D) with IC value 23.91 (100 µg/cm3), nIC value 0.53 in the
venous phase; E: Hematoxylin and eosin staining of a pathological section obtained from radical surgery shows poorly differentiated, diffused subtype in the Lauren
classification (× 400); F: CD34-staining shows endothelial cells stained brown; micro-vessels form clusters or have tiny hollow lumens (micro-vessel density 45/
magnification × 400). G: Weak vascular endothelial growth factor staining in the cytoplasm (× 400) with score 2.

A P-value of less than 0.05 was considered to indicate
a statistically significant difference. Nodal status was
classified as positive and negative for lymph node
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metastasis, and the depth of invasion was classified
as positive and negative serosal involvement. A single
highly differentiated patient was grouped together
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Figure 2 Detection of iodine concentration value in a 50-year-old man with moderate differentiated adenocarcinoma, of staging Ⅲa (T4aN1M0). A:
Monochromatic image shows focal wall thickening in the gastric cardia and lesser curvature; B: The iodine-water image with iodine concentration (IC) value 11.78 (100
µg/cm3), normalized IC (nIC) value 0.09 in the arterial phase; Monochromatic image (C) and (D) iodine-water image with IC value 18.63 (100 µg/cm3), nIC value 0.34
in the venous phase; E: Hematoxylin and eosin staining shows a moderately differentiated, intestinal Lauren subtype (× 400); F: Immunohistochemical staining shows
CD34 positive micro-vessel (micro-vessel density count: 27/magnification × 400); G: Strongly positive vascular endothelial growth factor staining (× 400) with score 5.

with the moderately differentiated patients. Data were
subjected to a Kolmogorov-Smirnov normality test and
continuous variables were presented as means and
standard errors of the mean. When analyzing the cor-

WJG|www.wjgnet.com

relation of nIC and MVD and VEGF, scatter plots were
made first between continuous variables, followed by
the Pearson or the Spearman rank-correlation test
(Figure 3). Student’s t-test, correct t test, and one-way
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0.6

nlCAP
nlCVP

Table 1 Clinical characteristics of the patients (n = 34)
Sex

0.4

Male
Female
30 -73 yr (56 ± 3.7 yr)
1.5 -13.0 cm (median 4.0 cm)
Cardia/Fundus
Gastricum
Antrum
N0
N1
N2
N3
pT2
pT3
pT4a
pT4b
Intestinal type
Mixed type
Diffuse type
Highly differentiated
Moderately differentiated
Poorly differentiated

nlC value

Age
Size
Tumor location

0.2
Nodal status
0.0

0

10

20

30

40

50
Depth of invasion

MVD (no/× 400)

Figure 3 Scatter plots of normalized iodine concentration in arterial
phase, normalized iodine concentration in venous phase, and
microvessel density counts in tumor lesions (r = 0.423 for normalized
iodine concentration in arterial phase, r = 0.606 for normalized iodine
concentration in venous phase). VEGF: Vascular endothelial growth factor;
nIC: Normalized iodine concentration; nIC-AP: nIC-arterial phase; nIC-VP: nICvenous phase; MVD: Microvessel density.

Lauren subtype

Histological grading

analysis of variance (ANOVA)-LSD test were performed
to analyze differences in categorical data between
groups (serosal involvement, lymph node metastasis,
histologic differentiation, Lauren subtype, tumor location, and gender).

67.65%
32.35%

14
9
11
11
8
7
8
5
2
22
5
15
7
12
1
16
17

41.18%
26.47%
32.35%
32.35%
23.53%
20.59%
23.53%
14.71%
5.89%
64.71%
14.71%
44.12%
20.59%
35.29%
2.38%
47.06%
50.00%

Table 2 Correlation of nIC values, microvessel density and
vascular endothelial growth factor expression
Varieties
nIC-AP
nIC-VP
MVD

RESULTS
A total of 34 advanced GC patients (23 males, 11
females; mean age: 56 ± 3.7 years; age range: 30-73
years) were included (Table 1). Tumor size ranged
from 1.5 cm to 13.0 cm (median: 4.0 cm). Fourteen
tumors located in the gastric cardia-fundus, nine in
the gastricum, and 11 in antrum. All patients were
treated surgically by radical gastrectomy and D2
lymph node dissection. Based on pathologic results,
the adenocarcinoma was well differentiated in one
patient, moderately differentiated in 16 patients, and
poorly differentiated in 17 patients. According to the
th
7 American Joint Committee on staging classification
(AJCC), five patients were classified as T2, two as T3,
twenty-two as T4a and five as T4b; eleven as N0,
eight as N1, seven as N2, and eight as N3. No patient
had distant metastasis. The Lauren classification was
as follows: 15 were intestinal type, seven were mixed
type, and 12 were diffuse type. Additionally, the immunostaining analysis revealed that 25 patients (73.53%)
stained positive for VEGF with a score of 4 (n = 11), 5 (n
= 9), or 6 (n = 5). The mean MVD count for these 34
tumors was 26.94 ± 1.35.
In general, the bi-phasic nIC values and the MVD
counts were positively correlated (P = 0.013, P <
0.001, respectively). VEGF did not correlate with either
nIC value or with MVD, as shown in Table 2. When
stratified by different clinical features, the correlation
coefficient value increased. nIC-AP positively correlated
with MVD in patients with tumor stage less than T4 (r
= 0.851, P = 0.015), tumor of N0 stage (r = 0.620, P

WJG|www.wjgnet.com

23
11

MVD

VEGF

r

P value

r

P value

0.423
0.606
1.000

0.013a
0.000a

0.170
0.311
0.210

0.358
0.073
0.233

a

P < 0.05. nIC-AP: Normalized iodine concentration in arterial phase; nICVP: Normalized iodine concentration in venous phase; MVD: Microvessel
density; VEGF: Vascular endothelial growth factor.

= 0.042), with a tumor located in the pylorus region (r
= 0.616, P = 0.044), and who were female (r = 0.696,
P = 0.017). On the other hand, nIC-VP correlated with
MVD in the more advanced group of patients, with
tumors above T4 stage (r = 0.656, P < 0.001), with
nodular involvement (r = 0.644, P = 0.001), that were
poorly differentiated (r = 0.799, P < 0.001), were of
mixed and diffused Lauren subtypes (r = 0.827, P =
0.022; r = 0.765, P = 0.004, respectively), and male
gender (r = 0.606, P = 0.002), as shown in Table 3.
The nIC values in the primary GC and normal
gastric wall were 0.116 ± 0.033 and 0.101 ± 0.023 in
arterial phase (P = 0.033), 0.386 ± 0.061, and 0.286
± 0.066 in the venous phase (P < 0.001) (Figure 4A).
For the VEGF-positive and -negative group, neither
nIC-AP nor nIC-VP showed statistically significant differences (Figure 4B).
When stratified by clinical subgroups, both nIC-AP
and nIC-VP were higher in patients with serosal
involvement, lymph node metastasis, poor differentiation, and diffused Lauren type than in those with depth
invasion under T4, nodal status N0, high and moderate
differentiation, intestinal and mixed Lauren type, but
these differences did not reach statistical significance.
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Table 3 Correlations between bi-phase normalized iodine concentration and microvessel density in different clinical-pathological
subgroups
n

Varieties
Depth of invasion
< T4
T4
Nodal status
N0
N1-3
Histologic differentiation
Highly and Moderately differentiated
Poorly differentiated
Lauren subtype
Intestinal type
Mixed type
Diffuse type
Tumor location
Cardia/Fundus
Gastricum
Antrum
Sex
Male
Female

nIC-AP vs MVD

nIC-VP vs MVD

r

P value

r

P value

7
27

0.851
0.370

0.015a
0.057

0.600
0.656

0.154
0.000a

11
23

0.620
0.330

0.042a
0.124

0.600
0.644

0.051
0.001a

17
17

0.250
0.427

0.334
0.087

0.190
0.799

0.466
0.000a

15
7
12

0.222
0.741
0.145

0.427
0.057a
0.653

0.101
0.827
0.765

0.719
0.022a
0.004a

14
9
11

0.311
0.385
0.616

0.279
0.307
0.044a

0.760
0.507
0.891

0.796
0.163
0.000a

23
11

0.385
0.696

0.070
0.017a

0.606
0.605

0.002a
0.049

a

P < 0.05. nIC-AP: Normalized iodine concentration in arterial phase; nIC-VP: Normalized iodine concentration in venous phase; MVD: Microvessel
density.

A

0.5

Normal
Tumor

0.3
0.2
0.1
0.0

0.5

VEGF(-)
VEGF(+)

0.4

b
nlC value

nlC value

0.4

B

a

0.3
0.2
0.1

AP

VP

0.0

AP

VP

Figure 4 Comparison of normalized iodine concentration in arterial phase; and normalized iodine concentration in venous phase between the normal
gastric wall and tumor site (A); comparison of normalized iodine concentration in arterial phase and normalized iodine concentration in venous phase
between the vascular endothelial growth factor-positive and -negative group (B). aP < 0.05, bP < 0.001. VEGF: Vascular endothelial growth factor; nIC:
Normalized iodine concentration; AP: Arterial phase; VP: Venous phase.

nIC-AP and nIC-VP showed statistically significant differences between differentiation categories (P = 0.003,
P = 0.001, respectively) and between Lauren subtypes
(P = 0.016, P = 0.006, respectively). The LSD test
revealed that nIC-AP and nIC-VP were significantly different between intestinal and diffuse Lauren subtypes
(P = 0.005, P = 0.004, respectively). nIC-VP was also
significantly different between intestinal and mixed
Lauren subtypes (P = 0.013), as shown in Table 4.

former correlated significantly with MVD in the relative
earlier stage of advanced GC, while the latter correlated with MVD in the more advanced stage. Second,
no significant correlation was found between nICs
and VEGF. Third, nIC values in the normal gastric wall
were observed to be significant lower than that in the
tumor. Fourth, nICs were observed to differ between
histological grades and Lauren subtypes of advanced
GC; the greater the malignancy, the higher the nICs.
Taken together, these observations demonstrate that
quantification of iodine in spectral CT imaging have the
potential to reflect angiogenesis of advanced GC.
Iodine, a commonly used CT contrast material, is
generally known to produce higher attenuation at low
[18]
tube voltage settings . Based on this effect, spectral
CT using high and low voltage switching settings could

DISCUSSION
There were four major findings from this study. First,
the bi-phasic nICs showed a significantly linear positive
relationship with MVD in primary GC. The nIC-AP and
nIC-VP correlated with MVD in different subgroups; the

WJG|www.wjgnet.com

1672

March 7, 2017|Volume 23|Issue 9|

Chen XH et al. Spectral CT study in gastric cancer
Table 4 Difference of bi-phase normalized iodine concentration between different clinical-pathological subgroups
n

Varieties
Depth of invasion
< T4
> T4
Nodal status
N0
N1-3
Histologic differentiation
Highly and moderately differentiated
Poorly differentiated
Lauren subtype
Intestinal type
Mixed type
Diffuse type
Tumor location
Cardia/Fundus
Gastricum
Antrum
Sex
Male
Female

nIC-AP

nIC-VP

mean ± SD

P value

mean ± SD

P value

7
27

0.101 ± 0.042
0.120 ± 0.031

0.195

0.363 ± 0.079
0.392 ± 0.063

0.302

11
23

0.112 ± 0.033
0.125 ± 0.035

0.321

0.385 ± 0.085
0.387 ± 0.057

0.923

17
17

0.100 ± 0.028
0.132 ± 0.031

0.003a

0.352 ± 0.048
0.421 ± 0.065

0.001a

15
7
12

0.099 ± 0.029
0.120 ± 0.032
0.135 ± 0.030

0.016a

0.347 ± 0.048
0.417 ± 0.061
0.417 ± 0.067

0.006a
0.0131,a
0.002,a

14
9
11

0.109 ± 0.033
0.128 ± 0.024
0.116 ± 0.040

0.445

0.385 ± 0.046
0.387 ± 0.064
0.387 ± 0.091

0.874

23
11

0.113 ± 0.033
0.124 ± 0.035

0.377

0.390 ± 0.069
0.378 ± 0.062

0.633

0.0052,a

1

One-way ANOVA-LSD, mixed type vs intestinal type; 2Diffuse type vs intestinal type. aP < 0.05. nIC-AP: Normalized iodine concentration in arterial phase;
nIC-VP: Normalized iodine concentration in venous phase; MVD: Microvessel density; SD: Standard deviation.

[19]

differentiate materials of the same density
and
[20]
the IC value could be extracted . With water-iodine
[9]
based material decomposition images, Lv et al concluded that the IC in images of hepatic lesions acquired
in a quantitative parameter was highly precise. Thieme
[21]
et al
found a very good correlation between vessel
occlusion depicted at CTA and IC defects in the dualenergy image, indicating that iodine distribution in the
parenchyma is closely related to pulmonary perfusion.
Therefore, the IC may be considered as an indirect
marker of perfusion and tumor vascularity.
Tumor angiogenesis is defined as the formation of
[22]
new blood vessels from pre-existing vessels . MVD
and identification of VEGF in tissues are commonly used
[23]
biomarkers of angiogenesis . In previous studies, the
relationships between dynamic contrast-enhanced perfusion CT parameters and immunohistological markers
of angiogenesis have been studied in different tumors,
[24]
[6,25]
including colorectal cancer , advanced GC
, lung
[26]
cancer , etc. However, the studies produced discrepant results on whether the use of blood flow or permeability surface area product were efficacious.
Our results proved a positive linear relationship
between IC and MVD in primary GC. The nIC values
were significantly elevated in the tumor as compared to
the normal gastric wall. Similar results were acquired
[27]
by Pang et al , who considered the nIC value of the
infarcted myocardium to be an important indicator of
MVD in the 1-min and 3-min CT images. Additionally,
[12]
the study by Hu et al indicated that the nIC values of
three-phase scans had a positive correlation with MVD
for detecting the therapeutic response in a pancreatic
carcinoma xenograft nude mouse model. Taken
together, spectral CT imaging can be used to evaluate

WJG|www.wjgnet.com

angiogenesis in disease.
On the other hand, nIC had a low correlation with
VEGF expression, and no significant differences were
found in the comparison between IC parameters
and VEGF group. VEGF, one of the most prominent
biomarkers of angiogenesis studied to date, has been
shown to correlate well with CT perfusion in peripheral
[28]
pulmonary nodules . Moreover, the study of Zhou
[13]
et al
in a rabbit VX2 liver model suggested that
nIC and contrast-enhanced ultrasound parameters
positively correlated with VEGF and FGF2 expression,
while several reports failed to show such a correlation,
[6]
for example, the GC study performed by Yao et al
[24]
and the colorectal cancer research by Goh et al . The
relationship between VEGF expression and imaging of
tumor vascularity is complex. Further investigations
of IC and VEGF in a large population with different
clinical-pathology are needed.
At the same time, nIC in arterial phase and venous
phase displayed different character when stratified.
The nIC-AP showed correlations with MVD in relative
earlier and differentiated advanced GC, while nIC-VP
correlated with MVD in more advanced stage and
poorly differentiated advanced GC.
In terms of the acquisition time of our routine
abdominal CT scanning, the AP was performed at
about 25-30 s after contrast media injection, when the
mucosa at the lesion presented as a focal enhanced
line. nIC-AP can reflect the blood supply and functional
capillary density. In the VP of GC, the markedly
increased interstitial fibrous tissue reduced the flow-out
[29]
speed of the contrast media ; thus, more dysfunctional neo-vessels should be considered. Therefore,
the nIC-VP may represent the distribution of iodine in
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histopathological counting of micro-vessel density (MVD). This is impractical for
patients who undergoing anti-angiogenesis or chemotherapy. The current trial
was designed to evaluate if the iodine concentration (IC) generated by spectral
computed tomography could non-invasively judge the features of tumoral MVD
and vascular endothelial growth factor with clinical data.

interstitial spaces. Under such conditions, the bi-phasic
nIC demonstrated the vascular character of GC, and
nIC-VP may be better correlated with MVD in advanced
GC.
Furthermore, both nICs were different between
histological differentiations and Lauren subgroups. The
nIC-VP was more effective than nIC-AP in displaying
the difference between Lauren subtypes. In general,
the nIC value was higher in poorly differentiated and
diffused types than that in highly or moderately dif[30]
ferentiated and intestinal types. A previous study
has found that the degree of tumor angiogenesis was
closely related to the pathological grade, that is, the
poorer the differentiation of the tumor, the higher the
[31]
MVD values. Another study
demonstrated a correlation between MVD and tumor histological type accor
ding to the Lauren classification. Accordingly, it is likely
that the nIC value can be used to evaluate histology by
mapping the neovascularization of advanced GC. The
finding in the present study was also supported by the
[15]
[32]
results of Pan et al and Wang et al in GC research.
The nICs increased in patients with serosal involvement and lymphatic metastasis, but the differences
from patients without serosal involvement and lymphatic metastasis did not reach significant difference,
for reasons that are not immediately clear, as these
clinical-pathological features should reflect the functional status of the vasculature. Both nIC-AP and
nIC-VP correlated with MVD of GC located in the
antrum and occurring in different genders. However,
nICs were not very effective in differentiating between
these groups.
There are several potential limitations in our study.
First, the tumor vasculature is spatially heterogeneous.
Although we selected specimens carefully under the
guide of two major specialists, the excision level
was barely achieved. It may be questioned whether
the part of the histopathological part selected and
matched to the imaging measurement represented the
angiogenesis of the whole tumor. Second, the sample
numbers were limited, especially when subdivided by
clinical classification. A larger prospective investigation
is needed to confirm the present findings. Third, given
the limitations of CT resolution, flat and light ulcerous
lesions without enhancement would have been missed
in the images, which inducing selection bias.
In conclusion, the bi-phasic nIC values had a positive linear correlation with MVD. nIC-AP reflected the
angiogenesis in relatively earlier and well-differentiated
advanced GC, while nIC-VP reflected this in further
advanced and poorly differentiated GC. Spectral CT
with quantitative IC value offers a new choice to evaluate the angiogenesis of gastric cancer noninvasively.

Research frontiers

Iodine-water material-decomposition (MD) images can quantitatively map the
IC of the tissue in enhanced scanning. In this study, there is suggestion that IC
value has the potential to reflect angiogenesis of advanced GC.

Innovations and breakthroughs

The authors measured the normalized IC value in spectral computed
tomography (CT) with manually drawn regions of interests to avoid the selection
bias. Data stratified by clinical subgroups further revealed the connection
between imaging index and patho-index. They finally proved that the normalized
IC value in different scanning phase could reflect angiogenesis in different
pathological subgroups of advanced GC.

Applications

Radiological-pathological correlation in angiogenesis, although with not much
high coefficient, will offer a new choice to clinical decision in judging the
status of GC, especially for neoadjuvant chemotherapy or radiochemotherapy
patients.

Terminology

IC: Iodine is a commonly used contrast material in performing enhanced CT
scanning. The iodine concentration here refers an imaging data, representing
iodine distribution of the organ with spectral CT modality, not the real iodine
concentration of contrast material itself.

Peer-review

The study on the spectral computed tomography in advanced gastric cancer is
quite interesting with novelties.
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Abstract
AIM
to evaluate the quality and accuracy of websites
written to the public on inflammatory bowel disease
(IBD) (Crohn’s disease and ulcerative colitis) and assess
their readability level.
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METHODS
Google™, Bing™, and Yahoo™ search engines were
searched independently by three researchers in
December 2014. Only English-language websites were
selected on the basis of predetermined inclusion and
exclusion criteria. Researchers independently evaluated
the quality of each website by using the DISCERN and
the HONcode instruments. The readability levels were
calculated using two formulas; the Flesch-Kincaid Grade
Level Index, and the Coleman-Liau Readability Index.
The agreement between the evaluators was calculated
using Cohen kappa coefficient.
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RESULTS
eighty-four websites were finally identified. Scores
varied from a minimum DISCERN score of 18 to a
maximum of 68 [mean ± SD, 42.2 ± 10.7; median =
41.5, interquartile range, interquartile range (IQR) =
15.8] and a minimum score of HONcode of 0.14 and a
maximum of 0.95 (mean ± SD, 0.16 ± 0.19; median
= 0.45, IQR = 0.29). Most of these websites were
reviewed in 2014 and 2015 (n = 51). The creators of
these websites were: universities and research centers
(n = 25, 30%), foundations and associations (n = 15,
18%), commercial and pharmaceutical companies (n =
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25, 30%), charities and volunteer work (n = 9, 10%),
and non-university educational bodies (n = 10, 12%).
The Flesch-Kincaid Grade Level readability score (mean
± SD) was 11.9 ± 2.4 and the Coleman-Liau Readability
Index score was 12.6 ± 1.5. Significant correlation was
2
found between the two readability scores (R = 0.509,
p = 0.001). The overall agreement between evaluators
measured by Cohen kappa coefficient was in the range
of 0.804-0.876; rated as “Good”.

with the highest incidence in developed countries
mainly North America, United Kingdom and northern
Europe. The incidence of ulcerative colitis in North
America is approximately 19.5 per 100000 person
years and 243 per 100000 person years in Europe
while the incidence of Crohn’s disease in North America
is approximately 20.2 per 100000 person years
[4]
and 12.7 per 100000 person years in Europe . The
aims of treatment are to induce remission in active
disease and to maintain remission/prevent relapse.
Therapeutic modalities include lifestyle modification,
nutritional support, and medications. Surgery is
reserved for the treatment of complications or when
the medical therapy is ineffective. In addition to other
complications, patients with IBD are at a higher risk of
developing colorectal cancer. Therefore, patients have
to undergo to regular checkup for early detection of
[5]
the development of colon cancer .
With this information in mind, patients with IBD,
as it is the case with other chronic diseases, usually
seek information about the nature of the disease, its
causes, investigations needed to diagnose the disease
and therapeutic options. The advances in treatment
modalities and options, and the increasing desire
for patients to participate in decision-making about
treatment choices necessitate the need for resources
to support these decisions. Nowadays, patients have
increasingly used the Internet as a source of health
information because of its global accessibility, speed,
[6]
and cost effectiveness . Approximately 80% of the
Internet users look for medical or health-related
[7]
information through the Internet . The topics most
searched were information about specific disease
or medical condition, treatment options, diet and
[7]
nutrition, exercise and fitness and medications . The
increasing use of the Internet embraces a variety of
aspects of topics searched, which gives the person an
opportunity to investigate their questions from several
resources. However, with the abundance of such information there is concern about the quality, accuracy,
and readability level of the information available on the
[8]
Internet about health care .
Therefore, the aims of this study were: to evaluate
the quality, and accuracy of web-based information
about IBD using two instruments, the DISCERN and
the HONcode, as well as calculate the readability level
by using two formulas, the Flesch-Kincaid Grade Level
Index, and the Coleman-Liau Readability Index. The
rationales for the study were to assess the educational
usefulness of web-based information on IBD particularly their quality, accuracy and areas of deficiencies
that need improvement. Also to assess whether these
resources are easily read and understood by the public. Therefore our research questions are: (1) for the
websites targeting the public and patients with IBD,
what is the accuracy and the quality of these information resources? and (2) does the readability level of
these online resources match with the recommended
level for the public?

CONCLUSION
The DISCERN and the HONcode scores of websites
varied and the readability levels of most websites
were above the public readability level. The study
highlights the areas that need further improvement
and development in patient education online materials
about IBD.
Key words: Inflammatory bowel disease; the internet;
patients’ information; Evidence; Patients’ education;
online resources
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: This is a comprehensive study analyzing the
quality and accuracy of content and the readability level
of websites in the English language on inflammatory
bowel disease dedicated to the public. Two standardized
instruments were used in assessing quality and accuracy
and two methods were used in calculating readability
level. The study showed variability in scores and the
readability levels of most websites were above that for
the public. Based on evidence, the study highlights the
need for improving online patient education.
Azer SA, AlOlayan TI, AlGhamdi MA, AlSanea MA.
Inflammatory bowel disease: An evaluation of health information
on the internet. World J Gastroenterol 2017; 23(9): 1676-1696
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i9/1676.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i9.1676

INTRODUCTION
Inflammatory bowel disease (IBD) refers to two
chronic inflammatory disorders, Crohn’s disease and
ulcerative colitis. Both are life long, relapsing disorders
of unknown etiology; possibly the result of interaction
[1]
between genetic and environmental factors . The
diagnosis of these disorders is based on clinical fea[2]
tures, endoscopy, and histological changes . Crohn’s
disease may affect any part of the gastrointestinal
tract but most commonly affects the distal ileum and
proximal colon. The disease is characterized by inflammatory changes involving all the layers of the affected
regions. In contrast, ulcerative colitis is characterized
by continuous ulceration starting in the rectum and
[3]
limited to the colonic mucosa . IBD occurs worldwide
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online resources
. More details about these two
instruments can be summarized as follows:

MATERIALS AND METHODS
Search design

In this study we assessed websites written for
patients and the public on IBD by searching three
search engines (Google™, Bing™ and Yahoo™), the
selection of these three search engines was based
on current statistical information that showed that
these engines are the most searched by the public
[9]
for health information . The quality and accuracy of
information provided on websites were assessed using
two instruments: the DISCERN (www.discern.org.uk)
and HONcode (www.hon.ch/HONcode/) instrument.
Details about these instruments and the justification
for selecting them are discussed later. The readability
of the websites was assessed using two methods:
the Flesch-Kincaid Grade Readability Level and the
Coleman-Liau Readability Index. After piloting the work
and ensuring satisfactory use of these instruments by
researchers, the work was carried out to assess the
quality of websites. The Institutional Review Board,
College of Medicine King Saud University, has approved
the project and the approval number: F06/2014.

DISCERN instrument: This instrument is a standardized set of criteria for judging the quality of health
information and is written for the public to assess
[8,10-12]
treatment options
. The DISCERN instrument was
created by the University of Oxford, and the project
was funded by the British Library and the National
Health Service (NHS) Research & Development
[13]
Programme The instrument consists of 15 questions
plus an overall quality rating question. The questions
can be grouped under the three key topics as follows:
Questions 1 to 8 addressing reliability, Questions 9
to 15 addressing specific detail about the information
provided and treatment choices, and Q16 covering
[14]
the overall quality rating . The instrument has been
used to assess healthcare-related websites and online
resources. For example, the quality of patients’ infor[12]
mation on surgical treatment of haemorrhoids , and
[11]
colorectal cancer information .
HONcode instrument: The Health on the Net (HON)
Foundation, a non-profit, and non-government organization created this instrument in 1995. The instrument
focuses on key questions on the provision of health
information available on the Net, and provides a code
of conduct addressing eight principles: (1) authoritative (indicates the qualifications of the authors); (2)
complementarity (Information should support, not
replace, the doctor-patient relationship); (3) privacy
(Respect the privacy and confidentiality of personal
data submitted to the site by the visitor); (4) attribution [cite the source(s) of published information, date
medical and health pages]; (5) justifiability (site must
back up claims relating to benefits and performance);
(6) transparency (Accessible presentation, accurate
email contact); (7) financial disclosure (Identify
funding sources); and (8) advertising policy (Clearly
[15-17]
distinguish advertising from editorial content)
. To
earn HONcode certification, a website must conform
to the eight principles of the HONcode of Conduct. An
HONcode expert then assesses the candidate website
using precise guidelines for each principle. Recently,
the HON Foundation has developed an automated
system to assist in detecting a website’s HONcode
conformity. Therefore, the automated assistance in
conducting HONcode reviews can expedite the current
time-consuming tasks of HONcode certification and
ongoing surveillance. A recent study showed that there
is concordance between automated and expert manual
[18]
compliance detection for the criteria . In this research
we have used the electronic system available at:
http://www.readabilityformulas.com/free-readabilityformula-tests.php.
The HONcode has been widely used in the literature
[19]
in assessing health-related websites . The two instruments, the DISCERN and HONcode, do not exactly
cover the same issues/topics, although there are some

Searching the internet

Using the following key words: “inflammatory bowel
disease”, “Crohn’s disease”, “ulcerative colitis”,
“inflammatory bowel disease patient information”,
“Crohn’s disease patient information”, and “ulcerative
colitis patient information”, three search engines
(Google™, Bing™ and Yahoo™) were searched.
Researchers independently from 1 to 20 December
2014 conducted the search. Information for each
website was recorded; these included: website title,
website URL, name of creator, year of publication on
the Internet, last date updated, and the objectives
of the website. This information about each website
was collected using the following online meter:
http://whois.domaintools.com/. The data collected
were evaluated on the bases of the inclusion and the
exclusion criteria.

Inclusion and exclusion criteria

The inclusion criteria included: (1) websites covering
public education about Crohn’s disease, ulcerative
colitis or IBD; and (2) websites focusing on patient
education and in the English language. The excision
criteria comprised: (1) websites addressing doctors or
health professionals; (2) lectures, and advertisement
on IBD; (3) websites in languages other than English;
and (4) presentations at conferences.

Assessing accuracy and quality of information

Two instruments were used in assessing the quality
and accuracy of information provided, namely the
DISCERN instrument and the HONcode instrument.
These two instruments have been widely used in the
literature in assessing information on the Internet particularly health related issues and patients’ education
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overlaps. Therefore, using these two instruments with
these differences in mind could provide a better evaluation of the websites.

the United States Navy, hence the name of the test .
The test is based on the word length and the sentence
length and is based on the following formula:
0.39 × [(total words)/(total sentences)] + 11.8 ×
[(total syllables)/(total words)] - 15.59
This method has been widely used in assessing the
[27]
readability of websites and educational material .

Piloting the study

The aims of piloting the study were: (1) to introduce
the two instruments to the researchers and orient
them on how to use each instrument in assessing
the websites; and (2) identify difficulties facing the
researchers on applying the two instruments and the
sources of disagreements among them. Such exercise
prior to the implementation of the two instruments
was vital for ensuring optimal use of the instruments
and maximizing the degree of agreement among
evaluators when they apply these two instruments in
the actual research. The piloting part was conducted
as follows: (1) approximately 10 websites other than
those identified for the research study were evaluated
independently by three researchers using the two
instruments; (2) the results of their evaluation were
discussed with the aim to identify sources for difficulties/disagreements; (3) the identified differences were
resolved after discussing them reaching to a solution;
and (4) the same process was repeated on another 10
websites until the agreement between the researchers
[20]
reached to an optimal level .

Coleman-Liau readability index: This test differs
from the above method in relying on characters instead
of syllables per word. It enables the users however to
grade the readability level. It has been widely used in
[27]
assessing the readability of educational material .
We used a free online calculator (www.readabilityformulas.com) to calculate the readability level using
the two readability methods. As per instructions
provided by the website, the top, middle and bottom
150-200 words of each website were placed in the
calculator and then the text readability was checked by
calculating the number of sentences, words, syllables,
and characters in the sample. A sufficient sample size
of four to five full sentences; approximately 200-500
words in total were used. The scores recorded for each
website were placed on an Excel sheet and reviewed
by two other researchers before conducting final
analysis for the means and standard deviations.

Grouping the websites under five categories

Conduction of the study

Assessment of the identified websites revealed variability in their creators. These can be grouped into
5 categories: (1) university, affiliated hospitals, and
research centres; (2) foundations and associations;
(3) commercial and pharmaceutical companies; (4)
charities and volunteer works; and (5) non-university
educational bodies such as colleges, academies, and
councils. The grouping of websites under these five categories was carried out by researchers independently
and was reviewed in a meeting for any disagreements.

Along with the same approach described under piloting
the study, the researchers evaluated the websites
identified by applying the two instruments on each
website and giving a score. The process was conducted
by each researcher independently first by applying the
DISCERN instrument then the HONcode instrument.
The results of the assessment were placed on an Excel
sheet for each researcher. The degree of agreement
[21]
was measured using Cohen kappa coefficient .

Calculating website readability

Statistical analysis

The aims of calculating readability level of websites
was to assess if they were written at the readability
level of the general public and patients; should not
th
[22,23]
exceed the 6 grade readability level
. Two methods were used to calculate readability: The Flesch[24]
Kincaid Grade Level Index , and the Coleman-Liau
[25,26]
Readability Index
. It was decided to use these
two methods rather than one method so that we can
compare the readability scores and examine if there
were an agreement between the two methods, and
hence strengthening the outcomes of our readability
assessment and our conclusions. The two methods can
be summarized as follows:

The collected data were placed on an Excel Sheet
(Microsoft Excel for Mac 2011, Microsoft Corporation,
Redmond, WA, United States). All analysis was conducted by using SPSS software (SPSS Statistics version 22 for Mac, IBM Corporation, Armonk, NY, United
States). For the data collected from measuring website
accuracy, and the readability scores, the means,
standard deviations, the median and interquartile
range (IQR) were calculated. Pearson correlation
studies and p-values for significance were calculated to
examine if there were correlations between the scores
[28]
obtained from the two readability methods . A p-value
of < 0.05 was considered significant. The agreement
between the evaluators measured by the degree of
inter-rater agreement using Cohen kappa coefficient
was also carried out using SPSS software. This has
been interpreted as “Poor”, if the results in the range:

Flesch-Kincaid grade level index: This test helps in
indicating how difficult a reading passage in the English
language to understand. The test was developed by
Rudolf Flesch and finalized by J Peter Kincaid for use by
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Identification

Websites identified
by searching Google
(n = 100)

Websites identified
by searching Bing
(n = 100)

Websites identified
by searching Yahoo
(n = 100)

Screening

Websites after duplicates removed
(n = 210)

Websites screened
(n = 210)

Websites excluded
(n = 26)

Eligibility

Websites examined
for eligibility
(n = 184)

Websites excluded
(n =100)
Addressing doctors or health professionals.
Advertisement on inflammatory bowel disease.
Websites in languages other than English.
Conference presentations.

Included

Websites included in
the study
(n = 84)

Figure 1 PRISMA flowchart showing the websites on inflammatory bowel disease searched on the Internet and those finally included in the study.

0.21-0.40; “Fair” 0.41-0.60; “Moderate” 0.61-0.80;
“Good” 0.81-1.00.

Of the 84 websites, 60 websites comprised 1-5
pages, 16 websites had 6-10 pages, 8 had more than
11 pages. The website titled Crohn’s disease by the
University of Maryland medical center had the highest
number of pages, 20 pages. The number of tables
varied from zero to 6. Out of the 84 websites only
24 websites used tables to explain their content. The
total number of tables in these websites was 55. The
number of images varied from zero to 27. Out of the
84 websites only 42 websites had images to explain
the content. The total number of images in these websites was 141. Again the number of illustrations varied
from zero to 10. Out of the 84 websites, only 28 had
illustrations to explain the content. The total number of
illustrations was 53.

RESULTS
General information about websites

The search of the three databases, Google™, Bing™
and Yahoo™, resulted in the identification of 300
websites. After the duplicates were removed we ended
with 210 websites. On applying the inclusion and
exclusion criteria, 84 websites were finally identified
and included in the study (Figure 1).
Table 1 summarizes the general information
about the 84 websites, including: website title, URL,
author/ownership, year created, last updated, number
of pages, number of tables, images and illustrations. The oldest two websites were created by the
University of North Carolina (UNC), School of Medicine,
North Carolina, United States and the Department
of Surgery, University of California, California, United
States, while the most recent was published in 2013
and created by New Health Guide, United States.
For other websites, four websites were published
in 1987-1994, 44 were published in 1995-2002, and
29 were published in the years 2003-2011. Only four
websites were difficult to identify the exact year of
their publication. Websites were updated regularly, 51
websites were updated in 2015 and 2014, while 33
websites were updated earlier, including one website
was updated in 2006.

WJG|www.wjgnet.com

DISCERN and the HONcode scores of websites

In order to calculate the accuracy of the websites, we
used two instruments, the DISCERN and the HONcode
instruments. Table 2 summarizes the scores calculated
from applying the DISCERN and the HONcode scores
expressed as mean ± SD for each website. The
DISCERN scores varied from a minimum of 18 to a
maximum of 68 (mean ± SD, 42.2 ± 10.7; median
= 41.5, IQR = 15.8). The lowest DISCERN score was
scored by the website, Crohn’s Disease Diagnosis,
New health guide, while the highest DISCERN score
was scored by the website, Crohn’s Disease, the
National Institute of Diabetes and Digestive and
Kidney Diseases. The HONcode trust worthy scores
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Table 1 Summarizes general information about websites on inflammatory bowel disease included in the study
No.

Website title,
Organisation

1

Inflammatory
Bowel Disease
(IBD), Mayo Clinic

2

Inflammatory
Bowel Disease
Health Center,
WebMd
Inflammatory
Bowel Disease
(IBD), Center for
Disease Control and
Prevention (CDC)
Inflammatory
Bowel Disease,
NHS Choices
What are Crohn's
and Colitis?
Crohn's and Colitis
Foundation
Inflammatory
Bowel Disease,
KidsHealth

3

4

5

6

7

8

9

10

11

12

13

14

15

16

URL

Authority/ownership, Year
state, country
created

http://www.mayoclinic.org/
Mayo Foundation for
diseases-conditions/inflammatory- Medical Education
bowel-disease/basics/definition/
and Research,
con-20034908
Arizona, United
States
http://www.webmd.
WebMD, Inc.,
com/ibd-crohns-disease/
Georgia, United
States.
http://www.cdc.gov/ibd/

http://www.nhs.uk/conditions/
inflammatory-bowel-disease/
pages/introduction.aspx
http://www.ccfa.
org/what-are-crohns-and-colitis/

http://kidshealth.org/parent/
medical/digestive/ibd.html

Inflammatory
Bowel
Disease (IBD).
FamilyDoctor
Inflammatory
Bowel Disease,
Healthline
Crohn's and Colitis,
Australia

http://familydoctor.org/
familydoctor/en/diseasesconditions/inflammatory-boweldisease.html
http://www.healthline.com/
health/inflammatory-boweldisease#Overview1
https://www.crohnsandcolitis.
com.au/about-crohns-colitis/
inflammatory-bowel-disease/
Crohn's and Colitis
http://www.crohnsandcolitis.
UK
org.uk/information-and-support/
information-about-ibd/what-is-IBD
Inflammatory
http://www.medicinenet.com/infla
Bowel Disease
mmatory_bowel_disease_intestinal_
(IBD) (Intestinal
problems/article.htm
Problems of IBD),
MedicineNet
Inflammatory
http://www.cedars-sinai.edu/
Bowel Disease
Patients/Programs-and-Services/
Center,
Inflammatory-Bowel-DiseaseCedars-Sinai
Center/
Inflammatory
http://www.livescience.com/39880Bowel Diseases
inflammatory-bowel-disease.html
Symptoms and
Treatment:
Livescience
Inflammatory
http://www.pennmedicine.
Bowel Diseases
org/gastroenterology/patient-care/
Program, Penn
gi-diseases/inflammatory-bowelMedicine.org
disease-ibd/
Inflammatory
http://www.ibdsupport.org/
Bowel Diseases
Support Groups,
IBDsupport.org
Inflammatory
http://www.abc.net.au/health/
Bowel Disease
library/stories/2012/02/22/343568
(IBD), ABC Health
8.htm
and wellbeing
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Last
updated

Number Number of Number Number of
of pages
tables
of images illustrations

1997

04 Feb 2014

11

0

0

0

1998

06 Sep 2013

2

0

3

0

Centers for Disease
Control and
Prevention (CDC),
Georgia, United
States.
NHS England,
Wakefield, United
Kingdom.
Crohns and Colitis
Foundation of
America, New York,
United States.
Kids Health
Organisaion,
The Nemours
Foundation, Orlando,
United States.
American Academy
of Family Physicians,
New Jersey, United
States.
Healthline,
California, United
States.
Crohn's and Colitis
Australia, Victoria,
Australia.
Crohn's and
Colitis UK, United
Kingdom.
Medicine.Net.com,
WebMed Network,
New York, United
States.

1999

04 Sep 2014

3

0

1

1

1996

29 Apr 2013

2

0

0

0

1996

14 Apr 2014

1

0

1

0

1995

27 Jan 2015

4

0

1

0

1998

22 Jan 2015

7

0

0

0

2004

29 Nov
2011

6

0

0

0

2009

24 Jul 2014

3

0

1

0

2010

13 Nov
2014

2

0

1

0

1995

6 Sep 2013

12

0

27

0

Cedars-Sinai Medical
Center, California,
United States.

1992

5 Jul 2013

2

0

0

0

Tanya Lewis,
LiveScience
Contributor, New
York, United States.

2001

10 Apr 2014

11

0

1

0

Penn Medicine,
Pennsylvania,
United Stats.

2003

6 Nov 2014

4

0

0

0

IBD support.org,
Utah, United States.

2011

30 May
2014

2

0

0

0

Australian
Broadcasting
Corporation, NSW,
Australia.

2001

3 Dec 2014

4

0

1

0
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17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

Inflammatory
Bowel Disease
(IBD), GIKids

http://www.gikids.
org/content/7/en/IBD

GIKids and The
NASPGHAN
Foundation,
Pennsylvania, United
States.
Inflammatory
https://www.vitamindcouncil.org/
The Vitamin D
Bowel Disease,
health-conditions/inflammatoryCouncil, California,
Vitamin D Council
bowel-disease/
United States.
Inflammatory
http://www.seattlechildrens.
Children's Hospital
Bowel Disease
org/medical-conditions/digestive- and Regional Med.
Symptoms and
gastrointestinal-conditions/ibdCtr, Washington,
Diagnosis, Seattle
symptoms/
United States.
children's
Crohn's Disease,
http://www.patient.
Patient, Patient
Patient.co.uk
co.uk/health/crohns-disease-leaflet
information
Publications, Leeds,
United Kingdom.
Patient Information
http://www.uptodate.com/
UpToDate, Wolters
Crohn Disease
contents/crohn-disease-beyond-theKluwer Health,
(Beyond and the
basics
Illinois, United
Basics), Uptodate
States.
Crohn's Disease,
http://www.cdd.com.au/pages/
The Centre for
Centre for digestive disease_info/crohns_disease.html
Digestive Diseases,
diseases
NSW, Australia.
Crohn's Disease,
http://www.bsg.org.uk/patients/
British Society of
Patients: British
general/crohn-s-disease.html
Gastroenterology,
Society for
London, United
Gastroenterology
Kingdom.
Crohn's Disease,
http://www.bupa.co.uk/healthThe British
Bupa
information/directory/c/crohnsUnited Provident
disease
Association Ltd,
London, United
Kingdom
Crohn's Disease,
http://umm.edu/health/medical/
University of
University of
reports/articles/crohns-disease
Maryland Medical
Maryland Medical
Center, Maryland,
Center
United States
Crohn's Disease, https://www.southerncross.co.nz/
Southern Cross
Symptoms,
AboutTheGroup/HealthResources/ Healthcare Group;
Diagnosis,
MedicalLibrary/tabid/178/vw/1/
Auckland, New
Treatment,
ItemID/523/Crohns-diseaseZealand.
Southern Cross
symptoms-diagnosis-treatment.aspx
Crohn's Disease,
http://www.aafp.org/
American Academy
American family
afp/2011/1215/p1379.html
of Family Physicians,
physician
Kansas, United States
What is Crohn's
http://www.medicalnewstoday. Christian Nordquist,
Disease? What
com/articles/151620.php
MNT, Sussex, United
Causes Crohn's
Kingdom.
Disease? MNT
Crohn's Disease,
http://www.netdoctor.co.uk/
NetDoctor.co. Ltd,
Netdoctor
diseases/facts/crohnsdisease.htm
London, United
Kingdom.
Crohn's Disease,
http://www.ucsfhealth.
University of
UCSF medical
org/conditions/crohns_disease/
California San
center
Francisco Medical
Center, California,
United States.
Crohn's Disease
http://health.usnews.com/
Guido Zanni, US
Symptoms and
health-news/health-wellness/
News, New York,
Treatment, US.news
articles/2013/08/03/crohnsUnited States,
Wellness
disease-symptoms-and-treatment
What are the
http://www.bidmc.org/Centers- Beth Israel Deaconess
treatments for
and-Departments/Departments/
Medical Center,
Crohn's disease?
Digestive-Disease-Center/
Massachusetts,
Beth Israel
Inflammatory-Bowel-DiseaseUnited States.
Deaconess Medical Program/Crohns-Disease/WhatCenter
are-the-treatments-for-Crohnsdisease.aspx
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2009
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2014
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0
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0
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33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Diagnosing Crohn's, http://www.crohnsandme.com/
UCB Multinational
2005
Crohn's and Me. crohns-information/crohns-disease- Biopharmaceutical
diagnosis.aspx
Company, Brussels,
Belgium
Understanding
http://www.crohnsandcolitisinfo. Crohn's and Colitis, 2011
Crohn's Disease,
com/Crohns/What-is-CrohnsIllinois, United States
Crohn's and Colitis.
Disease
Learning About http://www.genome.gov/25521854
National Human
Crohn's Disease,
Genome Research
National Human
Institute,
Genome Research
Massachusetts,
Institute
United States
Crohn's Disease,
http://www.upmc.com/services/
UPMC Digestive
1999
UPMC Life
digestive-disorders-center/services/ Disorders Center,
Changing Medicine
ibd/conditions/pages/crohnsUPMC Presbyterian,
disease.aspx
Pennsylvania, United
States
Crohn's Disease,
http://www.cincinnatichildrens. Cincinnati Children's 1998
Cincinnati
org/health/c/crohns/
Hospital Medical
Children's
Center, Ohio, United
States
Crohn's Disease,
http://my.clevelandclinic.org/
The Cleveland Clinic 1998
Cleveland clinic health/diseases_conditions/hic_Infl Foundation, Ohio,
ammatory_Bowel_Disease_IBD_Qan
United States
dA/hic_Crohns_Disease
Treatment
http://www.med.unc.edu/
UNC, School of
1986
of Crohn's
gi/specialties/ibd/about-ibd/
Medicine, North
Disease, UNC
treatment-of-ibd-1/treatment-ofCarolina, United
Multidisciplinary
crohns-disease
States
Center for IBD
Research and
Treatment
Crohn's Disease, http://www.emedicinehealth.com/ EMedicine.com Inc, 2003
Emedicine health
crohn_disease/article_em.htm
WebMD Network,
Georgia, United
States
Understanding
http://www.nevdgp.org.au/info/
Australian
Crohn's Disease
gastro/crohns.htm
Gastroenterology
and Ulcerative
Institute, Digestive
Colitis. Australian
Health Foundation,
Gastroenterology
New South Wales,
Institute.
Australia
Crohn's Disease,
http://www.drweil.com/drw/u/
Weil's Foundation,
1999
Health Centers
ART00339/Crohns-Disease.html
Arizona, United
States
Crohn's Diseasehttp://www.rch.org.au/kidsinfo/ The Royal Children's
An Overview, the fact_sheets/Crohns_Disease_an_ove Hospital Melbourne,
Royal Children's
rview/
Victoria, Australia
Hospital Melbourne
Fighting
http://www.iscc.ie/page.
The Irish Society for 2000
Inflammatory
php?id=18&title=What%20is%20IBD Colitis and Crohn's
Bowel Disease
Disease, Dublin,
Together, the
United Kingdom
Irish Society for
Colitis and Crohn's
Disease
Crohn's Disease
http://www.newhealthguide.org/ New Health Guide, 2013
Diagnosis, New
Crohn%27s-Disease-Diagnosis.html
United States
health guide
Crohn's Disease,
http://consumer.healthday.com/
HealthDay, New
2002
HealthDay.
encyclopedia/digestive-health-14/ York, United States
digestion-health-news-200/crohn-sdisease-644392.html
Ulcerative Colitis,
http://en.wikipedia.
Wikimedia
2001
Wikipedia
org/wiki/Ulcerative_colitis
Foundation, Inc,
California, United
States
Living with UC, Do
http://www.livingwithuc.ca/
Janssen Inc., Canada 2010,
You Know Your
Treatment Options?
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49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

What Is Ulcerative
http://www.everydayhealth.
Everyday Health
Colitis? Everyday
com/conditions/ulcerative-colitis
Media, LLC, New
Health
York, United States
What Is Ulcerative
http://www.news-medical.net/
The AZO Network,
Colitis? News
health/What-is-Ulcerative-Colitis.
New South Wales,
Medical
aspx
Australia
Crohn's Disease and http://www.betterhealth.vic.gov.
Crohn's and
Ulcerative Colitis,
au/bhcv2/bhcarticles.nsf/pages/
Colitis, The State
Better Health
Crohn%27s_disease_and_ulcerative_
Government of
Channel
colitis
Victoria, Victoria,
Australia
Ulcerative Colitis,
http://gicare.
Jackson
Jackson Siegelbaum com/diseases/ulcerative-colitis/
Gastroenterology
Gastroenterology
Ltd, Central
Pennsylvania,
Pennsylvania, United
States
Ulcerative Colitis,
http://www.crohnsandcolitis.ca/ Crohn's and Colitis,
Crohn's and Colitis site/c.dtJRL9NUJmL4H/b.9012449/
Canada
Canada
k.C223/Ulcerative_Colitis.htm
Ulcerative Colitis,
http://www.healthgrades.
HealthGrades, Inc,
Healthgrades
com/conditions/ulcerative-colitis
Colorado, United
States
Information
http://www.ulcerativecolitis.org.
Colitis UK,
for Those with
uk/
Buckinghamshire,
Ulcerative Colitis,
United Kingdom
Colitis UK
Colitis and Chronic https://www.virginiamason.org/
Virginia Mason
Ulcerative Colitis, ColitisandChronicUlcerativeColitis
Medical Center,
Virginia Mason
Washington, United
States
Ulcerative Colitis,
http://www.gastro.net.au/
GastroNet Australia
GastroNet
diseases/ulcerativecolitis.html
Pty Ltd, Canberra,
Australia
Ulcerative Colitis, http://www.ulcerativecolitis.net/
Serovera, Florida,
Ulcerative Colitis
United States
Net.
Inflammatory
http://labtestsonline.org/
American
Bowel Disease, Lab
understanding/conditions/
Association
Tests Online
inflammatory-bowel
for Clinical
Chemistry (AACC),
Washington, DC,
United States
Inflammatory
http://www.womenshealth.gov/ Womenshealth.gov,
Bowel Disease
publications/our-publications/fact- the US Department of
Fact Sheet,
sheet/inflammatory-bowel-disease. Health and Human
Womenshealth.gov
html
Services
Inflammatory
http://www.innerbody.
InnerBody,
Bowel Disease
com/diseases-conditions/ibd
California, United
(IBD), Innerbody
States
Inflammatory
http://www.rightdiagnosis.com/i/ Rightdiagnosis. com,
Bowel
inflammatory_bowel_disease/intro.
United States
Disease (IBD),
htm
Rightdiagnosis
Inflammatory
http://www.lifescript.com/
LifeScript, California,
Bowel Disease,
health/centers/digestive/
United States
Lifescript.com
related_conditions/inflammatory_b
owel_disease.aspx
Inflammatory
http://www.ddc.musc.edu/public/ Digestive Disease
Bowel Disease
symptomsDiseases/diseases/
Center, The Medical
(IBD), MUSC
smallBowel/IBD.html
University of South
Health
Carolina, South
Carolina, United
States
Inflammatory
http://nyp.org/services/digestive/
NewYorkBowel Disease
ibd.html
Presbyterian
(IBD): Ulcerative
Hospital, New York,
Colitis, Crohn's
United States
Disease, New
York-Presbyterian
Digestive Diseases.
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66

67

68

69

70

71

72

73

74

75
76

77

78

79

80

81

Inflammatory
http://www.humanillnesses.com/ Human Diseases and
Bowel Disease,
original/Her-Kid/InflammatoryConditions Forum,
Human Diseases
Bowel-Disease.html
United States
and Conditions
Forum.
Facts About Crohn's
http://www.fda.gov/
US Food and Drug
Disease, US.
ForConsumers/ConsumerUpdates/ Administration, The
Food and Drug
ucm107358.htm
US Department of
Administration
Health and Human
Services, Maryland,
United States
Crohn's Disease
http://www.symptomfind.com/ Symptom.Find.Com.
Symptoms and
diseases-conditions/crohns-diseaseUnited States
warning Signs,
symptoms-warning-signs/
SymptomFind
Crohn's Diseasehttp://www.sixpartswater.org/
SixPartsWater.Org,
At a Glance,
knowledge-centre/crohns-disease/
United Kingdom
SixPartsWater.Org
glance
Ulcerative Colitis,
http://colitis.emedtv.com/
eMedTV,
eMedTV
ulcerative-colitis/ulcerative-colitis. Washington, United
html
States
Crohn's Disease, http://colorectal.surgery.ucsf.edu/
Department of
Department of
conditions--procedures/crohnsSurgery, University
Surgery, University
disease.aspx
of California,
of California.
California, United
States
Crohn's Disease, the
http://www.niddk.nih.gov/
The National
National Institute health-information/health-topics/ Institutes of Diabetes
of Diabetes and
digestive-diseases/crohns-disease/ and Digestive and
Digestive and
Pages/facts.aspx
Kidney Diseases,
Kidney Diseases
NIDDK, Maryland,
United States
Crohn's Disease,
http://www.
Patient Education
Patient Education
patienteducationcenter.
Center, Harvard
Center
org/articles/crohns-disease/
Medical School,
Harvard Medical
Publications,
Massachusetts,
United States
Crohn's Disease
http://health.alot.com/conditions/ Alot Health.Com,
Information, alot
crohns-disease-information--163
Arkansas, United
health
States
Crohn's Disease,
http://www.diagnose-me.com/
Diagnose-me.Com,
Diagnose-me.Com symptoms-of/crohns-disease.html Hawaii, United States
Crohns Disease
http://www.colon-cleanseColon-CleanseInformation: Is
information.com/crohns-diseaseInformation.Com,
Colon Cleansing
information.html
MKR Concepts,
the Answer,
Oregon, United
Colon Cleanse
States
Information
Crohn's Disease or
http://www.medindia.net/
Medindia4u.com Pvt.
Regional Enteritis,
patients/patientinfo/CrohnsLtd, Chennai, India
MD India.
Disease.htm
Crohn's Disease
http://www.articleinsider.com/
Digestive Disorders,
Information,
health-and-fitness/digestiveUnited States
Digestive Disorders
disorders/crohns-diseaseinformation
Inflammatory
http://patients.gi.org/topics/
Patient Center,
Bowel Disease,
inflammatory-bowel-disease/
American College of
Patient Center,
Gastroenterology,
American College
Maryland, United
of Gastroenterology
States
Crohn's Disease:
http://www.disabled-world.com/
Disabled World.
Symptoms,
health/digestive/crohns-disease/
Com, New York,
Diagnosis and
United States
Treatment,
Disabled World.
Com
Crohn's Disease,
http://www.nutritionist-resource.
Nutritionist
Nutritionist
org.uk/articles/crohns-disease.html Resource, Surrey,
Resource
United Kingdom
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21 Jun 2014

3

2

1

2

2007

02 Oct 2012

2

1

3

0

2005

07 May
2014

3

0

5

2

1986

10 Oct 2013

1

1

4

1

2002

20 Jul 2014

1

1

2

0

2003

20 Jun 2014

2

0

3

0

1994

15 Aug
2014

3

1

1

1

2002

21 Jan 2014

1

3

4

1

2007

11 Nov
2014

3

0

5

0

2000

21 Nov
2014

5

0

1

0

2003

03 Sep 2014

2

1

2

1

1996

16 May
2013

4

3

1

2

2004

29 Oct 2012

1

3

4

1

2010

9 Feb 15

3

1

3

0
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82

83

84

Crohn's Disease:
Symptoms,
Diagnosis and
Treatment,
verywell.com
Ulcerative Colitis,
Halyard Surgical.

http://seniorhealth.about.com/cs/
digestivetract/a/crohns_2.htm

Verywell.com part
of about.com, Inc.,
United States

1999

10 Feb 14

6

0

4

0

http://www.ulcerative-colitis.org/

2003

7 Nov 14

2

0

6

1

Ulcerative Colitis
Overview, Health
Communities.com

http://www.healthcommunities.
com/colitis/ulcerative-colitisoverview.shtml

Halyard Surgical,
New South Wales,
Australia
Healthcommunities.
com, New York,
United States

1998

10 May 13

3

2

0

0

IBD: Inflammatory bowel disease; NHS: National Health Service; UNC: University of North Carolina.

Table 2 Summarizes websites included in the study on inflammatory bowel disease included in the study: The accuracy scores
(calculated using the DISCERN score and the HONcode score) and the readability scores
No.

1

2

3

4

5

6
7

8

9

10

11

12

13

14

Website title,
Organisation

URL

Inflammatory Bowel
Disease (IBD), Mayo
Clinic

http://www.mayoclinic.
org/diseases-conditions/
inflammatory-bowel-disease/
basics/definition/con-20034908
http://www.webmd.
com/ibd-crohns-disease/

Accuracy scores
The DISCERN Score
(mean ± SD)

Inflammatory Bowel
Disease Health Center,
WebMd
Inflammatory Bowel
http://www.cdc.gov/ibd/
Disease (IBD), Center
for Disease Control and
Prevention (CDC)
Inflammatory Bowel http://www.nhs.uk/conditions/
Disease, NHS Choices
inflammatory-bowel-disease/
pages/introduction.aspx
What are Crohn's and
http://www.ccfa.
Colitis? Crohn's and org/what-are-crohns-and-colitis/
Colitis Foundation
Inflammatory Bowel
http://kidshealth.org/parent/
Disease, KidsHealth
medical/digestive/ibd.html
Inflammatory Bowel
http://familydoctor.org/
Disease (IBD).
familydoctor/en/diseasesFamilyDoctor
conditions/inflammatory-boweldisease.html
Inflammatory Bowel
http://www.healthline.com/
Disease, Healthline
health/inflammatory-boweldisease#Overview1
Crohn's and Colitis,
https://www.crohnsandcolitis.
Australia
com.au/about-crohns-colitis/
inflammatory-bowel-disease/
Crohn's and Colitis UK http://www.crohnsandcolitis.
org.uk/information-and-support/
information-about-ibd/what-isIBD
Inflammatory
http://www.medicinenet.com/
Bowel Disease (IBD) inflammatory_bowel_disease_inte
(Intestinal Problems of
stinal_problems/article.htm
IBD), MedicineNet
Inflammatory Bowel
http://www.cedars-sinai.edu/
Disease Center,
Patients/Programs-and-Services/
Cedars-Sinai
Inflammatory-Bowel-DiseaseCenter/
Inflammatory Bowel
http://www.livescience.
Diseases Symptoms and com/39880-inflammatory-bowelTreatment: Livescience
disease.html
Inflammatory Bowel
http://www.pennmedicine.
Diseases Program, Penn org/gastroenterology/patientMedicine.org
care/gi-diseases/inflammatorybowel-disease-ibd/

WJG|www.wjgnet.com

Readability scores

The HONcode score The Flesch-Kincaid The Coleman-Liau
(Out of 100)*
Grade Level Index Readability Index

65.0 ± 1.0

0.86*

13.1 ± 0.0

15.0 ± 0.0

41.3 ± 1.1

0.70*

10.5 ± 3.2

13.3 ± 2.5

28.7 ± 0.6

0.90

10.9 ± 2.7

13.3 ± 0.6

53.7 ± 0.6

0.63

12.2 ± 1.6

12.3 ± 1.5

50.3 ± 0.6

0.81

16.2 ± 9.3

13.7 ± 0.6

50.7 ± 0.6

0.45

12.0 ± 0.7

11.7 ± 0.6

45.0 ± 1.0

0.63*

9.6 ± 1.4

10.7 ± 0.6

41.0 ± 1.0

0.59*

8.7 ± 0.6

11.7 ± 0.6

41.7 ± 0.6

0.34

13.6 ± 3.2

13.0 ± 1.0

60.7 ± 0.6

0.45

10.4 ± 1.6

10.3 ± 3.1

57.3 ± 1.5

0.75*

13.3 ± 1.5

14.3 ± 1.5

25.7 ± 1.1

0.27

13.1 ± 2.9

14.0 ± 3.6

39.3 ± 0.6

0.27

11.1 ± 1.4

11.3 ± 1.5

38.0 ± 0.0

0.54

15.1 ± 2.6

13.0 ± 2.0
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15

16

17
18

19

20
21

22
23

24

25

26

27

28

29
30
31

32

33

34

35

Inflammatory Bowel
Diseases Support
Groups, IBDsupport.
org
Inflammatory Bowel
Disease (IBD), ABC
Health and wellbeing
Inflammatory Bowel
Disease (IBD), GIKids
Inflammatory Bowel
Disease, Vitamin D
Council
Inflammatory Bowel
Disease Symptoms
and Diagnosis, Seattle
children's
Crohn's Disease,
Patient.co.uk
Patient Information
Crohn's Disease
(Beyond and the
Basics), Uptodate
Crohn's Disease, Centre
for digestive diseases
Crohn's Disease,
Patients: British Society
for Gastroenterology
Crohn's Disease, Bupa

http://www.ibdsupport.org/

52.0 ± 1.7

0.61*

12.8 ± 3.7

13.0 ± 3.6

http://www.abc.net.au/health/
library/stories/2012/02/22/3435
688.htm
http://www.gikids.
org/content/7/en/IBD
https://www.vitamindcouncil.
org/health-conditions/
inflammatory-bowel-disease/
http://www.seattlechildrens.org/
medical-conditions/digestivegastrointestinal-conditions/ibdsymptoms/
http://www.patient.co.uk/
health/crohns-disease-leaflet
http://www.uptodate.com/
contents/crohn-disease-beyondthe-basics

34.0 ± 0.0

0.45

11.1 ± 0.3

11.3 ± 0.6

31.0 ± 0.0

0.52

12.5 ± 0.3

12.7 ± 0.6

31.3 ± 1.1

0.43

11.0 ± 10.4

10.7 ± 1.5

37.3 ± 0.6

0.43

8.9 ± 1.0

11.0 ± 1.0

55.7 ± 1.5

0.59*

8.5 ± 2.0

10.0 ± 1.7

36.7 ± 1.1

0.70

11.2 ± 1.9

12.3 ± 0.6

http://www.cdd.com.au/pages/
disease_info/crohns_disease.html
http://www.bsg.org.uk/
patients/general/crohn-s-disease.
html
http://www.bupa.co.uk/healthinformation/directory/c/crohnsdisease
Crohn's Disease,
http://umm.edu/health/
University of Maryland medical/reports/articles/crohnsMedical Center
disease
Crohn's Disease,
https://www.southerncross.
Symptoms, Diagnosis,
co.nz/AboutTheGroup/
Treatment, Southern
HealthResources/
Cross
MedicalLibrary/tabid/178/
vw/1/ItemID/523/Crohnsdisease-symptoms-diagnosistreatment.aspx
Crohn's Disease,
http://www.aafp.org/
American family
afp/2011/1215/p1379.html
physician
What is Crohn's
http://www.medicalnewstoday.
Disease? What Causes
com/articles/151620.php
Crohn's Disease? MNT
Crohn's Disease,
http://www.netdoctor.co.uk/
Netdoctor
diseases/facts/crohnsdisease.htm
Crohn's Disease, UCSF
http://www.ucsfhealth.
medical center
org/conditions/crohns_disease/
Crohn's Disease
http://health.usnews.com/
Symptoms and
health-news/health-wellness/
Treatment, US.news
articles/2013/08/03/crohnsWellness
disease-symptoms-and-treatment
What are the treatments
http://www.bidmc.org/
for Crohn's disease?
Centers-and-Departments/
Beth Israel Deaconess Departments/Digestive-DiseaseMedical Center
Center/Inflammatory-BowelDisease-Program/CrohnsDisease/What-are-the-treatmentsfor-Crohns-disease.aspx
Diagnosing Crohn's,
http://www.crohnsandme.
Crohn's and Me.
com/crohns-information/crohnsdisease-diagnosis.aspx
Understanding Crohn's http://www.crohnsandcolitisinfo.
Disease, Crohn' and
com/Crohns/What-is-CrohnsColitis.
Disease
Learning About
http://www.genome.
Crohn's Disease,
gov/25521854
National Human Genome
Research Institute

34.7 ± 0.6

0.52

12.0 ± 0.6

14.3 ± 1.1

49.7 ± 0.6

0.56

11.3 ± 1.7

10.7 ± 1.1

52.0 ± 0.0

0.77*

8.2 ± 0.5

9.0 ± 1.7

64.7 ± 1.5

0.81

15.3 ± 4.8

15.0 ± 1.0

42.7 ± 0.6

0.40

13.8 ± 0.3

13.7 ± 0.6

42.3 ± 1.1

0.18

9.0 ± 2.9

12.3 ± 4.2

45.7 ± 1.5

0.50*

11.2 ± 2.1

10.7 ± 1.5

43.0 ± 0.0

0.59

10.0 ± 1.6

12.3 ± 1.5

41.0 ± 1.0

0.40

11.4 ± 0.5

11.3 ± 0.6

48.3 ± 0.6

0.50

6.7 ± 0.8

12.3 ± 2.5

41.7 ± 1.5

0.59

14.3 ± 2.2

14.3 ± 1.1

43.3 ± 1.1

0.27

13.6 ± 1.1

12.7 ± 2.5

41.7 ± 0.6

0.45

12.4 ± 2.0

12.0 ± 2.6

29.0 ± 0.0

0.40

10.8 ± 0.5

12.3 ± 1.5
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36

37
38

39

40

41

42
43

44

45

46

47
48

49

50

51

52

53

54
55

Crohn's Disease,
UPMC Life Changing
Medicine

http://www.upmc.com/
services/digestive-disorderscenter/services/ibd/conditions/
pages/crohns-disease.aspx
Crohn's Disease,
http://www.cincinnatichildrens.
Cincinnati Children's
org/health/c/crohns/
Crohn's Disease,
http://my.clevelandclinic.org/
Cleveland clinic
health/diseases_conditions/hic_I
nflammatory_Bowel_Disease_IBD
_QandA/hic_Crohns_Disease
Treatment of Crohn's
http://www.med.unc.edu/
Disease, UNC
gi/specialties/ibd/about-ibd/
Multidisciplinary
treatment-of-ibd-1/treatment-ofCenter for IBD Research
crohns-disease
and Treatment
Crohn's Disease,
http://www.emedicinehealth.
Emedicine health
com/crohn_disease/article_em.
htm
Understanding Crohn's
http://www.nevdgp.org.au/
Disease and Ulcerative
info/gastro/crohns.htm
Colitis. Australian
Gastroenterology
Institute.
Crohn's Disease, Health http://www.drweil.com/drw/u/
Centers
ART00339/Crohns-Disease.html
Crohn's Disease- An
http://www.rch.org.au/
Overview, the Royal kidsinfo/fact_sheets/Crohns_Dise
Children's Hospital
ase_an_overview/
Melbourne
Fighting Inflammatory http://www.iscc.ie/page.php?i
Bowel Disease
d=18&title=What%20is%20IBD
Together, the Irish
Society for Colitis and
Crohn's Disease
Crohn's Disease
http://www.newhealthguide.
Diagnosis, New health
org/Crohn%27s-Diseaseguide
Diagnosis.html
Crohn's Disease,
http://consumer.healthday.
HealthDay.
com/encyclopedia/digestivehealth-14/digestion-healthnews-200/crohn-s-disease-644392.
html
Ulcerative Colitis,
http://en.wikipedia.
Wikipedia
org/wiki/Ulcerative_colitis
Living with UC, Do
http://www.livingwithuc.ca/
You Know Your
Treatment Options?
What Is Ulcerative
http://www.everydayhealth.
Colitis? Everyday
com/conditions/ulcerative-colitis
Health
What Is Ulcerative
http://www.news-medical.
Colitis? News Medical net/health/What-is-UlcerativeColitis.aspx
Crohn's Disease and http://www.betterhealth.vic.gov.
Ulcerative Colitis,
au/bhcv2/bhcarticles.nsf/pages/
Better Health Channel Crohn%27s_disease_and_ulcerativ
e_colitis
Ulcerative Colitis,
http://gicare.
Jackson Siegelbaum
com/diseases/ulcerative-colitis/
Gastroenterology
Ulcerative Colitis,
http://www.crohnsandcolitis.
Crohn's and Colitis
ca/site/c.dtJRL9NUJmL4H/
Canada
b.9012449/k.C223/
Ulcerative_Colitis.htm
Ulcerative Colitis,
http://www.healthgrades.
Healthgrades
com/conditions/ulcerative-colitis
Information for Those http://www.ulcerativecolitis.org.
with Ulcerative Colitis,
uk/
Colitis UK

WJG|www.wjgnet.com

44.3 ± 0.6

0.27

20.3 ± 9.5

15.0 ± 2.0

44.7 ± 0.6

0.40

9.3 ± 1.1

10.7 ± 0.6

26.3 ± 1.1

0.50*

12.9 ± 1.2

12.3 ± 2.3

42.3 ± 0.6

0.45

12.3 ± 0.5

13.3 ± 0.6

59.3 ± 1.2

0.86*

13.0 ± 1.2

13.0 ± 1.7

42.3 ± 1.1

0.27

10.4 ± 0.7

11.3 ± 0.6

37.0 ± 0.0

0.50

11.9 ± 1.1

12.7 ± 1.5

33.7 ± 1.1

0.50

7.7 ± 2.0

11.3 ± 1.5

37.7 ± 0.6

0.40

11.6 ± 1.4

10.7 ± 0.6

18.3 ± 0.6

0.65

13.5 ± 0.7

13.7 ± 1.1

61.0 ± 1.0

0.86*

10.9 ± 1.4

12.0 ± 0.0

54.0 ± 0.0

0.63

15.2 ± 2.1

14.0 ± 2.6

44.3 ± 1.1

0.68

12.2 ± 1.6

11.3 ± 2.3

40.0 ± 0.0

0.54*

14.1 ± 0.7

13.0 ± 1.0

46.0 ± 1.0

0.59

11.9 ± 0.2

13.0 ± 1.0

34.3 ± 1.1

0.31

9.8 ± 2.4

11.3 ± 1.5

52.3 ± 0.6

0.36

10.6 ± 1.4

11.7 ± 2.1

19.7 ± 0.6

0.31

9.2 ± 1.8

10.0 ± 1.0

52.7 ± 1.1

0.68

14.5 ± 3.5

14.0 ± 1.0

49.0 ± 1.7

0.45

14.5 ± 2.0

11.7 ± 1.1
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56

57
58
59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Colitis and Chronic
https://www.virginiamason.
Ulcerative Colitis,
org/ColitisandChronicUlcerative
Virginia Mason
Colitis
Ulcerative Colitis,
http://www.gastro.net.au/
GastroNet
diseases/ulcerativecolitis.html
Ulcerative Colitis,
http://www.ulcerativecolitis.
Ulcerative Colitis Net.
net/
Inflammatory Bowel
http://labtestsonline.org/
Disease, Lab Tests
understanding/conditions/
Online
inflammatory-bowel
Inflammatory Bowel http://www.womenshealth.gov/
Disease Fact Sheet,
publications/our-publications/
Womenshealth.gov
fact-sheet/inflammatory-boweldisease.html
Inflammatory Bowel
http://www.innerbody.
Disease (IBD),
com/diseases-conditions/ibd
Innerbody
Inflammatory Bowel
http://www.rightdiagnosis.com/
Disease (IBD),
i/inflammatory_bowel_disease/
Rightdiagnosis
intro.htm
Inflammatory Bowel
http://www.lifescript.com/
Disease, Lifescript.com
health/centers/digestive/
related_conditions/inflammatory
_bowel_disease.aspx
Inflammatory Bowel
http://www.ddc.musc.edu/
Disease (IBD), MUSC
public/symptomsDiseases/
Health
diseases/smallBowel/IBD.html
Inflammatory Bowel
http://nyp.org/services/
Disease (IBD):
digestive/ibd.html
Ulcerative Colitis,
Crohn's Disease, New
York-Presbyterian
Digestive Diseases
Inflammatory Bowel
http://www.humanillnesses.
Disease, Human
com/original/Her-Kid/
Diseases and
Inflammatory-Bowel-Disease.html
Conditions Forum.
Facts About Crohn's
http://www.fda.
Disease, US. Food and
gov/ForConsumers/
Drug Administration
ConsumerUpdates/ucm107358.
htm
Crohn's Disease
http://www.symptomfind.com/
Symptoms and warning
diseases-conditions/crohnsSigns, SymptomFind
disease-symptoms-warningsigns/
Crohn's Disease-At a
http://www.sixpartswater.
Glance, SixPartsWater. org/knowledge-centre/crohnsOrg
disease/glance
Ulcerative Colitis,
http://colitis.emedtv.com/
eMedTV
ulcerative-colitis/ulcerativecolitis.html
Crohn's Disease,
http://colorectal.surgery.ucsf.
Department of
edu/conditions--procedures/
Surgery, University of
ulcerative-colitis.aspx
California.
Crohn's Disease, the
http://www.niddk.nih.gov/
National Institute of health-information/health-topics/
Diabetes and Digestive
digestive-diseases/crohnsand Kidney Diseases
disease/Pages/facts.aspx
Crohn's Disease, Patient
http://www.
Education Center
patienteducationcenter.
org/articles/crohns-disease/
Crohn's Disease
http://health.alot.com/
Information, alot health
conditions/crohns-diseaseinformation--163
Crohn's Disease,
http://www.diagnose-me.com/
Diagnose-me.Com
symptoms-of/crohns-disease.
html

WJG|www.wjgnet.com

40.7 ± 0.6

0.31

16.7 ± 3.9

15.0 ± 2.0

26.7 ± 0.6

0.60

13.1 ± 1.1

13.3 ± 2.3

41.3 ± 0.6

0.30

11.4 ± 3.3

12.0 ± 2.0

38.3 ± 0.6

0.32*

13.0 ± 0.7

12.0 ± 1.0

55.7 ± 1.5

0.40

8.8 ± 0.7

10.0 ± 1.0

39.0 ± 1.0

0.25

17.2 ± 5.7

16.7 ± 1.5

38.0 ± 1.0

0.33

15.9 ± 4.1

15.7 ± 2.1

32.0 ± 1.0

0.50

15.1 ± 2.8

12.7 ± 1.5

22.7 ± 1.1

0.27

14.2 ± 2.2

15.7 ± 2.9

32.3 ± 0.6

0.27

13.2 ± 0.5

12.7 ± 0.6

35.3 ± 1.5

0.14

10.7 ± 0.9

13.3 ± 2.3

34.7 ± 2.1

0.36

10.6 ± 2.6

13.7 ± 2.1

26.0 ± 1.0

0.26*

10.0 ± 1.9

13.7 ± 2.3

39.7 ± 0.6

0.15

18.3 ± 3.4

12.7 ± 0.6

55.3 ± 0.6

0.32*

12.1 ± 0.8

11.0 ± 2.0

51.0 ± 1.0

0.73

12.4 ± 0.8

12.3 ± 2.5

68.3 ± 1.2

0.95

13.6 ± 3.9

13.7 ± 5.5

38.0 ± 1.0

0.30

8.9 ± 0.8

12.3 ± 1.5

32.3 ± 0.6

0.22

10.4 ± 1.5

12.0 ± 2.6

32.0 ± 1.0

0.28

12.5 ± 1.6

14.3 ± 1.1
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76

77

78

79

80

81

82

83
84

Crohns Disease
http://www.colon-cleanseInformation: Is
information.com/crohns-diseaseColon Cleansing the
information.html
Answer, Colon Cleanse
Information
Crohn's Disease or
http://www.medindia.net/
Regional Enteritis, MD
patients/patientinfo/CrohnsIndia.
Disease.htm
Crohn's Disease
http://www.articleinsider.com/
Information, Digestive
health-and-fitness/digestiveDisorders
disorders/crohns-diseaseinformation
Inflammatory Bowel
http://patients.gi.org/topics/
Disease, Patient Center,
inflammatory-bowel-disease/
American College of
Gastroenterology
Crohn's Disease:
http://www.disabled-world.
Symptoms, Diagnosis
com/health/digestive/crohnsand Treatment,
disease/
Disabled World.Com
Crohn's Disease,
http://www.nutritionist-resource.
Nutritionist Resource
org.uk/articles/crohns-disease.
html
Crohn's Disease:
http://seniorhealth.about.com/
Symptoms, Diagnosis cs/digestivetract/a/crohns_2.htm
and Treatment,
verywell.com
Ulcerative Colitis,
http://www.ulcerative-colitis.
Halyard Surgical.
org/
Ulcerative Colitis
http://www.healthcommunities.
Overview, Health
com/colitis/ulcerative-colitisCommunities.com
overview.shtml

35.7 ± 2.5

0.36

13.2 ± 0.5

14.7 ± 1.5

46.3 ± 1.1

0.54

11.8 ± 1.3

14.0 ± 2.6

33.3 ± 0.6

0.60

10.2 ± 0.6

12.3 ± 0.6

58.3 ± 1.2

0.80

12.7 ± 1.3

13.0 ± 1.0

26.3 ± 2.3

0.19

8.6 ± 0.6

12.00 ± 1.73

39.3 ± 0.6

0.57

10.2 ± 2.6

11.3 ± 1.1

44.3 ± 1.5

0.37

12.6 ± 0.7

11.0 ± 1.0

51.7 ± 1.5

0.25

12.1 ± 0.6

12.7 ± 2.5

52.7 ± 1.5

0.23*

12.6 ± 1.2

12.7 ± 1.1

*Websites that received HONCode certificates. IBD: Inflammatory bowel disease; NHS: National Health Service; UNC: University of North Carolina.

also varied from a minimum of 0.14 to a maximum of
0.95 (mean ± SD, 0.16 ± 0.19; median = 0.45, IQR
= 0.29). The lowest HONcode score was scored by the
website, Crohn’s Disease, American family physician,
while the maximum score was scored by the website,
Crohn’s Disease, the National Institute of Diabetes
and Digestive and Kidney Diseases. Along with the
HONcode trust worthy scores, HONcode certificate
was indicated for websites that have received such
certificates, Table 2.
The top ten websites on IBD as per the DISCREN
scores were in the following order: The Crohn’s Disease,
the National Institute of Diabetes and Digestive and
Kidney Diseases (scored 68), Inflammatory Bowel
Disease, MayoClinic (Scored 65), Crohn’s Disease,
University of Maryland Medical Center (scored 64),
Crohn’s Disease, HealthDay (scored 61), Crohn’s
Disease and Colitis UK (scored 60), Crohn’s Disease,
eMedicine health (scored 59), Inflammatory Bowel
Disease, Patient Center, American College of
Gastroenterology (scored 58), Inflammatory Bowel
Disease, MedicineNet (scored 57), Inflammatory Bowel
Disease, Fact Sheet, Womenshealth.gov (scored 55),
Ulcerative Colitis, eMedTV (scored 55). The top ten
websites as per the HONcode tool were in the follo
wing order: Crohn’s Disease, the National Institute of
Diabetes and Digestive and Kidney Diseases (scored
0.95), Inflammatory Bowel Disease, Center for Disease

WJG|www.wjgnet.com

Control and Prevention (scored 0.90), Inflammatory
Bowel Disease, MayoClinic (scored 0.86), Crohn’s
Disease, eMedicine health (scored 0.86), Crohn’s
Disease, HealthDay (scored 0.86), What are Crohn’s
& Colitis? Crohn’s & Colitis Foundation (scored 0.81),
Crohn’s Disease, University of Maryland Medical Center
(scored 0.81), Inflammatory Bowel Disease, Patient
Center, American College of Gastroenterology (scored
0.80), Crohn’s Disease, Bupa (scored 0.77), and
Inflammatory Bowel Disease, MedicineNet (scored
0.75). It is interesting to note that the website, Crohn’s
Disease, the National Institute of Diabetes and
Digestive and Kidney Diseases was ranked number
one as per the two instruments. Seven websites in
total were among the top ten websites as per both the
DISCERN and the HONcode scores. Nine out of the ten
websites were created in United State.

Grouping the websites under five categories

Table 3 summarizes the grouping of the 84 websites
under five categories on the basis of the website
creators. Universities and research centers created 25
(%), professional foundations and associations created
15 (%), commercial and pharmaceutical companies
created 25 (%), charities and volunteers contributed
to 9 (%), non-university educational bodies such as
colleges, academies, councils, WebMed contributed to
10 (%). Further analysis revealed that there was no
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Table 3 Grouping the websites on inflammatory bowel disease included in the study under five categories
Category

Number

DISCERN score
6

mean ± SD
Universities and Research Centers1
Foundations and Associations2
Commercial and Pharmaceutical Companies3
Charities and Volunteer work4
Non-university Educational Bodies5
Total

25
15
25
9
10
84

41.3 ± 11.3
44.5 ± 10.5
40.4 ± 10.1
40.2 ± 11.9
46.7 ± 9.7
42.1 ± 10.7

HONcode score
7

95%CI for means

mean ± SD

95%CI for means

36.6-45.9
38.6-50.2
36.3-44.6
31.0-49.4
39.7-53-6
39.8-44.5

0.46 ± 0.20
0.53 ± 0.16
0.44 ± 0.18
0.39 ± 0.17
0.63 ± 0.20
0.48 ± 0.19

0.37-0.54
0.44-0.62
0.36-0.52
0.26-0.52
0.48-0.76
0.44-0.52

This category includes university-affiliated centers, state hospitals, national or state research centers; 2This category includes gastroenterological societies,
foundations, and associations- most were on inflammatory bowel disease, Crohn’s disease or ulcerative colitis; 3This category includes industrial bodies,
commercial and pharmaceutical companies aiming at serving the community and patients with inflammatory bowel disease; 4This category includes
charities and websites created by individuals, or groups; 5This category includes all other non-university educational bodies including colleges, academies,
councils, WebMed, etc.; 6The DISCERN scores were not significantly different between the groups as per ANOVA (combined, p = 0.472) or (linear term, p =
0.475); 7The HONcode scores were significantly different between the groups as per ANOVA (combined, p = 0.041). The linear term, p = 0.228.

The Cole man-Liau Read
ability Index Score

1

18
16
14
12
10
8
6
4
2
0

Significant correlation was found between the
Flesch-Kincaid Grade Level index scores and the
Coleman-Liau Index scores (R² = 0.509, P < 0.001)
(Figure 2).

y = 0.4565x + 7.1211
2
R = 0.50929
P = 0.001

0

5

10

15

20

The agreement between the evaluators

Table 5 summarizes the inter-rater agreement
between evaluators for the DISCERN instrument items.
The overall Cohen kappa scores were in the range of
0.804-0.876.

25

Flesch-Kincaid Grade Level Index Score

Figure 2 Correlation between the scores of the two readability methods:
Coleman-Liau Readability Index and Flesch-Kincaid Grade Level Index.

DISCUSSION
Several studies pointed to continuous progress from
paper to electronic and online-based patient educa[29,30]
tion
. The aims of the study were to evaluate the
quality and accuracy of information available on IBD
websites and calculate the readability level using two
methods. To maximize the yield of the search, we
searched three search engines commonly used by the
public seeking information related to healthcare. The
study showed that the 84 websites identified were created by universities, affiliated hospitals and research
centers, professional foundations and associations,
commercial and pharmaceutical companies created,
charities and volunteers, as well as non-university
educational bodies (such as colleges, academies,
councils, and WebMed). The involvement of universities, affiliated hospitals, and research centers is
directed at health information exchange as well as
public and patient education with the aim to improve
the quality of care, engage the patient in the decisionmaking processes and the journey of treatment as well
as enhance patient’s awareness about the nature of
their illness. Such educational approaches while having
multiple impacts on the patients’ healthcare; it can
[31]
also help in reducing the costs of treatment . The
current move from paper-based to online health care
education may be related to the progressive increases
[32]
in the use of the Internet by the public and patients .
[33]
Furthermore, Morgan et al
showed that patients
with genetic and chronic diseases have great interest

significant differences in the DISCERN scores between
the groups (p = 0.472) but the HONcode scores were
different (p = 0.041). Examples of content deficiencies
or scientific content inaccuracies and suggestions for
improvement are shown on Table 4.

Readability level of websites

Table 2 summarizes the readability scores calculated
by using two methods, the Flesch-Kincaid Grade Level
Index and Coleman-Liau Readability Index. The minimum score for the Flesch-Kincaid Grade Level Index
was 6.7 for the website Crohn’s Disease Symptoms
and Treatment, United States news Wellness, while
the maximum score was 20.3 for the website Crohn’s
Disease, UPMC Life Changing Medicine. Out of the 84
websites, 28 received a mean of 6.7 to 10.9, fortysix received a mean of 11.0 to 14.5, and ten websites
received a mean of 15.7 to 20.3. The overall mean
score for the 84 websites was 11.9 ± 2.4.
For the Coleman-Liau Readability Index the minimum score was 9.0 for the website Crohn’s Disease,
Bupa, while the maximum score was 16 for the
website Inflammatory Bowel Disease, Fact Sheet,
Womenshealth. Out of the 84 websites, eleven received
a mean score of 9.0 to 10.9, thirty-nine received a
score of 11.0 to 12.7, and thirty-four received a score
of 13.0 to 16.0. The overall mean score for the 84 websites was 12.6 ± 1.5.

WJG|www.wjgnet.com

1691

March 7, 2017|Volume 23|Issue 9|

Inflammatory Symptoms of inflammatory bowel disease are not
Bowel Disease clearly written. One would wonder, are “bowel
(IBD), MUSC
sores” and “intestinal bleeding” symptoms?
Health
Differential diagnosis is not mentioned. The
approach for diagnosing inflammatory bowel
disease is not mentioned and the treatment of IBD
is not explained.

Crohn's Disease
Although symptoms of Crohn's disease are
Symptoms and
mentioned briefly, they are not explained.
Warning Signs, Mild, moderate and severe inflammatory bowel
SymptomsFind disease are stated but not explained. This should
be explained in a simple language.
Complications are mentioned but there was no
mention how the disease is diagnosed, and what
investigations are needed.
Nothing is mentioned about nutritional changes,
medical and surgical treatment of inflammatory
bowel disease.

68

53

64

Areas of deficiencies

Crohn's Disease
Symptoms of Crohn's disease are briefly
Diagnosis, New mentioned. Some details are needed to explain
health guide the common presenting symptoms. No mention
of differential diagnosis.
No mention of investigations needed to confirm
the diagnosis.
Nothing is mentioned about treatment of Crohn's
disease.
Ulcerative
Symptoms are briefly stated. No mention of
Colitis, Crohn's
differential diagnosis, investigations and no
and Colitis
discussion of medical and surgical treatment.
Canada

Title

45

Website
Number

WJG|www.wjgnet.com
Patients are described to have mild ulcerative colitis when they have:
-Fewer than four bowel motions (stools) per day.
-No bleeding or small amounts of bleeding in their stools.
-Normal erythrocyte sedimentation rate (ESR)
-No fever, no anaemia and no increases in their heart rate,
Patients are described to have moderate ulcerative colitis when they have:
-More than four stools per day.
-Mild elevation in ESR.
Patients are described to have severe ulcerative colitis when they have:
-More than six stools a day (loose stools).
-Fever, rapid heartbeat, and anaemia.
-Elevated ESR.
The website may also mention changes that necessitate hospital admission and medical attention.
Websites may provide key questions that patients may use when they review their treating doctors. Examples of these questions:
•I wonder what's causing these symptoms?
•What type of tests do I need? Do these tests require any special preparation?
•What treatments are available, and which do you recommend?
•Are there any medications that I should avoid?
•Do I need to follow any dietary restrictions?
•Are there any risks if I become pregnant?
The MayoClinic website has listed a number of useful questions that patients can use.

Symptoms may include abdominal pain, typically in the right lower quadrant, diarrhoea, some blood may be present in stools, fatigue. In more
severe disease fever, and weight loss may be present. Some patients may have nausea, and abdominal distention together with abdominal pain.
It is worth to mention that Crohn's disease is a lifelong illness (chronic disease). People who have Crohn's will experience periods of flare-ups,
when their symptoms are active, and other times when their symptoms go into remission.
Up to 30% of patients may have changes in the area around the anus including anal fistulas (internal tracts connecting the anal lumen with the skin
around the anus), abscess, skin tags, and anal fissures.
About 10%-20% of patients also have joint pains, lower back pain, skin rash known as erythema nodosum, and eye changes. (images showing some
of these changes will enhance this part).
A section discussing investigations should be added. In addition to detailed medical history, the treating doctor will initiate the evaluation by
testing for infectious conditions that can cause inflammation of the colon, screen for endocrine-metabolic disorders such as excessive activity of the
thyroid gland. Therefore biochemical tests and stool tests are needed.
Endoscopic evaluation (colonoscopy) should be carried out in patients who have symptoms suggestive of inflammatory bowel disease and no
evidence for an infection to explain symptoms.
Small bowel images, computed tomography (CT) enterography may also be needed.
Nutritional changes, medical and surgical treatment should be briefly discussed.
As discussed earlier.

Suggestions for improvement

Table 4 Examples of assessment of the content of some websites on inflammatory bowel disease

Azer SA et al. Online resources on IBD
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Nutritional changes, medical and surgical
treatment are not explained.

Complications are provided but no signs are
stated. No mention of differential diagnosis, no
mention of investigations and possible findings.

Inflammatory Under symptoms of Crohn's disease, it is written,
Bowel Disease “The most common signs are pain in the stomach
Center,
area (usually on the right side) and diarrhea”, it
cedars-Sinai. is not clear what is meant by pain in the stomach
area on the right side?

1693
1.7 (1.5-2.0)
1.4 (0.9-1.8)
3.8 (3.6-4.0)
2.5 (2.2-2.9)
2.7 (2.4-3.1)
3.7 (3.5-4.0)
2.2 (1.9-2.5)
3.2 (3.0-3.4)
3.1 (2.8-3.4)
2.4 (2.2-2.7)
2.3 (2.0-2.6)
1.5 (1.3-1.7)
2.0 (1.8-2.2)
3.6 (3.4-3.9)
2.7 (2.4-2.9)
2.9 (2.7-3.2)

Evaluator 1

1.7 (1.5-2.0)
1.5 (1.0-1.9)
3.8 (3.6-4.0)
2.5 (2.2-2.8)
2.7 (2.3-3.0)
3.8 (3.6-4.0)
2.2 (1.9-2.5)
3.1 (3.0-3.3)
3.1 (2.8-3.4)
2.4 (2.2-2.7)
2.3 (2.0-2.6)
1.5 (1.3-1.7)
2.0 (1.8-2.2)
3.6 (3.4-3.9)
2.8 (2.6-3.0)
3.0 (2.7-3.2)

Evaluator 2

1.8 (1.5-2.0)
1.5 (1.0-1.9)
3.8 (3.6-4.0)
2.5 (2.2-2.8)
2.7 (2.3-3.0)
3.7 (3.5-3.9)
2.2 (1.9-2.5)
3.2 (3.0-3.3)
3.1 (2.8-3.4)
2.5 (2.2-2.8)
2.3 (2.0-2.7)
1.5 (1.3-1.8)
2.1 (1.9-2.3)
3.6 (3.4-3.8)
2.8 (2.5-3.0)
2.9 (2.6-3.2)

Evaluator3

0.885-0.953
0.790-0.904
0.792-0.887
0.879-0.880
0.793-0.875
0.796-0.890
0.792-0.827
0.764-0.832
0.859-0.874
0.782-0.841
0.772-0.902
0.870-0.923
0.859-0.906
0.773-0.849
0.767-0.854
0.900-0.959

Reviewer variability
(κ range)

in participating in clinical studies and a desire to understand information discussed during reviewing their healthcare provider. These patients may have more questions
[33]
after they leave the doctor’s clinic and usually tend to search the Internet for answers . Compared to paper-based health education, the Internet appears to provide a
[8,34]
wider range of answers and options. However, the quality of information provided and the readability level remain as areas of concern
.

1. Are the aims clear?
2. Does it achieve its aims?
3. Is it relevant?
4. Is it clear what sources of information were used to compile the publication (other than the author or producer)?
5. Is it clear when the information used or reported in the publication was produced?
6. Is it balanced and unbiased?
7. Does it provide details of additional sources of support and information?
8. Does it refer to areas of uncertainty?
9. Does it describe how each treatment works?
10. Does it describe the benefits of each treatment?
11. Does it describe the risks of each treatment?
12. Does it describe what would happen if no treatment is used?
13. Does it describe how the treatment choices affect overall quality of life?
14. Is it clear that there may be more than one possible treatment choice?
15. Does it provide support for shared decision-making?
16. Based on the answers to all of the above questions, rate the overall quality of the publication as a source of information about
treatment choices?

DISCERN items

Mean score (95%CI of the difference)

The authors should differentiate between symptoms and signs. Scientific errors are noted in the website and common presenting symptoms should
be stated. It may be useful to explain the symptoms under two main headings: symptoms in children, and symptoms in adults.
Investigations needed to diagnose the disease should be discussed. Patients are usually interested to know more detail about these investigations.
Information provided should answer questions such as
-Name of the test
-Why the test is need?
-What is the test about?
-Nature of the investigation (invasive vs non-invasive)
-Are there special preparations needed prior to the test?
-Any possible complications related to the investigation?
-What can the results of the test tell the patient and the treating doctor?
It is also important to state that IBD is an ongoing condition (chronic disease), so some of the tests may need to be repeated from time to time, or
extra tests may be needed.
These investigations may include: (1) Blood tests including full blood count, inflammatory markers tests including erythrocyte sedimentation rate
(ESR), c-reactive protein (CRP), liver function tests, urea and electrolytes, and other biochemical tests, (2) stool tests including stool microscopy,
stool culture and sensitivity, fecal markers such as fecal calprotectin, fecal lactoferrin, (3) Endoscopy including colonoscopy, sigmoidoscopy,
proctoscopy, with biopsies for histological studies (4) radiological studies such as barium studies, CT scans, MRI scans and PET scans.

Table 5 Summarizes the inter-rater agreement between evaluators calculated using Cohen kappa coefficient scores
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As per this study, the DISCERN and the HONcode
scores varied. However, no significant differences in
the DISCERN scores were found between the groups
but when the groups were compared on the basis of
the HONcode scores, the difference was significant.
A weak correlation was found between the DISCERN
2
scores and the HONcode scores (R = 0.217). The
results are consistent with the variability of the
DISCERN scores of websites in each group and the fact
that the two instruments are not measuring the same
[25]
characteristics . Interestingly, seven out of the top 10
websites on IBD scored higher on both the DISCERN
and the HONcode scales. Looking into the readability
levels of these seven websites, the readability using
the Flesch-Kincaid Grade level was in the range 11 to
15, while for the Coleman-Liau Readability Index the
range was 12 to 15. This indicates that even the top
7 websites had a readability level not adjusted to the
public level.
Out of the 84 websites, only 17 displayed the
HONcode certificate. A recent study found that only
three websites out of 78 showed HONcode certifi[35]
cates . Although the number of websites granted a
HONcode certificate is small yet there is no correlation
between the calculated HONcode scores and having
a certificate on the website. Absence of the HONcode
certificate from a website doesn’t necessarily indicate
poor quality of the website. This is because the process
of issuing the HONcode is based on a voluntary application for the certificate. Therefore, it is possible that
the owners/authority responsible for these websites
did not apply for the HONcode certificate.
The readability scores were calculated by using two
methods, the Flesch-Kincaid Grade Level Index and
Coleman-Liau Readability Index. The moderate correlation between the Flesch-Kincaid Grade Level index
scores and the Coleman-Liau Index scores is consistent
[20]
with other work
and indicates that the results from
the two calculations are consistent. The findings show
that the majority of the studies had a readability level
equivalent to year 11 and 12. However, the national
reading grade level average has been estimated to be
th
[36]
about the 6 -grade
and the general agreement is
that the reading level for patient information materials
should not exceed this level and be no less than what
th
[37]
a 4 -grade is capable of reading . With these findings
in mind, there is a need for editing the content of most
websites identified and adjusting the reading levels to
meet the recommended reading levels for the public.
This study has a number of strengths; first, we
searched three different search engines commonly
used by the public seeking health-related information
with the aim to maximize the yield of the search.
Second, we used two instruments the DISCERN and
the HONcode to measure the accuracy of contents.
Both instruments have been widely used in assessing
online health information material. Third, three evaluators independently conducted the evaluation and
the inter-rater agreement among the assessors was
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within the accepted limits. Finally, the readability was
measured by using two different methods. However,
this study is not without limitations; the study is just a
representation of websites identified at the time of the
search. Only websites in the English language were
included, and there is the possibility that there are
other websites in other languages that match with our
inclusion criteria and were not included. A multinational
study may be needed to identify any differences if any
and resolve gaps in this area. Therefore, despite all
efforts and the plans considered, we may have missed
some websites.
The results of this study may be of value to general
practitioners, physicians, gastroenterologists, nurses,
and allied health professionals, the public and medical
students interested in online education material on
IBD. The top 10 websites with the highest DISCERN
and the HONcode scores identified from this study
provide examples of educationally useful websites that
can be recommended by treating physicians to their
patients. However, their readability level was above
the recommended level for the public and they may be
suitable for educated patients only.

Future directions

This study highlights a number of future directions
in research in the area of Internet-based patient
education particularly patients with IBD. These can
be summarized as follows: First, planning for creating
online educational material for the public and patients
with IBD necessitates more care for innovation,
content accuracy and readability level to match the
recommended needs of the public. Second, more work
is needed to enhance the use of images, illustrations,
and videos in improving the educational usefulness
of websites on IBD and engage the patients and the
public using such online resources. The use of these
educational tools should aim at explaining difficult
concepts, and enhancing understanding of the message given. As shown from this study the use of these
educational tools was deficient in most websites. Third,
future research should aim at assessing the impact
of using Internet education and health literacy in
patients with IBD and whether such resources have
made impacts on number of hospital admissions, costs
associated with poor health literacy, effective health
education techniques, and how poor health literacy
influences management outcome in these patients.
In conclusion, health literacy about IBD and the use
of Internet as a medium for education appears to be
increasing. Universities, research centers, commercial
and pharmaceutical companies, professional foundations and associations were the major contributors to
online resources written for the public and patients.
Several deficiencies in the content were observed and
most websites failed to meet the recommendations
set by the National Institute of Health and American
Medical Association that patients resources should
th
be written about the 6 -grade level. Effective use of

1694

March 7, 2017|Volume 23|Issue 9|

Azer SA et al. Online resources on IBD
diagrams, illustrations, videos, and tables to explain
difficult concepts should be encouraged. Revising the
websites and resolving the gap between the readability
of written health information and the literacy skills of
the public will improve the purpose of these websites
and make them a useful healthcare resource to patients
with IBD.
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COMMENTS
COMMENTS
Background

9

Patients with inflammatory bowel disease (IBD), as it is the case with other
chronic diseases, seek information about the nature of their disease. The
increasing use of the Internet embraces the significance of online resources
educating patients and the public.

10

Research frontiers

With the abundance of information there is concern about the quality, accuracy
and readability level of information available on the web, thus it might be useful
to assess the quality of these resources, identify specific deficiencies and
examine whether these websites meet the recommendations of national bodies.

11
12

Innovations and breakthrough
The goal of this paper is to use comprehensive analysis to assess the quality
of websites, accuracy of content and readability levels of websites on IBD
dedicated to patients and the public.

13

Applications

14

The study highlights a number of future directions in the area of Internetbased patient education particularly patients with IBD and raises the need for
improving such resources particularly in relation to specific areas identified in
the study.

15

Terminology

Scientific accuracy and quality of content were evaluated using two standar
dised instruments widely used in research. The readability level was calculated
on the bases of word length, sentence length and syllables.

16
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Peer-review

This paper is an interesting evaluation of quality, accuracy, and readability of
websites dedicated to the public. It is a novelty and represents a beginning
point for judging and improving websites dedicated to IBD.
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Abstract
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AIM
To summarise the literature data on hepatitis C virus
(HCV)-infected patients concerning the prevalence of
glucose abnormalities and associated risk.
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METHODS
We conducted a PubMed search and selected all studies
found with the key words “HCV” or “hepatitis C virus”
and “diabetes” or “insulin resistance”. We included
only comparative studies written in English or in
French, published from January 2000 to April 2015. We
collected the literature data on HCV-infected patients
concerning the prevalence of glucose abnormalities
[diabetes mellitus (DM) and insulin resistance (IR)]
and associated risk [i.e. , severe liver fibrosis, response
to antivirals, and the occurrence of hepatocellular
carcinoma (HCC)].
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RESULTS
HCV infection is significantly associated with DM/IR
compared with healthy volunteers and patients with
hepatitis B virus infection. Glucose abnormalities
were associated with advanced liver fibrosis, lack of
sustained virologic response to interferon alfa-based
treatment and with a higher risk of HCC development.
As new antiviral therapies may offer a cure for HCV
infection, such data should be taken into account, from
a therapeutic and preventive point of view, for liver and
non-liver consequences of HCV disease. The efficacy
of antidiabetic treatment in improving the response to
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while others evaluated the impact of DM/IR on the
main liver-related HCV infection outcomes (i.e., liver
fibrosis, cirrhosis, HCC). However, the results appear
to be conflicting, with great heterogeneity between
studies.
In the present study, based on a literature data
review, we aimed to analyse: (1) the risk of glucose
abnormalities (GA) in HCV-infected patients; and (2)
the impact of GA on the main liver-related HCV outcomes, i.e., liver fibrosis, response to interferon alfabased treatment, and HCC.

antiviral treatment and in decreasing the risk of HCC
has been reported by some studies but not by others.
Thus, the effects of glucose abnormalities correction in
reducing liver events need further studies.
CONCLUSION
Glucose abnormalities are strongly associated with HCV
infection and show a negative impact on the main liver
related outcomes.
Key words: hepatitis C virus; diabetes mellitus; insulin
resistance; liver fibrosis; treatment
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

MATERIALS AND METHODS
We conducted a PubMed search and selected all
studies found with the key words “HCV” or “hepatitis C virus” and “diabetes” or “insulin resistance”. We
included only comparative studies written in English or
in French, published from January 2000 to April 2015.
We selected surveys that had evaluated the risk of
Type 2 DM or IR in HCV-infected patients compared
with healthy controls or with patients with hepatitis B
virus (HBV) infection. The definition of DM was usually based on a fasting plasma glucose > 1.26 g/L, or
a history of diabetes mellitus, or use of oral antidiabetic agents or insulin. The definition of IR was based
on the Homeostasis Model Assessment for Insulin
Resistance (HOMA-IR) according to the formula:
HOMA-IR = fasting glucose (mmol/L) × fasting insulin
(mIU/L)/22.5. We also included studies that assessed
the association between the presence of glucose
abnormalities (DM or IR) and the main HCV infection outcomes (i.e., liver fibrosis, cirrhosis, response
to antiviral treatment, HCC). Conversely, studies that
evaluated the impact of antiviral treatment on glucose
abnormalities were included. We excluded studies with
patients infected with the HBV or human immunodeficiency virus, and those for whom the entire manuscript
was not available.

Core tip: hepatitis C virus (HCV) infection is associated
with increased rates of glucose abnormalities, including
diabetes mellitus and insulin resistance. The presence
of glucose abnormalities in HCV infected patients,
including diabetes mellitus and insulin resistance, is
associated with negative liver-related outcomes (i.e. ,
severe liver fibrosis, decreased response to antivirals,
and increased occurrence of hepatocellular carcinoma).
Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance
and hepatitis C virus infection: A contemporary review. World
J Gastroenterol 2017; 23(9): 1697-1711 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v23/i9/1697.htm DOI:
http://dx.doi.org/10.3748/wjg.v23.i9.1697

INTRODUCTION
Hepatitis C virus (HCV) infection is a major health
problem. The World Health Organization (WHO) estimates that at least 150-170 million people, approximately 3% of the world’s population, are chronically
infected. These patients are known to be at risk of liver
related complications, i.e., cirrhosis and hepatocellular
carcinoma (HCC), with an estimated liver-related mortality of 350000 people/year. The total risks of morbidity and mortality are underestimated, because they
do not take into account extrahepatic consequences of
HCV infection. Numerous extrahepatic manifestations
have been reported, suggesting that HCV is more a
systemic disease than just a liver disorder. In large
prospective cohort studies, up to two-thirds of patients
with HCV infection experienced extra-hepatic mani[1]
festations . The majority of available data concern
HCV-related autoimmune and/or lymphoproliferative
disorders, from benign mixed cryoglobulinemia to
frank lymphomas, which is consistent with HCV
[2]
lymphotropism . More recently, other HCV-associated
disorders have been reported including cardiovascular,
renal, central nervous system and metabolic dis[3]
eases . Among the latter, some studies assessed the
risk of diabetes mellitus (DM) or insulin resistance (IR)

WJG|www.wjgnet.com

RESULTS
Is HCV infection associated with an increased
prevalence of glucose abnormalities?

We included two types of studies: (1) those that
assessed the HCV prevalence in diabetic patients
compared with non-diabetics; and (2) studies that
assessed the prevalence of DM and/or IR in HCVinfected patients compared with controls (healthy
volunteers or HBV carriers) (Table 1).
Six studies evaluated HCV prevalence rates in
diabetic patients compared with non-diabetic healthy
volunteers. The number of participants ranged from
180 to 13000. Four out of the six studies showed
a significant increased prevalence of HCV infection
markers [HCV antibodies (n = 3), HCV RNA (n = 1)]
in DM patients, with an odds ratio (OR) between 2.87
[4-7]
and 3.03 . Of note, only one study used multivariate
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Rouabhia et al[34]

Montenegro et al[9]
Ruhl et al[55]
Vs hepatitis B virus infection
Knobler et al[17]
Ryu et al[31]
Wang et al[32]
Huang et al[6]
Moucari et al[33]
White et al[12]

2014 United States
2013
Taiwan
2003 United States
2012 United States

Pothineni et al[29]
Dai et al[30]
Mehta et al[10]
Stepanova et al[11]
HCV
HCV

HCV
HCV
HCV
HCV
616
277

1434
160
12
791

85
97
93
329
40
177

45
230
190
239
478
683
62
38

HV
HV

HV2
HV2
HV2
HV

126

90
157
544
1363
100
-

1856
14571

14799
480
1072
38715

25
182
144
173/795
1780/88
19568

88
9611
575
10144
7927
515
172
12

HV2
HV
HV
HV
HV2
HV2
HV2
HV2
HV2
HV
HV
HV
HV
HV

1300
905
8595
10000
90
206

HV
HV
HV
HV
HV2
HV

2000
Israel
Case-control
HCV
45
HBV
2001 South Korea
Prospective HCV, F4
68
HBV
2007
Taiwan
Longitudinal
HCV
926
HBV
2007
Taiwan
Cross sectional HCV
478
HBV
2008
France
Retrospective
HCV
500
HBV2
2008 United States Meta-analysis
HCV 34 studies HBV/
HV
2010
Algeria
Prospective cross HCV1
290
HBV
sectional

Retrospective
Retrospective
Case-control
Nationwide
survey
2013
Italy
Prospective
2014 United States Cross sectional

2009
India
ND
2009
Italy
ND
2009
Taiwan
ND
2010
Egypt
ND
2013
Japan
Cross sectional
2013 United States Retrospective

Duseja et al[23]
Lonardo et al[24]
Huang et al[25]
Mostafa et al[26]
Miyajima et al[27]
Younossi et al[28]

HCV1
HCV1
HCV1
HCV
HCV
HCV

HCV
HCV
HCV
HCV
HCV
HCV
HCV1
HCV1

1514
820
1237
3000
90
206

RNA

RNA
Ab
Ab
RNA
RNA
Ab/RNA

Ab
RNA

RNA
RNA
RNA
RNA

RNA
RNA
Ab
RNA
RNA
RNA

RNA
Ab
RNA
ND
RNA
RNA
RNA
RNA

Ab
Ab
RNA
Ab
Ab
RNA

Univariate
Univariate adjusted
Univariate
Univariate
Univariate
Multivariate

DM

DM
DM
DM
DM
HOMA-IR
DM

DM
DM

DM
DM
DM
DM and IR

Multivariate

Univariate
Univariate
Multivariate
Univariate
Univariate
Meta-analysis

Univariate adjusted
Univariate adjusted

Univariate
Multivariate
Univariate
Multivariate

IR
Univariate
IR
Univariate
IR
Univariate
DM
Univariate adjusted
IR
Univariate
DM and IR
Multivariate

DM
Univariate
DM
Multivariate
DM
Multivariate
IR
Univariate adjusted
DM
Multivariate
DM/IGT1
Univariate
IR
Univariate
IR
Univariate

HCV
HCV
HCV
HCV
HCV
HCV

Yes

Yes
Yes
Yes
Yes
Yes
Yes

No
No

Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
No
No

Patients Patients Controls Controls Testing for HCV Endpoint Statistical methods Association
number
number
Ab or RNA

2000
Israel
Case-control
2000 United States Cross sectional
2007
Egypt
Cross sectional
2007 United States
ND
2007
Taiwan
Cross sectional
2008
Taiwan
ND
2008 South Korea
Prospective
2009
Egypt
Cross sectional

Study design

DM
DM
DM
DM
DM
DM

Italy
Taiwan
Taiwan
Pakistan
Nigeria
Brazil

Country

Retrospective
Cross sectional
Cross sectional
ND
case-control
Case-control

2000
2006
2007
2010
2006
2008

Year

HCV infection markers in patients with
type 2 diabetes mellitus
Sangiorgio et al[4]
Chen et al[5]
Huang et al[6]
Jadoon et al[7]
Balogun et al[53]
Costa et al[54]
Glucose abnormalities in HCV infected
patients vs different control groups
Vs healthy volunteers
Knobler et al[17]
Mehta et al[8]
Marzouk et al[18]
Shaheen et al[19]
Huang et al[6]
Huang et al[21]
Park et al[20]
Mohamed et al[22]

Ref.

Table 1 Glucose abnormalities and hepatitis C virus infection

33% vs 12%; p = 0.004
24% vs 10.4%; p = 0.001
HR = 1.7
18% vs 11.4%; p < 0.001
35% vs 5%; p < 0.001
Adjusted OR for HV 1.68 and for HBV
1.80
OR = 4.73 [1.7, 13.2]; p = 0.0029

NS
NS

33% vs 5.6%; p < 0.001
OR = 3.77 [1.8, 7.87]
HR = 3.05 [1.19, 7.81]
OR = 1.68; p = 0.02
OR = 1.53 [1.18, 1.98]; p <0.001
OR = 3.51 [2.7, 4.56]; p < 0.001
22.5% vs 5.2%; p < 0.001
HOMA-IR = 3.98 (normal ALT) and 2.69
(a normal ALT) vs 1.92; p < 0.001
62% vs 16%; p = 0.0002
p < 0.001
HOMA-IR 2.2 vs 1.6; p = 0.02
OR = 1.35 [1.06, 1.73]; p = 0.02
HOMA-IR 3.0 vs 1.3; p < 0.001
OR for DM 2.3 [1.18, 4.54]
OR for IR 2.06 [1.19, 3.57]
11.2% vs 5.1%; p < 0.01
OR = 1.208 [1.009, 2.799]; p = 0.004
NS
NS

p < 0.0001
OR = 2.87 [1.51, 5.46]; p < 0.001
6.9% vs 4.5%; p < 0.001
OR = 3.03 [2.64, 3.48]; p = 0.001
NS
NS

Statistics
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2008
2008
2008

2009

Imazeki et al[57]
Tanaka et al[58]
Mavrogiannaki et al[59]

Persico et al[60]

Italy

Japan
Japan
Greece

Italy

HCV

Retrospective
HCV
Case-control
HCV1
prospective case HCV
control
Retrospective
HCV

Retrospective

726

544
30
108

170

HBV

HBV
HBV2
HBV

HBV2

126

286
30
81

170

Ab

RNA
RNA
RNA

RNA

HOMA-IR
Univariate
and DM
DM and IR
Multivariate
IR
Multivariate
glucose Univariate adjusted
intolerance
DM
Univariate adjusted
No

No
No
No

Yes

NS

42.2% vs 25.9%, p = 0.002 and 8.8% vs
3.6%, p = 0.04
NS
NS
NS
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Twenty-six studies and three meta-analyses investigated whether GA had an impact on the response to interferon alfa-based antiviral treatment (Table 3). The studies
originated from Europe (n = 11), Asia (n = 4), Egypt (n = 4), the United States (n = 5), Australia (n = 1) and Saudi Arabia (n = 1). They included a mean of 503
patients (50 to 5944). Nineteen out of twenty-eight studies showed a significant negative effect of GA in response to interferon alfa-based therapy [i.e., lower sustained
viral response (SVR) rates], including 15 multivariate analyses and 3 meta-analyses. Of note, studies that did not find an impact of GA on SVR rates had some limitations, including small size of cohorts (60-600 patients), only G1 or G4 patients (3 out of 10 studies), and only Italian patients (4 out of 10). Two of them evaluated
patients treated with peginterferon/ribavirin and telaprevir. The three meta-analyses found a significant association between IR and the absence of SVR, regardless of
the genotype (OR for G1 = 2.2, G2 = 3, G3 = 4.45 and G4 = 6.7, respectively).

Do diabetes mellitus and insulin resistance have an impact on the virological response to HCV treatment?

Thirty studies investigated whether DM/IR was associated with liver fibrosis severity in HCV patients (Table 2). Studies were performed in Asia (Taiwan n = 3, Japan n = 3,
other n = 1), Europe (n = 13), the United States and Australia (n = 5), Saudi Arabia (n = 1), Turkey (n = 1) and Egypt (n = 3). The mean size of the cohorts was 451
patients (min-max range 10 to 3068). The authors searched for an association between liver fibrosis severity and DM (n = 9), IR (n = 19) or impaired fasting plasma
glucose (n = 2). All but two studies performed multivariate analyses. Twenty-six out of thirty studies reported a significant association of glucose abnormalities with liver
fibrosis severity (OR from 1.28 to 13.72). Three of the four “negative” studies were done on small cohorts. There were some differences related to HCV genotypes, but
no systematic relationship was found.

Are diabetes mellitus or insulin resistance associated with liver fibrosis severity in HCV infected patients?

logic regression analysis, while another adjusted the risk for age, gender, body mass index (BMI) and alanine aminotransferase (ALT) levels. One study showed an
increased HCV antibody prevalence rate in DM patients with abnormal ALT levels.
Thirty-two studies evaluated DM and/or IR prevalence rates in HCV patients compared with either healthy volunteers (n = 20) or HBV patients (n = 12). The size
of cohorts ranged from 50 to 39506 subjects. All but four studies assessed DM/IR prevalence in HCV-RNA positive patients. In 10 out of 20 studies that compared
HCV patients with healthy volunteers, multivariate or univariate analyses with adjustment for age, gender, BMI, socio-economic status and ethnicity were performed.
Thirteen studies evaluated DM prevalence (n = 11) or occurrence (n = 2), while others (n = 9) assessed IR in HCV infected patients. Overall, 16 out of 20 studies found
a significant association between the presence of glucose abnormalities (DM/IR) and HCV infection, including 7 out of 10 studies with multivariate or adjusted analyses
[8]
(OR between 1.2 and 3.77). One study reported a higher risk of DM only in patients older than 40 years . Four studies reported “negative” results. Three out these
[9]
four studies showed a higher risk of DM only in specific populations (i.e., HCV patients with increased ALT levels , HCV patients older than 55 years with a BMI > 25
2[10]
[11]
kg/m , and a cohort studied between 1988 and 1994, but not in the more recent cohort) .
[12]
When compared with HBV infected patients, 7 out of 11 studies found a significant association of HCV with DM. In one meta-analysis , a positive HCV viremia was
associated with an increased risk of DM compared with controls (adjusted OR = 1.68) and with HBV patients (adjusted OR = 1.80).

HCV infection not treated; 2Matched for confounding factors (age and/or gender and/or BMI and/or ALT…). HCV: hepatitis C virus infection; Ab: antibody; HV: healthy volunteers; G1: genotype 1; SVR: sustained virological
response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; IGT: impaired glucose tolerance [after oral glucose tolerance test (OGTT)];
CLD: Chronic liver disease; NAFLD: Non-alcoholic fatty liver disease; NS: not significant; ND: not determined.

1

2011

Petta et al[56]
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Table 2 Glucose abnormalities and severe liver fibrosis in hepatitis C virus-infected patients
Ref.

Year

Country

Number of
HCV patients

Patient
profile

Glucose
abnormality

Statistical
method

Association with
1
severe fibrosis

Konrad et al[42]
Sud et al[61]

2000
2004

Germany
Australia

10
170

Non DM
-

FPG
HOMA-IR

Multivariate
Multivariate

Yes
Yes

Muzzi et al[62]
D'souza et al[63]

2005
2005

221
59

Non DM
-

HOMA-IR
HOMA-IR

Multivariate
Multivariate

Yes
Yes

Taura et al[64]

2006

Switzerland
United
Kingdom
Japan

83

-

HOMA-IR

Multivariate

Yes

All

Leandro et al[65]

2006

Italy

3068

-

DM

Multivariate

Yes

G1

Bugianesi et al[66]

2006

Italy

132

Multivariate

Yes

G3

Kita et al[67]

2007

Japan

68

Multivariate

Yes

All

Petta et al[68]

2008

Italy

201

Multivariate

Yes

G1

Moucari et al[33]

2008

France

500

-

HOMA-IR

Multivariate

Yes

All

Cua et al[69]

2008

Australia

346

IR

Multivariate

Yes

G3

Hsu et al[70]

2009

Taiwan

528

G1, G3,
untreated
G1, G2

FPG

Multivariate

Yes

G1

Moucari et al[71]

2009

France

226

G4

HOMA-IR

Multivariate

Yes

G4

Persico et al[60]
Hung et al[14]
Patel et al[72]

2009
2011
2011

Italy
Taiwan
Asia

726
1470
263

G2, G3

DM
DM
HOMA-IR

Multivariate
Univariate
Multivariate

Yes
Yes
Yes

All
All
G2 and G3

Mohamed et al[73]

2011

Egypt

50

G4

HOMA-IR

Multivariate

Yes

G4

Miyaaki et al[74]

2011

Japan

171

-

DM

Multivariate

Yes

All

Conjeevaram et al[75] 2011 United States

341

G1

HOMA-IR

Multivariate

Yes

G1

Petta et al[56]

2011

Italy

170

G1

HOMA-IR

Multivariate

Yes

G1

Khattab et al[76]

2012

Egypt

107

G4

HOMA-IR

Multivariate

Yes

G4

Ziada et al[77]

2012

Egypt

140

Non DM

HOMA-IR

Multivariate

Yes

All

Thompson et al[13]

2012 United States

1038

Non DM

HOMA-IR

Multivariate

Yes

All

Alfaleh et al[78]

2013 Saudi Arabia

157

-

DM

Multivariate

Yes

Dokmeci et al[79]

2014

Turkey

104

-

HOMA-IR

Multivariate

Yes

All
(except G4)
All

Huang et al[80]

2015

Taiwan

1077

-

DM

Multivariate

Yes

All

Fartoux et al[81]
Elgouhari et al[82]
Petta et al[83]
Rueger et al[84]

2005
France
2008 United States
2009
Italy
2014 Switzerland

141
183
156
1461

Non DM
Non DM
-

HOMA-IR
DM
HOMA-IR
DM

Univariate
Multivariate
Multivariate
Multivariate

No
No
No
No

No
No
No
No

G3 with HOMA-IR
steatosis
Post
DM
tranfusion
hepatitis
G1
DM

Genotypes

Statistics

p = 0.01
OR = 1.47 [1.14, 1.89];
p = 0.003
All (except G3) OR = 1.57 [1.04, 2.39]
All
p = 0.001
All
All

OR = 7.32 [1.59, 33.73];
p = 0.01
OR = 4.52 [1.07, 19.1];
p = 0.011
OR = 2.98 [1.13, 7.89];
p = 0.028
OR = 8.4 [2.23, 31.54];
p = 0.002
OR = 2.69 [1.46, 4.95];
p < 0.001
OR = 1.8 [1.16, 2.81];
p = 0.009
OR = 3.15 [1.56, 6.35];
p = 0.001
OR = 13.72 [2.15, 87.7];
p < 0.05
OR = 3.86 [1.859, 8.034];
p < 0.001
p < 0.05
p < 0.001
OR = 8.42 [2.1, 34.3];
p = 0.003
OR = 3.73;
p = 0.001
OR = 8.739 [2.85, 26.85];
p = 0.0002
OR = 1.28 [1.07, 1.51];
p = 0.005
OR = 2.64 [1.11, 6.28];
p = 0.02
OR = 1.87 [1.09, 8.29];
p = 0.04
OR = 1.92 [0.97, 3.4];
p = 0.049
OR = 1.6 [1.1, 2.33];
p = 0.02
OR = 0.37 [0.148, 0.927];
p = 0.034
OR = 3.36 [1.32, 31.25];
p = 0.021
OR = 1.81 [1.14, 2.65];
p = 0.002
NS
NS
NS
NS

1

Severe liver fibrosis: F3 or F4 in Metavir scoring system. HCV: hepatitis C virus infection; G1: genotype 1; SVR: sustained virological response; HOMA-IR:
Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; NS: not significant.

What is the impact of interferon alfa-based treatment on
glucose abnormalities?

Improvement of GA after antiviral treatment was
analysed in fifteen surveys that included 13 to 1038
HCV treated patients. Most of these studies performed
univariate analyses. A significant decreased prevalence
of GA was noted in 12 out of 15 studies. Eleven of
these 12 studies reported a significant change of IR

Twenty studies assessed the impact of interferonbased antiviral treatment on DM/IR, either as an
improvement of GA after treatment or as the occurrence of GA after antiviral treatment (Table 4).
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Table 3 Impact of glucose abnormalities on virological response after interferon alpha based treatment
Association

Statistical
method

Impact on
virological
response

Genotypes

59

HOMA-IR

Multivariate

Yes

All

80

GMI

Univariate

Yes

Spain

159

HOMA-IR

Multivariate

Yes

China

98

HOMA-IR

Multivariate

Yes

G1, G2, G3

DM

Multivariates

Yes

G1

HOMA-IR

Multivariates

Yes

DM

Multivariate

Yes

HOMA-IR

Multivariate

Yes

FPG

Multivariate

Yes

Ref.

Year

Country

D'souza et al[63]

2005

Tarantino et al[85]

2005

United
Kingdom
Italy

Romero-Gomez et al[86] 2005
Jian Wu et al[87]

2006

Backus et al[88]

2007 United States

5944

Conjeevaram et al[89]

2007 United States

401

Elgouhari et al[82]

2008 United States

183

Poustchi et al[90]

2008

Australia

Patients
number

82

Patient
profile

G2, G3 non
DM

Romero-Gomez et al[91] 2008

Spain

1059

Moucari et al[71]

2009

France

226

G4

HOMA-IR

Multivariate

Yes

Dai et al[92]

2009

Taiwan

330

G1, G2

HOMA-IR

Multivariate

Yes

Hung et al[115]

2010

Taiwan

1470

DM

Multivariate

Yes

Khattab et al[93]

2010

Egypt

131

Non DM, G4

HOMA-IR

Multivariate

Yes

Deltenre et al[94]
Eslam et al[95]

2011
2011

France

2732
2129

G1-6
G1-6

IR
IR

Meta-analysis
Meta-analysis

Yes
Yes

Del Campo et al[96]

2012

Spain

240

Non DM

HOMA-IR

Multivariate

Yes

Ziada et al[77]

2012

Egypt

140

Non DM

HOMA-IR

Multivariate

Yes

Laurito et al[97]

2013

Brazil

2238

G1-6

IR

Meta-analysis

Yes

Abd El-Wahab et al[98]

2014

Egypt

392

Non DM

HOMA-IR

Multivariate

Yes

Grasso et al[99]
Fattovich et al[100]
Khattab et al[76]
Brandman et al[101]
Aghemo et al[102]
Fattovich et al[100]
Serfaty et al[103]
Alfaleh et al[78]
Younossi et al[104]

2009
Italy
2010
Italy
2012
Egypt
2012 United States
2012
Italy
2012
Italy
2012
France
2013 Saudi Arabia
2013 United States

No
No
No
No
No
No
No
No
No

Jung et al[105]

2014 Soutk Korea

Multivariate
Multivariate
Multivariate
Univariate
Univariate
Multivariate
Multivariate
Multivariate
Univariate
adjusted
Univariate

90 Non DM, G1 HOMA-IR
412
HOMA-IR
107
G4
HOMA-IR
23
Non DM IGT, FGP, SSGP
339
HOMA-IR
124
Non DM
HOMA-IR
1611
G4
HOMA-IR
157
DM
5781
G1
HOMA-IR
60

HOMA-IR

No

Statistics

OR of SVR: 0.44 [0.22, 0.88];
p = 0.02
All
40% vs 7.5%;
p = 0.0009
All
OR of SVR 0.55 [0.33, 0.93];
p = 0.012
All
OR of SVR: 0.17;
p = 0.015
All and G1
OR = 0.76 [0.64, 0.71];
p = 0.002
G1
OR = 0.87 [0.77, 0.99];
p = 0.028
All
OR of SVR 0.22 [0.07, 0.55];
p = 0.003
G2, G3
OR of SVR 0.16 [0.03, 0.77];
p = 0.02
All
OR of SVR 0.56 [0.34, 0.93];
p < 0.02
OR of SVR: 0.19 [0.07, 0.51];
p = 0.001
G1, G2
OR of SVR 0.872 [0.79, 097];
p = 0.01
All
OR of SVR 0.69 [0.5, 0.96];
p = 0.029
G4
OR of SVR 0.07 [0.01, 0.43];
p = 0.004
All
All
OR of SVR 0.35 [0.24, 0.51];
p = 0.0004
G1, G4
OR of SVR 0.44 [0.17, 0.97];
p = 0.04
All
OR of SVR 0.41 [0.18, 0.9];
p = 0.003
All
OR of SVR 0.41 [0.3, 0.56];
p = 0.022
All
OR of virological response:
0.19 [0.1, 0.38];
p = 0.0001
G1
NS
No
NS
G4
NS
No
NS
No
NS
No
NS
G4
NS
No
NS
G1
NS
No

NS

1

Treated with peginterferon/ribavirin telaprevir. HCV: hepatitis virus infection; G1: genotype 1; SVR: sustained virological response; HOMA-IR:
Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; IGT: Impaired glucose tolerance; DM: Diabetes mellitus; FPG: Fasting plasma
glucose; SSGP: steady-state plasma glucose; GMI: Glucose metabolism impairment; NS: not significant; ND: not determined.

occurrence and the absence of SVR.

only in patients who achieved a SVR. One survey found
a significant change of IR after antiviral treatment only
[13]
in genotype 1 patients .
Five studies evaluated the risk of GA occurrence
according to antiviral treatment response. They
included 202 to 2842 HCV treated patients, and all
performed multivariate analyses. Four out of five
studies showed a significant association between GA

WJG|www.wjgnet.com

Do glucose abnormalities increase the risk of HCC in
HCV infected patients?

Sixteen studies assessed the association between HCC
and DM/IR in HCV infected patients (Table 5). These
studies included from 120 to 5186 HCV patients,
both treated and non-treated. Most of them (10/16)
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Table 4 Glucose abnormalities after interferon alpha based treatment
Ref.

Year

Country

Improvement of glucose
abnormalities after HCV
treatment
Konrad et al[42]
Romero-Gomez et al[86]
Kawaguchi et al[106]
Chehadeh et al[107]
Kim et al[108]

2000 United States
2005
Spain
2007
Japan
2009
Kuwait
2009
Korea

13
50
89
181
28

Conjeevaram et al[75]
Khattab et al[76]

2011 United States
2012
Egypt

341
107

Thompson et al[13]
Serfaty et al[103]

2012 United States
2012
France

1038
161

Ziada et al[77]

2012

Chan et al[109]
Jung et al[105]
Mello et al[110]
Kawaguchi et al[111]

2013
Australia
2014 South Korea
2006
Brazil
2009
Japan

86
60
30
72

Brandman et al[101]

2012 United States

23

Egypt

Number
of HCV
patients

140

Significant Genotypes
association or
difference

Statistics

Patient
profile

Glucose metabolism
parameter

Statistical
method

G4
G1, G2

FPG and FI
HOMA-IR
HOMA-IR
FPG
HOMA-IR

Univariate
Univariate
Univariate
Univariate
Multivariate

Yes
Yes
Yes
Yes
Yes

All
All
All
G4
G1, G2

HOMA-IR
HOMA-IR

Univariate
Univariate

Yes
Yes

G1
G4

p < 0.05 and p < 0.01
In SVR; p < 0.05
In SVR; p < 0.01
In SVR; p < 0.001
In SVR, OR of decreased
IR 50 [3.74, 668.35]; p =
0.003
In SVR; p < 0.001
In SVR ; p = 0.001

HOMA-IR
HOMA-IR

Multivariate1
Univariate

Yes
Yes

All
G1

In G1 SVR; p = 0.007
In SVR ; p < 0.05

HOMA-IR

Univariate

Yes

All

p = 0.009

HOMA-IR
HOMA-IR
HOMA-IR
HOMA-IR, SI and
ISI

Univariate
Univariate
Univariate
Univariate1

Yes
Yes
No
No

All
All
All
No

SSGP

Univariate

No

No

In SVR; p = 0.04
In SVR; p = 0.036
NS
HOMA-IR: NS
In SVR, SI p = 0.002 and
ISI p = 0.009
NS

DM or IGT

Multivariate1

Yes

All

G1
G4, non
cirrhotic
G1, non
cirrhotic
Non
DM, non
cirrhotic
Non DM
G1, G3
Non
DM, non
cirrhotic
Non
cirrhotic

Occurrence of glucose
abnormalities after HCV
treatment
Simó et al[112]
2006

Spain

234

Romero-Gomez et al[91] 2008

Spain

1059

DM or IGT

Multivariate1

Yes

All

Arase et al[113]

2009

Japan

2842

DM

Multivariate1

Yes

All

Aghemo et al[102]

2012

Italy

339

Non DM

HOMA-IR

Multivariate1

Yes

All

Giordanino et al[114]

2008

Italy

202

Non DM

DM or IGT

Multivariate1

No

No

Non DM

In SVR, OR = 0.48 [0.24,
0.48]; p = 0.04
In SVR, OR = 0.44 [0.2,
0.97]; p = 0.04
In SVR, HR = 0.36 [0.24;
0.56]
In SVR, OR = 0.36 [0.18,
0.72]; p = 0.004
NS

1

association with SVR. HCV: hepatitis C virus infection; G1: genotype 1; SVR: sustained virological response; HOMA-IR: Homeostasis Model Assessment
of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; FI: fasting insulin; IGT: impaired glucose tolerance; ISI:
Insulin sensitivity index; SI: Serum insulin; SSGP: steady-state plasma glucose; NS: not significant.

included Asian patients, and all but one performed
multivariate analyses.
Five studies looked for the presence of DM/IR in
HCV infected patients with HCC compared with HCV
patients without HCC. Four out of five studies found
a significant association between DM/IR and HCC (as
compared with non-HCC) (OR from 2.0 to 11.6).
Nine out of eleven other studies found a significant
association between the presence of DM/IR and the
development of HCC in the follow-up of HCV infected
patients (HR from 1.10 to 6.9). One study found a
higher risk of HCC in diabetic patients only with SVR
[14]
and without cirrhosis , while 2 others reported an
increased risk of HCC only in diabetic patients with
[15,16]
advanced fibrosis
.

WJG|www.wjgnet.com

DISCUSSION
Many studies have evaluated the association between
HCV chronic infection, insulin-resistance and diabetes
mellitus. The abnormalities of carbohydrate metabolism, including hyperinsulinemia and IR, known to be
per se related to chronic hepatic diseases, were the
rationale for speculation on this relationship. Insulinresistance is an often undetected condition, commonly
coexisting with obesity and metabolic syndrome, and
possibly progressing to type 2 diabetes. HCV-related
type 2 diabetes mellitus may arise from a complex
interaction between IR, steatosis and inflammatory
processes. Epidemiologic studies supporting the associ
ation between type 2 diabetes and HCV infection were
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Table 5 Glucose abnormalities and hepatocellular carcinoma in hepatitis C virus-infected patients
Ref.

Year Country

Patient
number

Patient profile

Association

Statistical
method

Association
DM and HCC

Statistics

Diabetes mellitus/insulin
resistance in HCV-related HCC
K-Kutala et al[15]

2014

France

162

DM and HCC

Multivariate

Yes3

2010

Taiwan

188

DM and HCC

Multivariate

Yes

Hung et al[115]

2010

Taiwan

188

Yes

2012

Egypt

294

Multivariate

Yes

Mohamed et al[73]

2011

Egypt

100

HOMA-IR and
HCC
HOMA-IR and
HCC
HOMA-IR and
HCC

Multivariate

Khattab et al[116]

HCC, not treated
for HCV
59 HCC; 129
non-HCC
59 HCC; 129
non-HCC
147 HCC; 147
non-HCC
50 HCC; 50 nonHCC; 20 non HCV

Univariate

No

HR = 3.13 [1.17, 8.38];
p = 0.0223
OR = 11.6 [2.500, 53.800];
p = 0.002
OR = 2.0 [1.35, 3];
p = 0.001
OR = 2.5 [1.7, 3.69];
p = 0.001
NS

Hung et al[115]

2008

Taiwan

1095

-

DM and HCC

Multivariate

Yes

OR = 3.52 [1.29, 9.24]

Veldt et al[16]

2008

Europe

541

DM and HCC

Multivariate

Yes3

Konishi et al[118]

2009

Japan

197

Multivariate

Yes

Hung et al[14]

2010

Taiwan

1470

Non DM, treated DM1 and HCC
for HCV
Treated for HCV DM and HCC

Multivariate

Yes2

Nkontchou et al[119]

2010

France

248

Multivariate

Yes

Takahashi et al[120]

2011

Japan

203

Multivariate

Yes

Arase et al[121]

2013

Japan

4302

Multivariate

Yes

Elkrief et al[45]

2014

France

348

HOMA-IR and
HCC
Non DM, treated DM1 and HCC
for HCV
Non treated for DM and HCC
HCV
Cirrhotics
DM

Multivariate

Yes

Toyoda et al[122]

2015

Japan

522

Patients with SVR DM and HCC

Multivariate

Yes

Lai et al[123]
Chen et al[124]

2006
2013

Taiwan
Taiwan

2141
5186

Multivariate
Multivariate

No
No

OR = 3.28 [1.35, 7.97];
p = 0.0093
HR = 4.63 [1.677, 12.766];
p = 0.003
HR = 4.32 [1.23, 15.25];
p = 0.0232
HR = 1.10 [1.01, 1.21];
p = 0.026
HR = 6.9 [1.7, 28.4];
p < 0.05
HR = 1.73 [1.3, 2.3];
p < 0.001
HR = 1.938 [1.129 , 3.328];
p = 0.016
HR = 2.08 [1.0170, 4.0133];
p = 0.045
NS
NS

Diabetes mellitus/insulin
resistance and development of
HCC in HCV-infected patients
Chen et al[117]

Cirrhotics

-

DM and HCC
DM and HCC

1

Association of abnormal post-challenge hyperglycaemia and HCC; 2Only in SVR patients without cirrhosis; 3Only in advanced liver fibrosis. HCV:
hepatitis virus infection; HCC: hepatocellular carcinoma; SVR: sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin
Resistance; IR: Insulin resistance; DM: Diabetes mellitus; NS: not significant.
[6,8,12,17-34]

first published in the early 1990s. More recently, larger
epidemiologic studies gave more in-depth analyses
of the relationship between HCV chronic infection and
glucose abnormalities and were included in the present
analysis.

as healthy volunteers or HBV carriers
. The
variability of HOMA-IR cut-offs used (between 1.8 and
2.5 generally) may explain the heterogeneous results
reported in the literature. Confounding factors might
have also led to significant bias. Indeed, some studies
comparing HCV patients with healthy volunteers
did not perform multivariate analysis or adjust for
confounding factors. However, seven out of ten multivariate analyses found a significant increased risk of
DM/IR in HCV patients (OR = 1.2-3.7), after adjusting
for confounding variables such as age, gender, BMI,
ethnicity and education level.
How are we able to explain the increased risk of
DM in HCV infected patients? Some authors have suggested that diabetic patients might have been infected
by HCV due to injections or nosocomial transmission. The association of HCV infection with IR and the
widespread use of universal precautions nowadays
in hospitals to avoid virus transmission probably dis-

HCv infection is associated with increased rates of
glucose abnormalities, including diabetes mellitus and
insulin resistance

In the present analysis, most studies found a significant association between HCV infection (whether
active HCV RNA positive, or not i.e., HCV Ab positive)
and diabetes mellitus or insulin resistance. This tight
association was confirmed in both directions by the
increased rates of HCV infection markers in DM/IR
patients and the high rates of glucose abnormalities
in HCV infected patients. The consistency of this
association was supported by the confirmation of such
results compared with different control groups, such

WJG|www.wjgnet.com
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Presence of glucose abnormalities in HCV infected
patients, including diabetes mellitus and insulin
resistance, is associated with negative liver-related
outcomes

qualify this hypothesis. There are a variety of other
possible mechanisms of increased risk of DM/IR in HCV
patients. As shown in this study, glucose abnormalities
in HCV patients are associated with liver fibrosis severity. Severe liver fibrosis and cirrhosis are well-known
conditions that are able to induce glucose metabolism
impairment. However, studies with other liver diseases, including cirrhosis, still showed an excess of risk
[6,12,17,31-34]
in HCV patients compared with HBV patients
.
The ability of HCV, particularly genotype 3 viruses, to
induce liver steatosis on its own, which might in turn
increase the risk of DM/IR, has also been suggested in
[35,36]
previous studies
. Other underlying mechanisms
may involve HCV per se. Experimental data suggest
the role of inflammation. Increased HOMA-IR has
been correlated with soluble Tumor Necrosis Factor
[37]
Receptor1 (sTNFR1) and sTNFR2 levels . Increased
abnormal HOMA-IR was not associated with elevated
serum levels of TNFα, IL6 and adiponectin in another
[38]
study . Other studies have also suggested an impairment of glucose uptake in HCV-infected patients.
Glucose uptake and the surface expression of Glucose
Transporters (GLUT1 and 2) were suppressed in cells
[39]
infected by HCV compared with controls . Interferon
alfa restored glucose uptake, GLUT2 surface expression, mRNA expression and GLUT2 promoter activities.
HCV has also been shown to impair glucose uptake
and to promote IR by increasing suppressor of cytokine
signalling 3 (SOC3), which inhibits insulin phosphoryla[40]
tion of AKT and phosphoinositide 3-kinase (PI3K) .
HCV may be involved in the regulation of phosphorylation of insulin receptor substrate 1 (ISR-1), implicated
[41]
in the insulin pathway . In HCV core transgenic mice,
the viral protein was able to induce increasing TNFα
levels in the liver, which in turn promoted the induction of IR. The high levels of TNFα inhibited the ISR-1,
causing IR and its possible progression to diabetes. A
decreased expression of ISR-1 and ISR-2 mediated by
ubiquitination was observed and was inversely proportional to the liver fibrosis stage.
Interferon alfa use might lead to glucose metabolism impairment and is a potential bias. However,
increased DM/IR rates have been also reported in HCV
[20,22-25,34]
patients not taking interferon alfa
. Many studies found a decreased rate of glucose abnormalities in
HCV patients who showed a SVR after interferon alfabased therapy, and even in non virological responders
[42]
in one study . This strongly suggests a direct/indirect
role of HCV on glucose metabolism impairment. As
eradication of HCV seems to be effective in decreasing
the occurrence rate of DM/IR, it will very be interesting
to analyse the impact of new direct antiviral agents
(DAAs) for preventing DM/IR and eventually cardiovascular disorders. Indeed, in a recent study, IFN-free
antiviral regimen resulted in rapid changes in serum
lipid profiles and intrahepatic expression of lipid-related
[43]
genes in G1 patients .

WJG|www.wjgnet.com

Severe liver fibrosis, the absence of SVR after interferon alfa-based treatment, and the development of HCC
are the main negative outcomes of chronic HCV infection. Interestingly, the presence of DM or IR in HCV
patients showed a pejorative impact on each of these
end points. Most studies found an independent association of glucose abnormalities with advanced liver
fibrosis, absence of SVR after antiviral treatment and
HCC occurrence. Only few studies did not confirm such
associations. This might be explained by the small size
cohort of such studies, the heterogeneity of criteria for
DM or HOMA-IR and the very high prevalence of other
metabolic risk factors (such as elevated BMI) which
may underestimates the impact of DM/IR. Our data is
consistent with recent studies that demonstrated that
DM increases cumulative incidence of decompensated
[44]
cirrhosis . In another recent survey, diabetes was
independently associated with transplantation-free
survival, development of ascites, renal dysfunction,
[45]
bacterial infections, and HCC during the follow-up .
Experimental data suggest that increased insulin
levels after hyperglycaemia leads to interferon signalling impairment. Insulin may inhibit the ability of interferon alfa to block HCV replication due to the activation
of PI3K by insulin, thus leading to inhibition of STAT-1,
[40]
which is involved in the interferon alfa pathway .
The impact of glucose abnormalities on virological
response needs to be further evaluated with new DAA,
interferon-free combinations. To date, there is very
few data on the impact of GA on virological response
to new DAA. Preliminary results suggest that the
presence of diabetes does not appear to be predictive
[46,47]
of treatment failure in G1 patients
. Further studies
are needed to confirm these data and to evaluate
the impact of DM on SVR in patients without poor
prognostic factors.

Should glucose abnormalities be corrected to increase
SVR rates?

A prospective study, including 155 HCV genotype 1
patients with IR, showed no difference in SVR rates
after peginterferon alfa and ribavirin were given,
regardless of whether or not patients had received
[48]
pioglitazone, an antidiabetic drug . Of note, most
glycemic control indexes improved significantly in the
pioglitazone group except for HbA1c. Another study
found higher SVR rates in G4 patients treated with
[49]
pioglitazone . Pioglitazone may alter NK cell functions
[48]
and thus impair clearance of infected hepatocytes .
A retrospective cohort from Taiwan (19349 diabetic
patients, 1.7% HCV positive) showed that patients
taking metformin and thiazolidinediones had the
lowest risk of HCC (HR 0.49 and 0.56, respectively)
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Applications

[50]

after adjusting for age, gender and comorbidities .
Consistently, in a prospective cohort of 100 HCV
patients with ongoing cirrhosis, metformin treatment
was independently associated with a decrease of HCC
occurrence and liver-related death or transplanta[51]
tion . In a two-year prospective follow-up of 85
patients with HCV-related HCC, HCC recurrence-free
survival was increased in diabetics taking pioglitazone
vs non-treated diabetics (44.2% vs 36.5%, respec[52]
tively, p = 0.37) . A significant decrease in HCC
recurrence was observed in the pioglitazone group for
patients with a BMI > 24.
We acknowledge some limitations of this study.
Although we tried to include all published studies, we
may have missed others in non-English literature or
data only presented at meetings. Some studies were
done with a limited number of patients. For some
studies included in the present analysis, it is possible
that there are some remaining bias and residual
confounding factors. Despite multivariate analyses,
the association between glucose abnormalities
improvement and improved outcome may have been
influenced by unmeasured confounding factors. Such
final confirmation should arise from controlled clinical
trials with long-term follow-up.
In conclusion, HCV chronic infection is associated
with an increased risk of DM or IR, by a likely direct
effect on glucose metabolism. In such patients, DM
and IR are associated with a pejorative liver-related
prognosis, as shown by increased rates of severe liver
fibrosis, HCC occurrence, and decreased SVR rates
after interferon-based therapy. This tight relationship
between DM/IR and HCV infection needs to be further
analysed with new DAAs, interferon-free combinations,
with special attention to improvement in glucose
abnormalities and long-term follow-up.

These data strongly encourage clinicians to systematically screen HCV-infected
patients for the presence of glucose abnormalities. Considering the impact
of glucose abnormalities on liver-related outcomes in HCV infected patients,
antiviral treatment should also be considered in HCV-infected patients with
metabolic syndrome.

Peer-review

This review talks about the relationship between HCV infection and glucose
abnormalities. There are already lots of articles about the topic. This review
summarizes those articles published from January 2000 to April 2015 in
PubMed and gives us a conclusion about the topic.
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METHODS
®
A review of the databases MEDLINE and Embase™
was conducted, and relevant scientific articles
published between January 1960 and June 2016 were
examined. The anatomy of the sacrum and its venous
plexus, as well as the factors that influence bleeding,
the causes of this complication, and its surgical
management were defined.

AIM
To analyze the anatomy of sacral venous plexus flow,
the causes of injuries and the methods for controlling
presacral hemorrhage during surgery for rectal cancer.
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RESULTS
This is a review of 58 published articles on presacral
venous plexus injury during the mobilization of the
rectum and on techniques used to treat presacral
venous bleeding. Due to the lack of cases published in
the literature, there is no consensus on which is the best
technique to use if there is presacral bleeding during
mobilization in surgery for rectal cancer. This review
may provide a tool to help surgeons make decisions
regarding how to resolve this serious complication.
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CONCLUSION
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of the rectum and on techniques used to treat pre
sacral venous bleeding. We believe that this work is
potentially relevant to helping surgeons understand the
physiopathology of this complication and making them
aware of possible surgical strategies for its treatment.

RESULTS
Anatomical considerations

The vascular anatomy of the SVP is complex and
includes a wide and intricate network of veins primarily
formed by the anastomosis between the medial and
lateral sacral veins. The medial sacral vein usually
drains into the left common iliac vein, whereas the
lateral veins drain into the internal iliac vein. The SVP
receives contributions from the lumbar veins of the
posterior abdominal wall and the basivertebral veins
that pass through the sacral foramen. Morphological
studies of human sacral bones show that 100% of the
specimens feature foramina that communicate with
the anterior sacral face and the cancellous bone of
the vertebral bodies. Between 16% and 22% of these
foramina are 2 to 5 mm in diameter, are located on
the anterior face of S4-S5, and are penetrated by the
basivertebral veins originating in the cancellous bone,
which measures between 0.7 mm and 1.5 mm in this
[4,5]
region
(Figure 1). The small basivertebral veins,
which are very thin, allow the bidirectional passage
of blood because they lack valves; these veins flow in
long, tortuous channels through the spongy tissue of
the vertebral bodies. The lateral sacral veins, the medial sacral vein, and the basivertebral veins constitute
a wide network of anastomoses that form the venous
[4,6]
plexus on the anterior sacral surface
(Figure 2). The
medial sacral vein can be located to the left or the right
[7]
of the midline and is duplicated in 80% of cases . The
vascular anastomoses between the medial sacral vein
and the lateral veins are often less than 3 cm from
the sacral promontory; specifically, this distance is 2
cm in 90% of cases, and the anastomosis is located
rd
th
at the level of the 3 and 4 sacral foramen in 70% of
[6,7]
cases . The retrosacral fascia, also called Waldeyer’s
fascia, has been described as a sheet of connective tissue that extends from the periosteum of the sacrum to
the posterior wall of the rectum approximately 3-4 cm
above the anorectal junction. Anatomical and radiological studies have revealed that although its insertion
st
into the sacrum can occur between the 1 coccygeal
vertebra and S2, it is located at the level of S3 and S4
[8-11]
in 84%-94% of cases
, just where the foramen that
give rise to the basivertebral veins are thickest.

Casal Núñez JE, Vigorita V, Ruano Poblador A, Gay Fernández
AM, Toscano Novella MA, Cáceres Alvarado N, Pérez
Dominguez L. Presacral venous bleeding during mobilization
in rectal cancer. World J Gastroenterol 2017; 23(9): 1712-1719
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i9/1712.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i9.1712

INTRODUCTION
Presacral venous plexus injury during the mobilization of the rectum is one of the most frequent intra[1]
operative complications during rectal cancer surgery .
[2,3]
With an incidence that ranges from 0.25% to 8.6% ,
it can cause rapid hemodynamic instability in the
[4]
patient and can even be lethal . The presacral venous
plexus cannot be visualized by the surgeon, and injury
to the presacral fascia or avulsion of the rectosacral
fascia from its insertion into the sacral periosteum can
injure the presacral and basivertebral veins, causing
bleeding that is difficult to manage with conventional
hemostatic maneuvers. Accordingly, a series of techniques that offer alternatives to traditional hemostatic
methods for the treatment of presacral venous bleeding have been described. This review aimed to analyze
the anatomy of the sacral venous plexus (SVP), the
factors influencing the incidence of presacral venous
plexus injury, and the flow of bleeding in an effort to
classify the available treatment techniques and make
surgeons aware of possible strategies for the management of this complication.

MATERIALS AND METHODS
®

®

The databases MEDLINE , PubMed , and Embase™
were searched for manuscripts published between
January 1960 and June 2016 using the following
keywords: presacral bleeding, presacral hemorrhage,
pelvic surgery, rectal surgery, presacral venous plexus,
presacral anatomy, and pelvic packing. The reference lists from the articles were reviewed to identify
additional pertinent articles. This review includes 58
articles on the anatomical vascular data of the SVP,
the essential factors that influence the flow of bleeding
after venous injury, the causes and types of injury, the
incidence of presacral bleeding, and treatments applied
to control this bleeding in rectal cancer surgery. Due to
the limited number of cases reported in most publications and the variety of procedures used to control
this complication, conventional systematic review and
meta-analysis could not be performed.

WJG|www.wjgnet.com

Hydrodynamic studies

The essential factors that influence the flow of blood
from an injured vein are the size of the vein and
the intravenous pressure at the broken point of the
vein. Hydrostatic pressure in the SVP depends on the
following: the pressure of the inferior vena cava, the
distance from S4-S5 to the coronal axis of the inferior
vena cava traced from the renal veins to the iliac
bifurcation, and the elevated pressure on the inferior
vena cava due to the lithotomy position. Experimental
studies and the application of general hydrodynamic
principles suggest that the hydrostatic pressure in the
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Table 1 Classification of techniques for the control of
presacral bleeding
Pelvic plugging
Traditional with compresses
Sengstaken-Blakemore tube
Linton balloon
Compartmental hemostatic balloon
IV Saline Bag
Breast implant
Plugging with rectus abdominis
muscle
Plugging with Bonewax®
Plugging with bone cement
Bakri balloon

Figure 1 Sacrum specimen. Multiple sacral basivertebral vein foramin,
between 2-4 mm, are seen on S4-S5.

Metal implants
Simple pins
Helical titanium pins + Surgicel®
Staples + cancellous bone + Surgicel®
Ligaclips®

sacral plexus in the lithotomy position is approximately
twice the venous pressure of the inferior vena cava in
the supine decubitus position, and injury to a vein with
diameter between 0.5 mm and 4 mm can cause blood
[4,5]
flow of 32 mL/min to 1994 mL/min .

Topical hemostatic agents
Cyanoacrylate
Cyanoacrylate + Surgicel®
Ankaferd Blood Stopper®
Floseal® + Surgicel®
Direct suture

Causes types of injury

Infrarenal aorta clamp + PVS suture
Suture-circular ligature

Although the height of the tumor in the rectum, the
infiltration of the presacral fascia by the tumor, the use
of adjuvant radiotherapy, prior rectal surgery, and poor
visualization of the surgical field have been described
as risk factors that influence the incidence of presacral
bleeding during rectal resection, the most common
cause is the anatomical relationship of the anorectal
fascia. The fascia and its surrounding tissues, including
the presacral veins, can be lacerated by the surgeon
due to inadequate dissection of the posterior wall of
the rectum in the sacral concavity. This maneuver
can be caused instrumentally and, more frequently,
by blunt dissection by the fingers of the surgeon. The
average distance between the ventral surface of the
sacrum and the mesorectum is 12 mm or 13 mm as
measured by magnetic resonance (MR) and computed
[12]
tomography (CT), respectively . Laceration of the
presacral fascia due to dissection of the sacrum very
close to the surface and lifting of this fascia with or
without the periosteum are other common causes of
[3,4,13-15]
presacral bleeding
.
[4]
Wang et al describe 3 types of venous injury and
direct implications for their handling: injury to the
presacral veins (type Ⅰ), injury to the presacral veins
and/or basivertebral veins of diameter < 2 mm (type
Ⅱ), and injury to the presacral veins and/or basivertebral veins of diameter > 2 mm (type Ⅲ).

Direct/indirect electrocoagulation
Spray electrocautery
Bipolar coagulation
Argon coagulation
Electrocoagulation on a piece of
epiploic appendix/muscle fragment

and ligation of the internal iliac vein makes venous
drainage of its tributaries difficult, increases pressure
[4,16-18]
on the sacral plexus, and exacerbates bleeding
.
[19]
Similarly, Celentano et al
we propose a classification of techniques (Table 1) and an algorithm for the
management of sacral venous bleeding (Figure 3).

Pelvic plugging

Traditional plugging with compresses has been dem[20]
onstrated to be effective , and surgeons should be
familiar with this procedure because it may be the
only successful mechanism to control potentially fatal
[21]
bleeding . After abdominoperineal resection, plugging can be performed through the abdomen following
closure of the perineum or entirely via the perineum.
In this case, explantation will require one or more
additional laparotomies, and if the perineal route is
used, re-bleeding after the explantation will complicate
hemostatic maneuvers. The risk of re-bleeding, the
increase in infection, the predisposition to dehiscence
if the plug is placed adjacent to an anastomosis, and
longer hospital admission are the main disadvantages
[2,14,20,22-24]
of this procedure
.
Alternatives to classic plugging that attempt to
avoid re-intervention have been described, such as
[25]
the use of an expandable pelvic prosthesis or the
[26]
use of the Sengstaken-Blakemore probe . Holman

Surgical management

In addition to the application of temporary direct
pressure on the bleeding area as the first maneuver,
various methods have been employed to treat this
complication. Ligature of the internal iliac artery is not
[16]
effective and can cause gluteal and vesical necrosis ,
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BVV

IVVS

PVP

LSV
RSV
MSV

Figure 2 Diagram showing the sacral venous system. RSV: Right sacral vein; LSV: Left sacral vein; MSV: Middle sacral vein; PVP: Presacral venous plexus;
IVVS: Internal vertebral venous system; BVV: Basivertebral vein.

Compression and aspiration
Patient hemodynamic stability

Yes

No

Bleeding area identified

Yes

No

Indirect
electrocoagulation;
Topical hemostatic
agents; Pins

Enlarge the field:
rectal resection

Bleeding stopped

Bleeding zone identified

Yes
Yes

No
Plugging, alternatives without
reintervention?

No

Figure 3 Presacral venous hemorrhaging: treatment algorithm.
[27]

et al developed a model hemostatic balloon using
MR images of the pelvis. After testing in cadavers, the
balloons were used to treat 9 patients with presacral
venous bleeding and produced good results in 89% of
[28]
patients. Ng et al describe an alternative to classic
plugging after abdominoperineal resection using an
empty IV bag filled with 850 mL of saline inserted
through the perineum. The advantages of this technique include its adaptability to the sacral concavity
and the ease of modifying the hemostatic pressure
by infusing or withdrawing fluid through the infusion
port. Moreover, the bag can be withdrawn through the
perineal wound without requiring additional surgery.
After failed attempts at hemostasis with classic plug[29]
ging and metal implants, some authors successfully
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used plugging, applying traction with a breast implant
that was inflated with 520 mL of saline solution placed
in the presacral space and maintaining pressure on
the SVP using the traction of the implant, which was
connected to a 1-L bag of saline suspended at the end
[30]
of the bed. Remzi et al recommend plugging with a
free graft of the rectus abdominis muscle measuring
4 cm × 2 cm × 1 cm sutured to the presacral tissue
over the area of bleeding. The absence of necrosis and
lack of abscesses with this technique are attributed to
the hypervascularization of the presacral area and the
[31]
revascularization of the graft. Civelek et al applied
®
bone wax (Bonewax ) directly to the presacral fascia
and the periosteum and simultaneously used pelvic
plugging. After the failure of classic pelvic plugging and

1715

March 7, 2017|Volume 23|Issue 9|

Casal Núñez JE et al. Presacral venous bleeding in rectal cancer
[32]

metal implants, Becker et al recommend plugging
the bleeding area directly with bone cement (polymethyl methacrylate). Moreover, the Bakri balloon,
created specifically to be introduced into the uterine
[33]
cavity to control bleeding , has been successfully
used in 2 patients for the treatment of presacral bleed[34]
ing after colorectal surgery .

to the bleeding area with absorbable hemostatic gauze
for 20-30 min. This gauze was similar to collagen and
was created from cellulose that had been chemically
treated and combined with alpha-cyanoacrylate as an
[51]
adhesive. Karaman et al achieved excellent results
®
with the use of topical Ankaferd Blood Stopper (ABS).
ABS exhibits antihemorrhagic properties and is an
extract of 5 medicinal plants that exert antithrombotic,
antiplatelet, antioxidant, antiatherosclerotic, and
[14]
antitumoral activities. Germanos et al suggest that
after several techniques have been tried and failed,
presacral bleeding should be treated with direct
hemostatic agents. Specifically, they used a gel formed
®
by combining gelatin and thrombin (Floseal ) granules
®
and an absorbable hemostatic agent, Surgicel ,
prepared by the controlled oxidation of regenerated
cellulose.

Metal implants
[4]

Wang et al first used pins in 1985 to control presacral bleeding. Since then, their implementation has
been the subject of multiple communications, most
[35-40]
of which reported good results
. However, pin
[22,37]
placement can be technically difficult
, especially
[41]
in narrow pelvises , when the contour of the sacrum
is not sufficiently smooth and regular or when osteo[29,42]
porotic disease is present in the bone
. Failure of
[14,32,41,43]
the technique
, development of a presacral
hematoma, chronic pelvic pain, release, migration,
[42]
and perianal extrusion of the implant , and the need
for equipment that is not always routinely available
[14,24]
in surgery
are complications and inconveniences
associated with the implementation of this procedure.
[44]
Its ineffectiveness for diffuse bleeding has led to the
[13,45]
development of other alternatives. Some authors
use the ProTack™ device to fix hemostatic sponges
®
(Surgicel ) to the sacrum using helical titanium tacks.
[43]
Wang et al
used saw-tooth staples of different
sizes that fit into the gap between the staple and the
sacrum, along with a spongy bone graft and a plate
®
[46]
of Surgicel . Jivapaisarnpong
reported the cessa®
tion of bleeding using vascular clips (Ligaclips ) in 3
patients in whom several other techniques, such as
electrocauterization, coagulation with argon, indirect
coagulation, and pelvic plugging, had failed.

Direct suture

Topical hemostatic agents

Topical hemostatic agents have been widely used,
especially in cases of diffuse bleeding or when other
methods have failed. For example, cyanoacrylate is a
monomer that is purified by removing toxic products
during its synthesis. Its contact with anionic substances
such as blood causes it to polymerize into long chains
[47]
that form a solid layer, resulting in hemostasis .
[48]
Losanoff et al achieved hemostasis in 3 patients
by evenly applying cyanoacrylate glue to the surface
of a gelatin sponge measuring 3 cm × 2 cm; the
sponge was then compressed for several minutes to
ensure adequate contact with the presacral fascia and
[49]
polymerization of the adhesive. Chen et al used a
combination of oxidized cellulose and cyanoacrylate.
Specifically, they placed 2 to 5 pieces of 2 cm × 2
cm oxidized cellulose in a Kelly clamp and applied
pressure to the injury for a few minutes. They then
evenly applied 1 ml of cyanoacrylate to the cellulose
surface and to the tissue surrounding the pieces of
[50]
oxidized cellulose. Zhang et al reported the control
of bleeding in 5 patients by the application of pressure
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[14]

Some authors report that clotting and direct suture
are ineffective and should be avoided because they
can exacerbate bleeding and cause significant blood
[14]
[52]
loss . Alternatively, Papalambros et al report the
potential benefits of temporarily clamping the infrarenal
aorta, which hypothetically decreases blood flow in the
vena cava and its tributaries and should reduce the
hydrostatic pressure in the sacral plexus and bleeding.
This approach would allow the identification of the
point of bleeding and its suture. This procedure could
be effective for treatment of type Ⅰ injuries described
[4]
by Wang et al , which are easiest to treat and can be
addressed with less bloody methods. However, in the
[23]
opinion of other authors , this approach would be
difficult to apply successfully to injuries of the basivertebral veins after retraction in the sacral periosteum.
Ligature and circular suturing were described by Jiang
[53]
et al in 2013 as a method to control presacral venous
bleeding. Once the bleeding points have been identified, the venous plexus is ligated and circularly sutured
with 4/0 silk. The suture includes the presacral fascia,
the presacral veins, and the deep connective tissue.
Bleeding that continues after the first suture suggests
that the blood originates from the communicating
veins or the basivertebral veins, which necessitates
a second or even a third suture. However, if bleeding
originates from veins retracted in the bone, Jiang
[53]
et al
recommend the implementation of a combination of techniques as more efficient than the use of
a single method for the control of bleeding in this
situation.

Direct or indirect electrocoagulation
[54]

Filippakis et al controlled bleeding in 4 patients using
electrocauterization in the spraying position at the
bleeding points of the presacral fascia. Furthermore,
[55]
Li et al
proposed direct bipolar coagulation as a
simple and effective method for the management of
presacral venous bleeding after demonstrating the
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cessation of this type of bleeding in 7 patients. Kandeel
[56]
[57]
et al and Saurabh et al reported 1 and 2 patients,
respectively, in whom bleeding was controlled using
argon coagulation.
Indirect monopolar electrocoagulation has been
successfully used on a portion of an epiploic appendix
by maintaining pressure on the bleeding area with a
[2,3]
dissection clip . Moreover, indirect electrocoagulation
through a fragment of the anterior rectus abdominis
[58]
muscle was described by Xu et al
and applied
with success in 11 patients. The technique involves
resecting a fragment of the anterior rectus abdominis
muscle approximately 2 cm × 2 cm, placing it in a
long dissection clip, applying pressure to the area of
bleeding, and applying a monopolar current to induce
clotting. Muscle is a soft tissue that contains approximately 75% water and is easily moldable to the bone
surface. Water is an excellent conductor of energy due
to the solutes dissolved in it. Thus, the implementation
of electrocoagulation in muscle results in surgical
smoke when the muscle is heated, and the cellular
fluid is vaporized by the thermal action of the energy
source. The temperature of the muscle gradually
increases and reaches the boiling point after 90-120
s of application of monopolar current at maximum
power. This temperature is the optimal coagulation
point and ensures that the muscle adheres to the
[23,58]
bone surface
. This method has been validated and
[22-24]
used by other authors
with satisfactory results,
in some cases after the failure of other alternatives.
Specifically, it is a rapid, easily executed, and effective
method that is usually free of intra- or post-operative
complications and that can be used at several bleeding
points. Furthermore, if the muscle does not adhere to
the bone, the technique does not fail.
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CASE REPORT

Gastrointestinal stromal tumor of the stomach with axillary
lymph node metastasis: A case report
Naoki Kubo, Nobumichi Takeuchi

Abstract

Naoki Kubo, Nobumichi Takeuchi, Department of Surgery, Ina
central Hospital, Inashi, Nagano 396-8555, Japan

Gastrointestinal stromal tumors (GISTs) are the most
common type of gastrointestinal mesenchymal tumors,
although metastasis to the perigastric lymph nodes
is relatively rare, compared with liver or peritoneal
metastasis. In this report, we describe a case of
stomach GIST with a solitary simultaneous metastasis
in the left axillary lymph node. A 68-year-old man
was diagnosed with a large upper-stomach GIST,
and computed tomography and positron emission
tomography revealed masses in the left axilla and right
mediastinum. We did not detect evidence of metastases
to the liver, or other sites including the perigastric
lymph nodes, although findings from the surgically
resected axillary lymph nodes were compatible with
GIST metastasis. Treatment using imatinib markedly
reduced the gastric and mediastinal lesions, and this
response persisted for 3 years. The patient subse
quently experienced rapid growth of the gastric lesion
without mediastinal or axilla recurrence, which required
palliative surgery. Despite continuing medical treatment
(sunitinib and regorafenib), the patient died of liver
metastases 23 mo after the surgery. Based on our
findings, it appears that the axillary lymph nodes can
be a potential metastatic site for GIST metastasis.
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Core tip: Gastrointestinal stromal tumors (GISTs) are
the most common type of gastrointestinal mesenchymal
tumors, although metastasis to the perigastric lymph
nodes is relatively rare, compared to liver or peritoneal
metastasis. In this report, we describe a case of
stomach GIST with a solitary simultaneous metastasis
in the left axillary lymph node. Based on our findings,
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it appears the axillary lymph nodes can be a potential
metastatic site of GIST metastasis.

A

Kubo N, Takeuchi N. Gastrointestinal stromal tumor of the
stomach with axillary lymph node metastasis: A case report.
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URL: http://www.wjgnet.com/1007-9327/full/v23/i9/1720.htm
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INTRODUCTION

B

Gastrointestinal stromal tumors (GISTs) are the most
common type of gastrointestinal mesenchymal tumor,
although GIST only accounts for approximately 1% of
[1]
gastric malignancies . GISTs frequently metastasize
to the liver or peritoneum, although lymph node
[2]
metastasis is very rare , even to the perigastric area.
Therefore, we report the first documented case of
stomach GIST with simultaneous axillary lymph node
metastasis.

CASE REPORT
Figure 1 Gastroscopy revealed a large tumor with ulceration in the upper
body of the stomach.

A 68-year-old man was admitted to our hospital after
complaining of anorexia and obvious weight loss.
Gastroscopy revealed a large tumor with ulceration in
the upper stomach body (Figure 1), and histological
evaluation confirmed a diagnosis of a GIST (positive
for c-kit and CD34). The mitotic index was 5/50 in
high-power field and the MIB-1 labeling index was
10%. Computed tomography (CT) and positron emission tomography revealed a primary gastric tumor
(diameter: 5 cm), a right mediastinal tumor (diameter:
2 cm), and a left axilla mass (diameter: 1 cm) (Figure
2). Based on these findings, we performed a complete
gross excision of the left axilla mass. The specimen
was 1.4 cm in diameter, and there was no extranodal
extension, it exhibited monotonous spindle cells (Figure
3A-D) and was diagnosed as a metastasis of the GIST,
because it exhibited positive immunohistochemical
staining for c-kit (Figure 3E) and DOG1 (Figure 3F),
the mitotic index was 15/50 in high-power field and
the MIB-1 labeling index was 10%. Based on these
findings, we started treatment using oral imatinib (400
mg/d), and in the next year, after starting imatinib, we
followed up the patient every 3 mo by using CT and
every 6 mo by using PET. The 6-mo follow-up revealed
rapid response of the primary lesion and complete
remission in the mediastinal lymph nodes. However,
after 3 years of imatinib treatment, the primary gastric
tumor exhibited rapid growth that resulted in obstructive symptoms and continuous bleeding, although we
did not detect recurrence in the mediastinal and axillary lymph nodes. We performed total gastrectomy as
palliative surgery, and all 13 resected perigastric lymph
nodes were negative for metastasis; the mitotic index
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was 20/50 in high-power field and the MIB-1 labeling
index was 30%. The patient subsequently recovered,
and we started postoperative adjuvant treatment using
imatinib. However, liver metastases appeared after 13
mo of treatment using imatinib, which we attempted
to treat using regorafenib because gene sequence
analysis of the tumor showed a KIT exon 11 mutation.
The liver metastasis increased 2 mo later, and we
started treatment with sunitinib. However, the patient
developed renal dysfunction, and died of the liver
metastasis 23 mo after the surgery with gastretomy.

DISCUSSION
GIST is the most common type of gastrointestinal
mesenchymal tumor, and commonly exhibits muta[3]
tions in the c-kit proto-oncogene . GIST frequently
metastasizes to the liver or peritoneum, although nodal
[2]
metastasis is very rare . Among 200 reported patients
with digestive tract GIST, 94 patients exhibited metastasis, which included 61 liver metastases (65%), 20
peritoneal metastases (21%), and only 6 lymph node
[4]
metastases (6%) . To the best of our knowledge,
there is only one documented case of distant lymph
node metastasis from a stomach GIST, and that case
[5]
involved inguinal lymph node metastasis . Although
a few cases of peripheral lymph nodes metastasis
[6]
from GIST have been reported , the present case is
the first documented case of a GIST presenting with
solitary axillary lymph node metastasis.
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A

B

Figure 2 Computed tomography reveals a tumor in the left axilla (A, diameter: 1 cm) and a tumor in the right mediastinum (B, diameter: 2 cm).

A

B

C

D

E

F

Figure 3 Pathological findings of the biopsied left axilla lymph node. Analysis of the tumor revealed tunicate formation and the survival of lymphoid tissue
[hematoxylin and eosin staining(A), silver impregnation (B), and Leukocyte common antigen (C) (magnification × 40)]. The tumor exhibited monotonous spindle cells (D,
hematoxylin and eosin staining), and the cells were positive for c-kit (E) and DOG1 (F, magnification × 100).

The three major routes of metastasis to the
axillary lymph nodes are clearly documented in lung
[7,8]
cancer . The first route involves newly developed

WJG|www.wjgnet.com

lymphatic channels that arise from the pleural lesions
of adhesive lung tumors. The second route involves
retrograde spread in the presence of supraclavicular
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lymph node metastasis. The third route involves
systemic axial lymph node metastasis. In this context,
systemic metastases could be caused by the primary
tumor invading nearby blood vessels and the subsequent dissemination of tumor cells into the venous
[9,10]
system through the thoracic duct
. In the present
case, the tumor was likely caused by systemic metastasis, as the recurrence was only detected in the right
mediastinum, without lung or supraclavicular lymph
node metastases.
Tumor size, location, mitotic rate, and C-KIT and
PDGFRA genotype are the major determinants of the
malignant potential of the tumor, and have significant
[11]
impact on prognosis . In the TNM (tumor-nodemetastasis) system for GISTs, the presences of lymph
node metastasis is classified as stage Ⅳ, which generally portends a poor prognosis, but cases with long[5,12]
term survival have also been reported
. Valadao
reported that lymph node metastasis is not related to
poor prognosis; however, the study included a small
[13]
number of patients . Furthermore, it is unclear
whether there is a difference of prognosis according to
the site of lymph node metastasis, because reports of
distant lymph node metastasis are very rare.
The appropriate therapy for GIST with distant
metastasis remains controversial. Surgery is recommended if curative resection is possible, although imatinib therapy is occasionally selected in cases that have
complications or may require expansive surgery. In the
present case, we performed complete gross excision
of the left axilla mass, and imaging revealed that only
right mediastinum metastasis remained. However,
we selected imatinib therapy, based on the tumor’s
stage and the patient’s surgical stress. Six months of
imatinib therapy markedly reduced the gastric lesion
and the mediastinal lesion completely disappeared. In
this context, resection of residual disease after imatinib
pre-treatment is feasible in patients with metastatic
GIST, even those with advanced hepatic and peritoneal
[14]
metastasis , and surgery after achieving the best
clinical response may be associated with a survival
benefit (vs historical patients who were treated using
[15]
imatinib alone) . Therefore, we assumed that the
distant metastasis had been controlled by imatinib
and that curative resection was possible. However, the
patient refused to undergo gastrectomy and elected
to continue receiving imatinib. Unfortunately, the
primary lesion exhibited rapid regrowth after 3 years
of imatinib treatment without reappearance of the
mediastinal lesion or other distinct metastases, which
led to obstructive symptoms and continuous bleeding.
At this point, we performed palliative total gastrectomy
and provided ongoing medical treatment (sunitinib
and regorafenib), although the patient ultimately
died of liver metastases at 23 mo after the surgery.
Nevertheless, the patient did not exhibit signs of
distant lymph node metastasis.
In conclusion, the axillary lymph nodes can be a
site of GIST metastasis, and imatinib chemotherapy
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may be useful for controlling distant lymph node
metastasis from GIST. Although we performed a resection for the original lesion because the distant metastasis had been controlled by imatinib, the appropriate
therapy for GIST with distant metastasis remains
controversial. Further studies are needed to clarify the
duration of chemotherapy and an appropriate surgical
intervention that will be effective for treating distant
lymph node metastasis.
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Abstract
Multiple liver tumors represent a challenging condition
for abdominal surgeons both in the selection of technique and the rarity of diagnosis. There are no case
reports on co-existence of liver metastases from both
intestinal leiomyosarcoma and adenocarcinoma. The
patient described in this report successfully underwent
resection of both primary lesions and liver metastases
in combination with chemotherapy. As for the leiomyosarcoma, the primary cecal lesion was revealed more
than three years after the patient’s first visit. Peritoneal, lymph-node, and lung recurrences were observed
afterward, and thus surgeries on those regions were
performed. Pathologically, the peritoneal and lung
recurrences comprised leiomyosarcoma and the lymphnode recurrence was diagnosed as adenocarcinoma.
Despite newly discovered multiple lung recurrences
and regional lymph-node metastases, the patient
lived a normal life for 73 mo after the initial operation
based on multidisciplinary therapy. He ultimately died
of liver failure due to invasive lymph-node recurrence
from the rectal adenocarcinoma, in addition to multiple
lung recurrences from the leiomyosarcoma. Hepatic
recurrence did not occur in this patient’s case, which
appears to be one reason for his long-term survival.
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medical examination in October 2009. His past medical history involved only hypertension starting at the
age of 57. At the examination, he underwent a
colonoscopy examination, whereupon type 2 adenocarcinoma was discovered in the rectum. In addition,
an abdominal computed tomography (CT) scan and
gadoxetic acid enhanced magnetic resonance imaging
revealed liver tumors in Segment 3, Segment 4, and
Segment 8 (Figures 1 and 2). Anterior rectal resection
with regional lymph-node dissection was carried out in
December 2009. A pathological examination revealed
extra serosal invasion by a moderately differentiated adenocarcinoma and metastases in eight of 14
resected lymph nodes.
Because genetic analysis confirmed wild-type
KRAS, the patient received chemotherapy with modified FOLFOX6 plus bevacizumab after the rectal
resection. Following four courses of FOLFOX, the S3
liver tumor disappeared and the S8 tumor decreased
in size, but the S4 tumor was found to be enlarged.
The patient then underwent seven courses of FOLFIRI
plus bevacizumab followed by one course of irrinotecan plus cetuximab; as a result, the S4 and S8 tumors
decreased in size (Figure 3). Positron emission tomography-CT after the chemotherapy series showed no
significant uptake of fluorodeoxyglucose in the liver.
The patient subsequently underwent a central bi-segmentectomy and a partial S3 resection in September
2010 (the second operation).
A pathological examination revealed fibrosis and
calcification in the S3 and S8 tumors, with a few
degenerated residual adenocarcinoma cells, which was
compatible with rectal adenocarcinoma metastasis. In
contrast, the S4 tumor consisted of irregular fascicles
of spindle-shaped cells with eosinophilic cytoplasm and
nuclear atypia. An immunohistochemical examination
demonstrated that the S4 tumor cells were positive for
α-smooth muscle actin and desmin, while negative for
CD34, S-100, c-kit, and cytokeratin AE1/3 (Figure 4).
Based on these findings, the S4 tumor was designated
as leiomyosarcoma. The tumor grade was high accord[3]
ing to the classification by Hajdu et al .
Histologically, chemotherapy had no apparent effect
on this tumor. The patient underwent six courses of
FOLFIRI plus bevacizumab as adjuvant chemotherapy
after hepatic resection. Twenty-two months later (in
July 2012), an abdominal CT scan was performed as
part of an annual medical examination. A cecal tumor
and lymph-node swelling around the common hepatic
artery were discovered. Moreover, accumulation at
both sites was discovered in a positron emission
tomography (PET)-CT scan (Figure 5). The tumor had
not been identified in a colonoscopy. Three months
later, a type 2 tumor was discovered and a biopsy
via colonoscopy revealed leiomyosarcoma. Ileocecal
resection with lymph-node dissection and lymph-node
sampling around the common hepatic artery were
carried out in November 2012 (the third operation).

Core tip: There have been no case reports on coexistence of liver metastases from intestinal leiomyosarcoma and adenocarcinoma. This patient underwent
resection of primary lesions and liver metastases in
combination with chemotherapy. As for leiomyosarcoma, liver metastasis was discovered three years
prior to discovery of the primary lesion. Peritoneal,
lymph-node, and lung recurrences were discovered
afterward, and therefore surgeries on those regions
were performed. Despite newly discovered multiple
lung recurrences and regional lymph-node metastases, the patient lived a normal life for 73 mo after the
initial operation. He ultimately died of liver failure due
to invasive lymph-node recurrence from the rectal
adenocarcinoma.
Aoki H, Arata T, Utsumi M, Mushiake Y, Kunitomo T, Yasuhara
I, Taniguchi F, Katsuda K, Tanakaya K, Takeuchi H, Yamasaki
R. Synchronous coexistence of liver metastases from cecal
leiomyosarcoma and rectal adenocarcinoma: A case report. World
J Gastroenterol 2017; 23(9): 1725-1734 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v23/i9/1725.htm DOI:
http://dx.doi.org/10.3748/wjg.v23.i9.1725

INTRODUCTION
Since the appearance of gastrointestinal stromal tumor
as a distinctly defined entity, the diagnosis of intestinal
leiomyosarcoma has not been common. Among the
different types of this sarcoma, cecal leiomyosarcoma
[1]
is extremely rare . Hepatic leiomyosarcoma is also
[2]
rare, particularly as a primary cancer . Abdominal
surgeons often confront multiple liver tumors, making
treatment of such cases challenging. This is particularly the case if the diagnoses of hepatic tumors differ
from each other. Until now, there had been no case
reports regarding co-existence of liver metastases
from a combination of intestinal leiomyosarcoma and
adenocarcinoma. We hereby report on a patient who
underwent successful treatment involving resection
of both primary lesions and liver metastases along
with chemotherapy. Peritoneal, lymph-node, and lung
recurrences were observed afterward, and thus surgeries on those regions were also performed. Multiple
lung recurrences and regional lymph-node metastases
were newly discovered, but the patient could live a
normal life for 73 mo after the initial surgery based on
multidisciplinary therapy, which we will discuss in detail
in this report.

CASE REPORT
A 61-year-old male visited our hospital with occult
blood in stool and multiple liver tumors at an annual
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Figure 1 Computed tomography before treatment. An abdominal computed tomography scan revealed liver tumors in Segment 3, Segment 4, and Segment 8.
The tumor in Segment 8 is hypodense with peripheral enhancement. The tumor in Segment 4 is a well-defined isodense tumor with homogeneous enhancement.

A pathological examination revealed cecal leiomyosarcoma with regional lymph-node metastases
and metastasis from rectal adenocarcinoma in the
lymph node around the common hepatic artery.
Retrospectively, accumulation had been observed
in the cecum in a PET-CT scan in September 2010,
and a submucosal tumor had been suspected in a
colonoscopy in July 2011. It is likely that rectal adenocarcinoma and cecal leiomyosarcoma existed
synchronously from the beginning, and that both
tumors had metastasized to the liver synchronously.
The patient was then treated with nine courses of
XELOX plus bevacizumab.
In a follow-up CT scan in June 2013, a tumor just
below the peritoneum was discovered. Because this
accumulation was identified in a PET-CT scan and
no other accumulation was observed, extirpation of
the tumor was carried out (the fourth operation).
Pathological diagnosis was leiomyosarcoma of the
omentum, compatible with recurrence (Figure 6). The
patient was treated with XELOX plus bevacizumab
following the surgery. Three months later, in a chest
CT scan, two coin lesions were discovered in the left
lung. There was no indication of accumulation at
both lesions in a PET-CT scan, but lung metastases
were strongly suspected. In October 2013 (46 mo
after the first operation), partial resections of the left
upper lobe and left lower lobe were performed (the
fifth operation). Pathological diagnosis was metastatic
leiomyosarcoma of the lung (Figure 7).
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The patient was subsequently treated with XELOX
plus bevacizumab again following surgery (the fifth
and final operation). The hepatic hilum lymph node
was found to be enlarged in July 2014, and multiple
lung metastases were newly discovered in November
2014. Chemotherapy was changed to treatment consisting of CPT-11 plus cetuximab, due to neuropathy
experienced by the patient. This clinical time course is
demonstrated in Figure 8.
Although lymph-node and multiple lung metastases were present, the patient survived for more
than six years after the initial operation. Since the left
hepatic duct was constricted by lymph-node metastasis, a plastic stent was inserted in October 2015.
The patient received chemotherapy with doxorubicin
afterward as an outpatient but was hospitalized
with cholangitis due to lymph-node metastatic
recurrence in January 2016. The patient died from
liver failure due to lymph-node invasion from rectal
adenocarcinoma in March 2016 (76 mo after the
initial operation). The extended treatment proved
worthwhile, given that the patient could live a normal
life for 73 mo after the initial operation with help from
the multidisciplinary therapy we employed.

DISCUSSION
Hepatic resection for liver metastases from colorectal
cancer or neuroendocrine tumor, in combination with
chemotherapy, has been established as a safe and
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B
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30 s

120 s

Hepatocellular phase

Figure 2 Ethoxibenzyl-magnetic resonance imaging before treatment. The tumors in Segments 3 and 8 showed gradual peripheral enhancement, while the tumor
in Segment 4 showed heterogeneous enhancement and washout characteristics. A: S3 and S8 gradual peripheral enhancement; B: S4 heterogeneous enhancement.
[4]

standard treatment. The issue in question, however,
is how to determine effective treatment for noncolorectal non-neuroendocrine liver metastases
(NCNNLM). Hepatic metastasectomy had been thought
ineffective for such cases. According to Gladdy’s report
of 353 patients with primary resectable leiomyosar-

WJG|www.wjgnet.com

coma , recurrence occurred in 51% of abdominal and
retroperitoneal leiomyosarcoma cases, including 29%
of lung, 23% of liver, and 15% of other cases (brain
and lymph nodes). Predictive factors for disease-free
survival in patients with leiomyosarcoma were size and
[5]
tumor grade. In addition, DeMatteo et al reported
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A

B

Before treatment

After four courses of mFOLFOX plus bevacizumab

After seven courses of FOLFIRI plus bevacizumab

After one course of irrinotecan plus cetuximab

Figure 3 Changes in computed tomography images during treatment. The tumors in Segments 3 and 8 showed a gradual decrease in size, while the tumor in
Segment 4 exhibited a one-time increase and then a decrease in size. A: S8 gradually decreased in size/S3 disappeared; B: S4 once increased then decreased in
size.

that the rate of recurrence reached as high as 84%
even after complete hepatic resection for sarcoma
metastasis, although this definition of sarcoma includes
gastrointestinal stromal tumors.
[6]
Ng et al reviewed 191 cases of gastrointestinal
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leiomyosarcomas, of which colorectal leiomyosarcoma
numbered 22 cases (12%). Without hepatectomy, the
median survival time for patients with liver metastases
from leiomyosarcoma was no more than 14 mo. Before
st
the 21 century, metastases from leiomyosarcomas
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Metastatic adenocarcinoma in S3 and S8

S3

S8

S8

Fibrosis and calcification with a few
degenerated residual adenocarcinoma
Chemotherapy effect: grade 2
Leiomyosarcoma in S4

S4

Spindle-shaped cell with eosinophilic
cytoplasm and atypia

S4

S4

CD34(-)

α-SMA positive

c-kit(-)

Figure 4 Pathological diagnoses of live lesions. The tumors in Segments 3 and 8 revealed fibrosis and calcification, with a few degenerated residual
adenocarcinomas, while the tumor in Segment 4 consisted of irregular fascicles of spindle-shaped cells and was positive for SMA and negative for CD34 and c-kit.
SMA: Smooth muscle actin.
[7]

were thought to not be sensitive to chemotherapy .
[8]
Lang et al reported on 26 cases of hepatic metastases from leiomyosarcomas. Only one of these 26
cases (3.8%) originated from the colon. The median
survival and five-year survival rate after R0 resection
were 32 months and 20%, respectively. The presence
of extrahepatic tumor growth should be regarded
as a contraindication for liver resection only if an R0
resection does not appear possible. Marudanayagam
[9]
et al also emphasized the importance of R0 resection
for hepatic metastasectomy of soft tissue sarcomas.
Among soft tissue sarcomas, leiomyosarcoma was
associated with poor prognosis.
[10]
Groeschl et al
reported on 420 patients who
underwent hepatectomy for NCNNLM. The five-year
survival rate in recent years was 32% after hepatectomy for liver metastases from sarcomas. Although
the rate of recurrence after hepatectomy is as high
as 66.5%, NCNNLM can be resected with reasonable
survival outcomes when that surgery is appropriately
selected as a treatment option. Prognostic factors for
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NCNNLM are tumor size (greater than 5 cm), lymphovascular invasion, and time-interval to liver metastasis
of less than two years. Hepatic recurrence did not
occur in the case we present here, which was one of
the reasons for the patient’s long-term survival.
We reported this patient’s case as a primary
hepatic leiomyosarcoma with liver metastasis of rectal
[2]
cancer , before our finding of cecal leiomyosarcoma.
The cecal leiomyosarcoma was discovered almost
three years after the patient’s first visit. From a
pathological perspective, it was difficult to distinguish
[11]
the site of primary lesion. Mourra et al
published a
multi-institutional study on metastatic tumors in the
colon and rectum. In that paper, only 35 of 10365
patients with colorectal malignancies (0.338%) were
identified as having true metastases to the colon and
rectum. Of those 35 metastatic colorectal tumors,
leiomyosarcoma was identified in only two cases,
with both tumors originating from soft tissue. This
indicates only a small probability of the primary
hepatic leiomyosarcoma metastasizing to the cecum.
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2010.9

2011.7

2012.7

2012.10

Leiomyosarcoma of cecum with lymph-node metastasis

α-SMA(+)
CD34(-)

Lymph-node recurrence of rectal adenocarcinoma
(surrounding common hepatic artery)

2012.7

c-kit(-)
S-100(-)

Figure 5 Cecal leiomyosarcoma and lymph-node recurrence. A cecal tumor and lymph-node swelling around the common hepatic artery were discovered in a
positron emission tomography-computed tomography (PET-CT) scan. Retrospectively, accumulation had been observed in the cecum in a PET-CT scan in September
2010, and a submucosal tumor was suspected based on a colonoscopy taken in July 2011. SMA: Smooth muscle actin.

In contrast, hepatic metastasis is reported to occur in
20%-66.5% of patients with visceral or retroperitoneal
[9,10]
sarcomas
. Moreover, all 35 patients had a history
of metastatic disease in extragastrointestinal sites,
with a mean disease-free interval of 10.6 years for sarcomas. We feel that these clinical characteristics were
not compatible with our case, and for that reason we
concluded that the cecum was the primary lesion site
in the patient case we present here. We were aware
that primary hepatic leiomyosarcoma is rare, and this
patient’s case has taught that its diagnosis should
be made carefully only after long-term observation.
However, rare are cases in which cecal leiomyosarcoma
and rectal adenocarcinoma coexisted and metasta[12]
sized to the liver. Hamai et al
reported a case of
gastric adenocarcinoma with multiple liver tumors.
After 14 mo of chemotherapy, the patient underwent
total gastrectomy with partial liver resection, upon
which the liver tumors were diagnosed pathologically
as leiomyosarcomas. During adjuvant chemotherapy
two years and five months after the first visit, a new
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hepatic tumor appeared and a tumor in the colon was
discovered. The patient underwent partial colectomy
and partial liver resection. The colon tumor and liver
tumors were all immunohistochemically diagnosed as
leiomyosarcomas. Seven months later, a third liver
resection was carried out for the newly discovered liver
tumors. Multiple liver and lung metastases eventually
developed, and the patient died four years and 10 mo
after the first visit. When a liver tumor is diagnosed as
leiomyosarcoma, therefore, careful follow-up is needed
to identify the primary site.
Leiomyosarcoma was for some time considered
to be a relatively chemo-resistant sarcoma subtype.
Recent data have demonstrated a reasonable
response rate exhibited by some histological subtypes
exposed to specific histology-tailored treatments with
[13]
doxorubicin-containing chemotherapy . Since without
chemotherapy median survival is generally up to 12
[14]
mo , chemotherapy appears to be necessary for leiomyosarcoma treatment. However, the type of adjuvant
therapy appropriate for leiomyosarcoma is an issue
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2013.6

HE

SMA

Figure 6 Peritoneal recurrences. A tumor just below the peritoneum was discovered. As the accumulation was recognized in a positron emission tomographycomputed tomography scan and no other accumulation was observed, extirpation of the tumor was carried out. Pathological diagnosis was leiomyosarcoma of the
omentum, compatible with recurrence. SMA: Smooth muscle actin.

requiring debate. Pazopanib was recently reported to
be a feasible option for patients who had been heavily
[15]
pretreated for metastatic sarcoma . In that report,
patients with leiomyosarcomas comprised the majority
of long-term responders and survivors.
Both leiomyosarcoma and adenocarcinoma recurred
after resection of primary lesions and hepatic metastases, making determination of a chemotherapy regimen
for the patient in this report difficult. As we are familiar with adenocarcinomas and the distant lymphnode recurrence was adenocarcinoma pathologically,
we chose a regimen mainly designed for colorectal adenocarcinoma. After peritoneal and lung tumors
were diagnosed as leiomyosarcoma recurrence, we
selected the treatment doxorubicin. At the patient’s
final hospitalization, lymph-node metastases to the
hepatic hilum caused liver failure, which proved to be
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fatal, and chest X-rays showed numerous nodules in
the lung field, which had caused a persistent cough in
the patient. The former problem derived from adenocarcinoma and the latter from leiomyosarcoma. By that
time, chemotherapy was no longer a treatment option.
The patient survived more than six years after
initial diagnosis, even though he had both stage Ⅳ
rectal cancer and cecal leiomyosarcoma with liver
[4]
metastasis. As for long-term survival, Gladdy et al
reported on late disease-specific mortality in primary
leiomyosarcoma. In that report, 6% of extremity and
9% of abdominal or retroperitoneal patients developed
distant recurrence more than five years after the
primary tumor diagnosis. The authors emphasized the
need for long-term follow up.
The prognosis for patients with leiomyosarcoma
might be prolonged in the future as chemotherapy
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Pathological diagnosis: Metastatic leiomyosarcoma of lung

HE

SMA

Figure 7 Lung recurrences. In a chest CT scan, two coin lesions were discovered in the left lung. As lung metastases were strongly suspected, partial resections of
the left upper lobe and left lower lobe were performed. Pathological diagnosis was metastatic leiomyosarcoma of the lung.

2009.12
Anterior resection

2013.10
Lt lung partial
resection

2010.9
Hepatic central
bilobectomy
Partial resection of S3

9 mo
4 courses of modified FOLFOX
plus bevacizumab

2012.11
Ileocecal
resection

26 mo
6 courses of FOLFIRI
plus bevacizumab

2016.1
Admission due to
cholangitis

2013.7
Tumor extirpation

8 mo

3 mo

29 mo

9 courses of XELOX plus
bevacizumab

7 courses of FOLFIRI plus
bevacizumab

XELOX plus bevacizumab
Doxorubicin

1 course of irrinotecan plus
cetuximab

2016.3
Liver failure

Figure 8 Clinical courses.

continues to advance. Long-term follow-up is important and should be considered.
This patient case was extremely rare for the points
mentioned below: (1) cecal leiomyosarcoma and rectal
adenocarcinoma coexisted; (2) both metastasized to
the liver and were resected successfully; (3) primary
colon leiomyosarcoma was diagnosed two years after
resection of the hepatic metastatic lesion; and (4)
long-term survival was attained based on multidisciplinary therapy.
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COMMENTS
COMMENTS
Case characteristics

A 61-year-old male patient with occult blood in stool and multiple liver tumors
discovered at an annual medical examination.

Clinical diagnosis

Rectal adenocarcinoma with multiple liver metastases.

Differential diagnosis

The authors did not at first recognize a differential diagnosis.
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Laboratory diagnosis

5

All lab measurements were within normal ranges except for slightly elevated
serum carcino-embryonic antigen.

Imaging diagnosis

6

An abdominal computed tomography scan and gadoxetic acid enhanced
magnetic resonance imaging revealed liver tumors in Segment 3, Segment 4,
and Segment 8.

7

Pathological diagnosis

The patient had synchronous liver metastases from both cecal leiomyosarcoma
and rectal adenocarcinoma.

Treatment

The patient successfully underwent resection of both primary lesions and liver
metastases in combination with chemotherapy.

8

Related reports

There have been no case reports on co-existence of liver metastases from
both cecal leiomyosarcoma and rectal adenocarcinoma. Only one report was
published regarding a gastric adenocarcinoma with multiple liver tumors,
which were diagnosed pathologically as leiomyosarcoma after gastrectomy
and hepatectomy. Fifteen months later, a tumor in the colon was discovered,
after which a partial colectomy was carried out. The colon tumor was immuno
histochemically diagnosed as leiomyosarcoma.

9

10

Experiences and lessons

Treatment for multiple liver tumors is challenging, particularly if the diagnoses of
hepatic tumors differ from each other.
11

Peer-review

The main issue regarding diagnosis is whether the hepatic leiomyosarcoma
is a primary lesion or a metastasis from the cecum. From a pathological
perspective, it is difficult to distinguish which of the sites is a primary lesion. The
authors therefore went about trying to make a clinical determination.

12

REFERENCES
1

2

3
4

13

Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J.
Gastrointestinal stromal tumors and leiomyosarcomas in the colon:
a clinicopathologic, immunohistochemical, and molecular genetic
study of 44 cases. Am J Surg Pathol 2000; 24: 1339-1352 [PMID:
11023095 DOI: 10.1097/00000478-200010000-00003]
Takehara K, Aoki H, Takehara Y, Yamasaki R, Tanakaya K,
Takeuchi H. Primary hepatic leiomyosarcoma with liver metastasis
of rectal cancer. World J Gastroenterol 2012; 18: 5479-5484
[PMID: 23082067 DOI: 10.3748/wjg.v18.i38.5479]
Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in
the management of soft tissue sarcomas. World J Surg 1988; 12:
326-331 [PMID: 3400243 DOI: 10.1007/bf01655665]
Gladdy RA, Qin LX, Moraco N, Agaram NP, Brennan MF, Singer
S. Predictors of survival and recurrence in primary leiomyosarcoma. Ann Surg Oncol 2013; 20: 1851-1857 [PMID: 23354568

14

15

DOI: 10.1245/s10434-013-2876-y]
DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH,
Brennan MF. Results of hepatic resection for sarcoma metastatic to
liver. Ann Surg 2001; 234: 540-557; discussion 540-557; [PMID:
11573047 DOI: 10.1097/00000658-200110000-00013]
Ng EH, Pollock RE and Ramsdahl MM. Prognostic implications
of patterns of failure for gastrointestinal leiomyosarcomas. Cancer
1992; 69: 1334-1341 [PMID: 1540870 DOI: 10.1002/1097-0142
(19920315)69:6<1334]
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen
H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J,
Tursz T. Prognostic factors for the outcome of chemotherapy in
advanced soft tissue sarcoma: an analysis of 2,185 patients treated
with anthracycline-containing first-line regimens--a European
Organization for Research and Treatment of Cancer Soft Tissue
and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157
[PMID: 10458228]
Lang H, Nussbaum KT, Kaudel P, Frühauf N, Flemming P, Raab
R. Hepatic metastases from leiomyosarcoma: A single-center
experience with 34 liver resections during a 15-year period.
Ann Surg 2000; 231: 500-505 [PMID: 10749609 DOI: 10.1097/
00000658-200004000-00007]
Marudanayagam R, Sandhu B, Perera MT, Bramhall SR, Mayer
D, Buckels JA, Mirza DF. Liver resection for metastatic soft tissue
sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 2011;
37: 87-92 [PMID: 21163386 DOI: 10.1016/j.ejso.2010.11.006]
Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, de
Jong MC, Pawlik TM, Geller DA, Tsung A, Marsh JW, Clary BM,
Curley SA, Gamblin TC. Hepatectomy for noncolorectal nonneuroendocrine metastatic cancer: a multi-institutional analysis.
J Am Coll Surg 2012; 214: 769-777 [PMID: 22425166 DOI:
10.1016/j.jamcollsurg.2011.12.048]
Mourra N, Jouret-Mourin A, Lazure T, Audard V, Albiges L,
Malbois M, Bouzourene H, Duvillard P. Metastatic tumors to the
colon and rectum: a multi-institutional study. Arch Pathol Lab
Med 2012; 136: 1397-1401 [PMID: 23106585 DOI: 10.5858/arpa.
2011-0432-OA]
Hamai Y, Hihara J, Emi M, Aoki Y, Kushitani K, Tanabe K, Okada
M. Leiomyosarcoma of the sigmoid colon with multiple liver
metastases and gastric cancer: a case report. BMC Gastroenterol
2012; 12: 98 [PMID: 22849696 DOI: 10.1186/1471-230X-12-98]
Penel N, Italiano A, Isambert N, Bompas E, Bousquet G, Duffaud
F. Factors affecting the outcome of patients with metastatic
leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol 2010; 21: 1361-1365 [PMID: 19880438 DOI:
10.1093/annonc/mdp485]
Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le
Cesne A, Oosterhuis JW, Judson I, Nielsen OS. Advanced softtissue sarcoma: a disease that is potentially curable for a subset of
patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-69
[PMID: 12504660 DOI: 10.1016/S0959-8049(02)00480-X]
Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi
Y, Shin KH, Cho YJ, Lee J, Rha SY. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic
soft tissue sarcoma: a retrospective case series. BMC Cancer 2015;
15: 154 [PMID: 25885855 DOI: 10.1186/s12885-015-1160-x]
P- Reviewer: Facciorusso A, Lim SC, Seicean R
S- Editor: Qi Y L- Editor: A E- Editor: Liu WX

WJG|www.wjgnet.com

1734

March 7, 2017|Volume 23|Issue 9|

Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

I S S N 1 0  0 7  -   9  3 2  7
09

9   7 7 10  0 7   9 3 2 0 45
© 2017 Baishideng Publishing Group Inc. All rights reserved.

